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Aberrations in the adult hippocampal neurogenesis in AD patients include dysfunctional 
maturation indicated by accumulated number of immature neurons. The hippocampus receives 
cholinergic afferents from the medial septum/diagonal band of Broca (MS/DB). Plasticity of 
septohippocampal cholinergic innervation in AD was reported by multiple studies including 
higher hippocampal choline acetyltransferase (ChAT) activity in MCI cases with Braak stage III-
IV than control and AD cases. Septohippocampal cholinergic pathway is crucial to adult 
hippocampal neurogenesis in rodents. While several studies have reported association between 
these two factors in human cases, a range of markers investigated have been limited and the 
mechanisms remain unclear.  
The aim of this first project is to use immunohistochemistry (IHC) to measure the extents of 
cholinergic innervation with ChAT and vesicular acetylcholine transporter (VAChT) and to 
evaluate the changes in adult hippocampal neurogenesis with immature neuron markers DCX, 
HuB/D, and proliferative marker PCNA. Statistical power for the main study was calculated from 
the pilot study and reported to request for the main cohort cases. The main cohort consisted of 
36 cases of all Braak stages with low to negligible vascular conditions from the MRC brain bank. 
ChAT staining in the dentate gyrus (DG) was significantly higher in the cases with Braak III than 
cases with Braak IV-VI. The number of HuB/D positive cells without PCNA was significantly 
correlated with ChAT staining and significantly lower in Braak IV-V cases compared with others. 
The number of DCX-positive cells, unlike the pilot study and other studies, was not different 
across the groups. 
Since the third year of the project, Dr Emily Clarke has started her project on D427V 
heterozygous GBA1 mouse as a potential model for dementia with Lewy bodies (DLB). Several 
studies demonstrated AD-like abnormal adult hippocampal neurogenesis in DLB and even more 
severe degeneration of the septohippocampal cholinergic tracts in DLB than in AD cases. This 
led to our collaboration and the second part of this thesis on characterising the cholinergic 
innervation and adult hippocampal neurogenesis in this mouse model. 
The aim is to use IHC to investigate the distribution of ChAT, VAChT, and synaptophysin; to 
compare/confirm IHC findings on cholinergic profiles with Western blot; and to evaluate the 
changes in adult hippocampal neurogenesis with immature neuron markers DCX, HuB/D, and 
PCNA. Although ChAT staining was slightly higher in the hippocampus and cortex of the 12 
month-old GBA1 D427V mice, VAChT staining was significantly reduced. The number of 
cholinergic neurons in the basal forebrain was not different but upregulation of ChAT level and 
ectopic fibre sprouting was observed. In the DG, 12 month-old GBA1 D427V mice had higher 
density of DCX-positive neurons. Furthermore, cells double-positive for DCX and HuB/D are 
more common in human than in mouse.      
This study confirmed the potential of HuB/D as a human-specific biomarker for healthy adult 
hippocampal neurogenesis and also demonstrated differential regulation of VAChT and ChAT in 
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1    Introduction 
 
1.1 Cholinergic basal forebrain system 
1.1.1 Background 
The cholinergic basal forebrain can be divided into 4 subparts based on the targets of their 
respective cholinergic projections (Mesulam et al., 1983b; Zaborszky et al., 2012) (Figure 1.1 and 
1.2). Ch1 the medial septum (MS) and Ch2 the vertical limbs of the diagonal band of Broca (VDB) 
project to the hippocampal formation and entorhinal cortex. Ch3 the horizontal limbs of the 
diagonal band of Broca (HDB) and the magnocellular preoptic nucleus (MCPO) project to the 
hypothalamus, olfactory bulb, prefrontal cortex, and entorhinal cortex. Ch4 the nucleus basalis 
of Meynert/substantia innominata (nbM/SI) and ventral pallidum (VP) project to the entire 
neocortex and amygdala. Interestingly, these organizations can differ across different classes of 
mammals. For example, projection neurons from the MS/DB constitute approximately 66% of 
the entorhinal-projecting basal forebrain neurons in rats (Manns et al., 2001) (Figure 1.2), but 
only 15% of the parahippocampal-projecting basal forebrain neurons in the rhesus monkey 
(Mesulam et al., 1983a).  
 
Figure 1.1 – Structure of the basal forebrain in human 
(Adapted from Zaborszky et al., 2008; TheHumanBrain.info, 2018b) Different sectors of the human basal 
forebrain are shown here from the maximum probabilistic map on the Montreal Neurological Institute 





Figure 1.2 – Schematic of BFCN projections in the mouse brain 
(Taken from Ballinger et al., 2016 with permission from Elsevier, Appendix Table A.9) MS/VDB in the 
rostral part of the brain project to the hippocampus (Hipp) and the entorhinal cortex (Ent). The nucleus 
basalis/substantia innominata (NB/SI) including the HDB in the more caudal part (around mid-Bregma) 
project to the cortex. HDB and the medial anterior parts of the NbM/SI complex project to the frontal 
cortices. The lateral and posterior parts of the complex project to the remaining cortices including visual 
(V), auditory (Au), and perirhinal (Prh) and amygdala (Amyg).  
 
1.1.2 Cholinergic neurons  
Key morphological features of the basal forebrain cholinergic neurons (BFCNs) include extensive 
terminal arborisation within the target region as a single BFCN may innervate up to 3 cortical 
areas (Wu et al., 2014a). Along these highly branched axons also lie numerous en passant 
presynaptic boutons. Immense total axon length of up to 100 m in human, based on the 
calculation from BFCNS axon length in mouse of 30 cm, which demands high energy processing 
and hence renders BFCN more susceptible to aging (reviewed in Ballinger et al., 2016). 
Most BFCNs express low affinity p75 neurotrophin receptor (p75NTR) which can bind to all 
trophic factors of neurotrophin family. Mammalian neurotrophins are composed of brain-
derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), and 
neurotrophin-3 (NT-4). Neurotrophins are first translated as precursors that can be cleaved into 
mature forms. The precursor proneutrophins bind to the p75NTR and the coreceptor of VPS10 
family, but the mature neurotrophins bind to the p75NTR and tropomyosin receptor kinase (Trk) 
coreceptor family (Lee et al., 2001).  
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However, some BFCNs do not express p75NTR. Some subtypes of p75NTR-negative BFCNs also 
express VGluT3, which transports glutamate into a synaptic vesicle and likely implies corelease 
of acetylcholine and glutamate in these subpopulations (Yang et al., 2017). Only few BFCNs 
express both VGluT3 and p75NTR (Nickerson Poulin et al., 2006). The majority of VGluT3-positive 
BFCNs are in the Ch4 (nbM/SI, VP) and the rest are in the Ch3 (HDB, MCPO). Most VGluT3-
positive BFCNs especially in the Ch4 project to the basolateral amygdala. While VGluT3 enables 
corelease of acetylcholine and glutamate by striatal fast-spiking interneurons (Nelson et al., 
2014), almost all VGluT3-positive BFCNs of the HDB innervate and co-transmit acetylcholine and 
GABA to glomerulus-projecting GABAergic interneurons in the olfactory bulb (Case et al., 2017).    
Acetylcholine (ACh) was one of the first neurotransmitters identified. Its synthesis from acetyl-
CoA and choline is catalysed by choline-acetyltransferase (ChAT) in the cytoplasm (Jones et al., 
2012). ACh is then transported into a synaptic vesicle by vesicular acetylcholine transporter 
(VAChT) (reviewed in Prado et al., 2013). Upon depolarisation, ACh is released from a synaptic 
bouton. ACh then can bind to either nAChRs or mAChRs before it is degraded by 
acetylcholinesterase (AChE) into acetate and choline. Choline is transported back into a 
presynaptic axon by high-affinity choline transporter (CHT1) and subsequently converted to ACh 
by ChAT. The proteins ChAT, VAChT and CHT1 provide specific targets for identification of 
cholinergic neurons. The catabolic enzyme AChE is produced mostly by both cholinergic neurons 
and cholinoceptive cells. Understanding of the components in cholinergic synapses has allowed 
the visualisation of cholinergic neurons and their processes. For example, BFCNs have been 
identified using immunohistochemistry against ChAT and p75NTR, while cholinergic axons and 
processes have been stained for VAChT, CHT1, and AChE. Early study focused on cholinergic 
axons using histochemistry for AChE (Mesulam et al., 1983a)    
1.1.2.1    The structure of cholinergic synaptic terminals 
There are 2 modes of ACh signalling from cholinergic terminals: either a traditional synaptic 
specialization or non-synaptic volume transmission. At the beginning, it was speculated that 
volume transmission was the major mode of ACh transmission since several studies found low 
density of synaptic specialization on cholinergic terminals in the rat parietal cortex (14% overall, 
21% in the layer V) and monkey prefrontal cortex (40%) (Umbriaco et al., 1994; Mrzljak et al., 
1995), inconsistency between fluctuations of ACh level and local clearance pattern (reviewed in 
Picciotto et al., 2012) and relatively distant locations of terminals and receptors. In contrast, a 
later study on the rat parietal cortex specifically in the layer V (Turrini et al., 2001) showed 66% 
synaptic specialization incidence from VAChT-positive cholinergic terminals, which was lower 
than the 92% incidence from total unlabelled terminals but still much higher than which were 
reported in previous literatures. A study in the human temporal cortex also revealed high 
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synaptic incidence from ChAT-positive varicosities of 67% (Smiley et al., 1997). Nonetheless, 
most studies lent support to the notion that non-synaptic transmission still has significant 
contribution. Furthermore, the local effects of non-synaptic ACh transmission can be regulated 
by various factors including characteristics of the extracellular space around the terminals, 
differential local concentration of AChE, and local density and subcellular compartmentalization 
of the receptors (reviewed in Coppola et al., 2016). However, the concept of mixed synaptic and 
non-synaptic cholinergic terminals was recently challenged by a discovery that all cholinergic 
terminals in the hippocampus form synapses (Takács et al., 2018). Interestingly, without 
immunogold labelling for neuroligin-2 and gephyrin, some of them would not have been 
counted as synapses in older studies because of their thin postsynaptic densities and narrow 
synaptic gap.  
These incidences of synaptic specialization reported by electron microscopy studies likely 
include synapse-like contacts between astrocyte and cholinergic terminals (Zhang et al., 2016). 
Each of these synapse-like structures between cholinergic varicosities and astrocytes may be 
directly connected to the synapse between that very same cholinergic terminal and a 
postsynaptic structure of another neuron; this structure is referred to as a tripartite synapse. 
Astrocyte-mediated cholinergic signalling phenomena have also been reported in ACh-induced 
LTP at CA3-CA1 synapses (Navarrete et al., 2012) and ACh-induced dentate granule neuron 
inhibition by mossy cells and hilar inhibitory interneurons (Pabst et al., 2016).     
1.1.2.2    Cholinergic locus: VAChT and ChAT 
Cholinergic locus refers the region with shared transcriptional regulatory regions and 
juxtaposition of both VAChT and ChAT encoding genes. VAChT-encoding gene SLC18A3 is located 
3' to the first shared untranslated exon of the locus namely the R-exon and 5' to the second (N-
exon) and third (M-exons) non-coding exons followed by the first coding exon of the ChAT gene. 
Both VAChT and ChAT have various mRNA transcripts depending on a combination of 5' non-
coding exons and each transcript is usually named after the first 5' non-coding exon, which 
contains the promoter, of that transcript (Figure 1.3) (Kengaku et al., 1993; Bejanin et al., 1994; 
reviewed in Eiden, 1998). R-exon-containing VAChT transcripts are relatively rare in rat brain 
and spinal cord and still have not been discovered in human (Hahm et al., 1997). Upstream to 
the R-exon is a regulatory sequence RE1/NRSE which can recruit a silencing transcription factor 
REST/NRSF to suppress VAChT and ChAT expression (De Gois et al., 2000). TrkA activation by 
NGF upregulates cholinergic gene locus through the 2 AP-1 sites and cAMP response element 
site upstream to the R-exon and produces 3.8 kb ChAT transcript and 3.0 kb VAChT transcript 
(Berse et al., 1999).     
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VAChT is one of the Major Facilitator Superfamily transporters, which also include vesicular 
monoamine transporter (VMAT) 1 and 2 (reviewed in Prado et al., 2013). Transporters of this 
family use vesicular electrochemical proton gradient generated by V-ATPase to load 
neurotransmitters into vesicles. Specifically, VAChT exchanges two luminal protons for one 
cytoplasmic ACh molecule. VAChT has a dileucine motif in the C-terminal that facilitate clathrin-
dependent endocytosis. Phosphorylation at S480 regulates this dileucine-dependent 
internalisation by shifting the localisation of VAChT from neurotransmitter rapid-releasing 
synaptic vesicles toward slow-releasing large dense core vesicles (Krantz et al., 2000).       
While all transcripts of ChAT in rat encode the same protein of 69 kDa, an M-transcript in human 
has an extra start codon on M-exon and can also encode for an 82kDa ChAT protein (Misawa et 
al., 1997). Subcellular localisation of the 82kDa ChAT has been shown to change during aging 
and cognitive decline. In the basal forebrain, while the 69kDa ChAT is steadily decreased in 
cognitively healthy aged and demented age individuals respectively, the cytoplasmic 82kDa 
ChAT level is upregulated in normal aged individuals but drastically reduced in cognitively 
impaired cases (Gill et al., 2007). In the claustrum, the 82kDa ChAT is absent in young adults, 
abundant in the cell nucleus in aged individual, and significantly decreased again in demented 
aged cases.  
 
Figure 1.3 – Schematic for VAChT and ChAT transcription from the cholinergic locus 
(Taken from Eiden, 1998 with permission from John Wiley and Sons; Appendix Table A.10) VAChT and 
ChAT transcription from multiple putative promoters. Downward arrows indicate the positions of 
initiating methionine of VAChT (+1V) and ChAT (+1C). In human gene, +1C is 30 bp downstream to the 
ACG which is analogous to the rat initiating ATG. N1 transcript, unlike M-transcript, lacks the 5ʹ segment 




1.1.2.3    CHT High-affinity Choline transporter 
CHT1, encoded by the gene SLC5A7, is a transmembrane membrane sodium-dependent 
transporter of choline. CHT1 is expressed as a single mRNA transcript of 5 kb. While it is 
expressed at high level comparable to that of adult as early as E14 in the spinal cord during 
mouse development, its expression in the septum is very low at E14 and steadily increases until 
its peak at around P30 (Berse et al., 2005). Choline is an essential nutrient and important for 
cognitive development (reviewed in Blusztajn et al., 2017). Therefore, choline needs to be 
transported back to the presynaptic terminals for the production of ACh and this reuptake 
process by CHT1 has been suggested to be a rate-limiting step of ACh synthesis (reviewed in 
Kuhar and Murrin, 1978; Tucek, 1985). NGF also promotes expression of CHT1 and cholinergic 
locus genes (VAChT/ChAT) through PI3K/Akt-dependent pathways (Berse et al., 2005). 
Nonetheless, some factors may regulate CHT1 differently from cholinergic locus genes. For 
example, higher level of cAMP decreases CHT1 mRNA expression but increases VAChT/ChAT 
mRNA (Brock et al., 2007).     
Similar to VAChT, CHT1 also has a C-terminal dileucine motif for clathrin-mediated endocytosis 
(Ribeiro et al., 2005). However, there is an activity-dependent trafficking to the plasma 
membrane for CHT1 but not VAChT (Ferguson et al., 2003). CHT1 and APP were found in Rab5-
positive endosome; and both presynaptic localisation and endocytic vesicular recycling of CHT1 
required APP (Wang et al., 2007). Congruent with the finding that CHT1 was upregulated in AD 
patients (Bissette et al., 1996), Rab5 gene expression in the BFCNs (Ginsberg et al., 2011) and 
CA1 pyramidal neurons (Ginsberg et al., 2010) was also higher in MCI and AD patients. Activity-
dependent CHT1 plasma membrane trafficking induced by potassium pulse was also suppressed 
by Aβ42 oligomers (Parikh et al., 2014).      
   
1.1.2.4    Acetylcholine receptors 
Acetylcholine receptors (AChR) can be classified into two types: muscarinic receptor (mAChR) 
and nicotinic receptor (nAChR). The mAChR is a metabotropic receptor that, once it binds to the 
ACh, activates heterotrimeric G protein to regulate potassium and calcium channels (reviewed 
in Ballinger et al., 2016). The nAChR on the other hand is an ionotropic receptor that constitute 
a non-selective cation channel. As their names suggest, the mAChR and nAChR are preferentially 
sensitive to muscarine and nicotine respectively.  
The mAChRs can be categorised into 2 main groups based on the types of G proteins in the 
cascade: Gq/11 for M1, M3, and M5; and Gi/o for M2 and M4 (reviewed in Ballinger et al., 2016). 
M1-mAChRs are generally expressed in the cell bodies and dendrites of both GABAergic 
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interneurons and glutamatergic pyramidal neurons and also in the axons of the DGCs (Martinello 
et al., 2015). Activation of M1 mAChR usually increases cell excitability. M2-mAChRs, in contrast, 
mainly have presynaptic inhibitory effects for decreasing the release of neurotransmitters such 
as ACh or GABA.  
There are multiple types of nAChR subunits: α2-10 and β2-4. In theory, the ion channel can be a 
homomeric or heteromeric pentamer of these subunits in any order. Nonetheless, the α4β2- 
and the α7-containing receptors are the most common in the brain. The α7-nAChRs have lower 
affinity for an agonist but higher Ca2+ conductance than do the α4β2-nAChRs (Dani and Bertrand, 
2007). The α7-nAChRs are potential targets for AD treatment because their expressions in 
astrocytes are significantly elevated in AD patients (Teaktong et al., 2003; Teaktong et al., 2004) 
and its binding to Aβ42 oligomer may induce glutamate release from the astrocytes and 
consequently cause excitotoxicity (Talantova et al., 2013). Furthermore, there has been an 
evidence of physiological interaction between the two proteins as monomeric Aβ42 can activate 
α7-nAChR in the hippocampal presynaptic terminals to enhance glutamate release (Hascup and 
Hascup, 2016). While the most common form of α7-containing nAChRs is the α7 homo-
pentameric nAChR, α7β2-nAChRs are expressed in the BFCNs (Liu et al., 2009) and in the 
hippocampal CA1 GABAergic interneurons (Liu et al., 2012a) and have significantly higher affinity 
to be inhibited by oligomeric Aβ42 than do the homopentameric α7-nAChRs.              
1.1.2.5    Acetylcholinesterase  
AChE is encoded by ACHE gene with multiple splicing combinations. The spliced form most 
relevant to nervous functions is AChE-T, a subunit of tetrameric functional AChE. At a 
neuromuscular junction, 2 AChE-T subunits are covalently linked to collagen Q (ColQ) by 
disulphide bond and this ColQ-AChE unit together with a disulphide-linked homodimer AChE-T 
form a functional AChE complex on the extracellular basal lamina (Noureddine et al., 2008). On 
both pre- and post-synaptic membranes, all 4 AChE-T subunits are disulphide linked to a 20-kDa 
transmembrane protein PRiMA (Perrier et al., 2002). Dimeric erythrocytic AChE or AChE-E is 
anchored to phosphoinositol on the membrane of a mammalian red blood cell (Futerman et al., 
1985). Monomeric AChE-R is found during embryonic brain development (Muller et al., 1985) 
and in some types of tumour cells such as glioblastoma (Karpel et al., 1996; Perry et al., 2004). 
Furthermore, its expression can be upregulated during stress. AChE activity can be visualised by 
enzyme histochemistry technique. Acetylthiocholine is hydrolysed by the AChE to produce 
thiocholine and acetate.  After thiocholine reduces hexacyanoferrate (III) to hexacyanoferrate 
(II), the soluble hexacyanoferrate (II) reacts with Cu(II) ion to form Hatchett brown precipitate 





1.1.3 Other types of neurons in the basal forebrain               
1.1.3.1    GABAergic neurons 
GABAergic neurons in the basal forebrain are heterogeneous in terms of morphology and 
functions. GAD67-GFP knock-in mice enable clearer visualization and identification of GABAergic 
interneurons: most interneurons project locally but some of them are large projection neurons 
(McKenna et al., 2013). Most of these projection neurons are fast-spiking parvalbumin (PV)-
positive and their highest density is in the MCPO. GABAergic projection neurons preferentially 
innervate GABAergic interneurons of the projected region e.g. cortex or hippocampus McKenna 
et al., 2013; Bao et al., 2017. Even in the same region of the basal forebrain, MS in this example, 
a distinct subpopulation of GABAergic neurons may target a single subregion i.e. PV- and special 
AT-rich sequence-binding protein-1 (SATB1)-positive Teevra cells in the MS selectively 
innervating GABAergic interneurons of the CA3 (Joshi et al., 2017). In addition, while all 
GABAergic projection neurons in the MS rhythmically fire action potential, their burst duration 
and rhythmicity are diverse across different subpopulations. Teevra neurons exhibit short burst 
duration but Komal neurons exhibit long burst duration. For the cortical projection, GABAergic 
projection neurons can be categorized into 3 types based on specific markers. First, PV-positive 
neurons have high firing rate and control cortical gamma oscillation. Second, voltage-gated 
delayed-rectifier potassium channel (Kv2.2)-positive neurons comprise about 60% of GABAergic 
projection neurons in the Ch3. Last, Neurokinin B receptor type 3 (NK3R)-positive neurons play 
roles in the production of gonadotrophin-releasing hormone. Calbindin is also expressed in some 
GABAergic projection neurons (Zaborszky et al., 2012). 
GABAergic interneurons may express somatostatin (SST), neuropeptide-Y (NPY), neuronal nitric 
oxide synthase, or calretinin (CR) and can be either wake or sleep active (Yang et al., 2017). 
These neurons target local neurons in the basal forebrain or innervate neurons in a nearby 
caudal brain region.  
1.1.3.2    Glutamatergic neurons 
Most glutamatergic neurons in the basal forebrain express VGluT2. Most VGluT2-positive 
projection neurons innervate subcortical regions (Do et al., 2016). Nonetheless, a few of VGluT2-
positive neurons also express calbindin and target the cortex, while several others express 
calretinin and project locally (Anaclet et al., 2015). Glutamatergic projection neurons of the basal 
forebrain have been demonstrated to have diverse characteristics and functions. Cortically-
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projecting VGluT2-positive neurons positively regulate wakefulness (Yang et al., 2017). A 
subgroup of VGluT2-positive neurons in the Ch1-3 (MS/DB/MCPO) produce gonadotrophin-
releasing hormone in response to kisspeptin to promote reproductive maturation (Dumalska et 
al., 2008; Wu et al., 2009). VGluT2-positive neurons of the MS/DB have been shown to control 
locomotion speed-dependent firing of the hippocampus (Fuhrmann et al., 2015).  These VGluT2-
positive neurons also relay this speed information to the spatial cells of the medial entorhinal 
cortex (MEC) layer 2/3 for integration into dynamic representation of self-location (Justus et al., 
2017). 
1.1.3.3    Monoaminergic neurons 
Dopaminergic neurons in the basal forebrain have been found in humans (Gouras et al., 1992), 
monkeys (Wisniowski et al., 1992), and even hamster (Vincent, 1988) despite the lack of 
evidence of their presence in mice and rats. Nonetheless, there are conspicuous differences 
between these neurons in humans and those in monkeys. The majority of dopaminergic neurons 
found in the human basal forebrain were in the MS/DB and they did not express ChAT (Gouras 
et al., 1992). However, the distribution of dopaminergic neurons in the marmoset basal 
forebrain was the opposite: the majority in the NbM and almost none in the MS/DB (Wisniowski 
et al., 1992). Functional characteristics and connections of these neurons have not been 
investigated.       
1.1.4 Cognitive functions of the basal forebrain and cholinergic signalling 
1.1.4.1    Hippocampus-associated memory 
Multiple reports have confirmed the significance of cholinergic system in learning and memory. 
ACh is released at the dorsal CA3-CA1 during contextual fear inhibitory-avoidance learning to 
strengthen both excitatory and inhibitory synaptic responses via M1-mAChR and nAChR 
respectively (Mitsushima et al., 2013). Furthermore, plasticity types mediated by α7-nAChR, 
whether long-term potentiation (LTP) or short-term depression (STD) depend on the relative 
intermission between stimulation of CA3-CA1 input and innervating cholinergic axons; and this 
plasticity-inducing effects have to be coordinated by both presynaptic and postsynaptic 
cholinergic input (Gu et al., 2012). Stabilization of LTP in the CA1 involving S845 phosphorylation 
of GluA1 subunits of AMPAR and F-actin production also depends on the activation α7-nAChR 
(Galvez et al., 2016). Activation of α7-nAChR also mediates LTP at CA1-mPFC synapses 
(Stoiljkovic et al., 2016).    
Activation of M1 mAChR on the axon of dentate granule neurons increases axonal excitability 
by sustaining influx of Ca2+ through T-type Ca2+ channels and therefore lowering action potential 
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threshold (Martinello et al., 2015). Although plasticity mechanisms of granule neurons include 
lower excitability from axon initial segment shortening (Evans et al., 2015), the M1-mediated 
plasticity does not change the length or location of the axon initial segment (Martinello et al., 
2015).  
Accurate memory association needs a proper balance and separation between memory 
encoding and retrieval, both of which are mediated by theta oscillation (Hasselmo, 2014; 
Hasselmo and Stern, 2014). Theta peak and trough correspond to encoding and retrieval 
respectively.  Muscarinic antagonist scopolamine impairs CA1 encoding Newman et al., 2014 
and knockout of α7-nAChR gene inhibits theta oscillation (Lu and Henderson, 2010).  
1.1.4.2    Wakefulness 
BFCNs are active when animals are awake or in rapid eye movement (REM) sleep, but less active 
during non-REM (NREM) sleep. However, they are not the master regulator of sleep-/wake cycle 
Yang et al., 2017. Optogenetic activation of cortical-projecting BFCNs transiently increased 
wakefulness, promoted cortical electroencephalogram (EEG) theta activity and plasticity, and 
suppressed cortical EEG delta activity (Zant et al., 2016). Inhibition of BFCNs slightly affected 
wakefulness and prolonged activation also did not considerably enhance the amount of 
wakefulness. In addition, the amount of wakefulness depends on the activity of other basal 
forebrain neurons. Nevertheless, BFCNs have been demonstrated to play a crucial role in 
homeostatic sleep response (Yang et al., 2017). Lesions of p75NTR-positive BFCNs subpopulation 
by 192-IgG saporin relinquished sleep upregulation and increase in adenosine after sleep 
deprivation (Kalinchuk et al., 2008).     
Cortically-projecting GABAergic neurons exhibit EEG gamma activity-correlated maximal 
discharge during wakefulness and REM sleep (Hassani et al., 2009). PV-positive neurons, the 
major subtype of cortical-projecting GABAergic neurons, enhance cortical gamma band 
oscillations and increase the amount of wakefulness (Yang et al., 2017). The other two subtypes 
of projection GABAergic neurons – Kv2.2-positive and NK3R-positive – are also wake-active but 
their electrophysiological characteristics have much to be studied. While the majority of local 
GABAergic interneurons that express either SST or NPY are active during REM, stimulation of 
these populations overall decreased wakefulness and promoted NREM sleep (Xu et al., 2015). 
Another GABAergic subpopulation with REM-associated maximal discharge has not been 
sufficiently investigated. For glutamatergic neurons, VGluT2-positive neurons are active during 
wake and REM sleep and stimulation of these neurons was shown to promote wakefulness (Xu 
et al., 2015). Glial cells in the basal forebrain have not been extensively studied but they were 
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shown to corelease ATP which is later converted to adenosine during sleep deprivation (Halassa 
et al., 2009). 
Overall, cortically projecting PV-positive neurons are the fundamental direct activator of 
wakefulness. Cholinergic neurons, on the other hand, mediate the wakefulness both by distal 
projection to cortical GABAergic interneurons and by local innervation to wake-inducing PV 
projection neurons, VGluT2 glutamatergic neurons, and sleep-inducing SST interneurons (Xu et 
al., 2015). Sleep deprivation induces accumulation of ATP-derived adenosine, which inhibits 
glutamatergic signals from VGluT2 neurons to cholinergic and PV projection neurons, to 
suppress wakefulness.                
1.1.4.3    Attention and reward 
Attention has been theorized to consist of two independent processes: “bottom-up” and “top-
down” (reviewed in Katsuki and Constantinidis, 2014). “Bottom-up” attention mainly involves a 
feedforward process of automatic selection of highly distinguishable signals in the stimuli during 
the transmission to the cortex. “Top-down” attention, on the other hand, is driven by a feedback 
process of sensory signal modulation by the cortex to detect a task-relevant cue or goal. The 
medial prefrontal cortex is innervated by all subregions of the basal forebrain from Ch1 to Ch4 
(Bloem et al., 2014) and is essential to the “top-down” attention process (Ballinger et al., 2016). 
Transient surge of ACh was induced when task-related cues were present in the stimuli (Howe 
et al., 2013) and cue detection was also improved by ACh transients after optogenetic 
stimulation of the basal forebrain (Gritton et al., 2016). In addition, stimulation during a cue-
lacking session induced detection of false cue and inhibition also caused failure to detect the 
cues. Overall, cholinergic signalling induces and enhances “top-down” cue detection by the 
medial prefrontal cortex.  
Increased signal-to-noise ratio is crucial to the detection of task-relevant cue. This process 
namely desynchronization can be achieved through decorrelation of increased activity of task-
relevant sensory cortical neurons. Desynchronization enhances neuronal response reliability to 
task-relevant stimuli (Mitchell et al., 2009) and cholinergic signalling to the sensory cortex 
facilitates the desynchronization with SST-positive interneurons as the major mediators (Chen 
et al., 2015a). Congruent with the findings that the medial prefrontal cortex is also innervated 
by the hippocampus-targeting MS/VDB, both wakefulness-predicting tonic ACh release during 
spatial memory training and reward/attention-associated phasic ACh release are coordinated 




In summary, BFCNs are important contributors to many higher mental functions including 




1.2 The Hippocampus 
1.2.1 Anatomy and historical backgrounds    
The hippocampus is a part of the limbic system in the medial temporal lobe (MTL) in human 
(reviewed in Eichenbaum et al., 2016). Mammals have two hippocampi, each of which has a 
fibre bundle called fimbriae that joins each other to form the fornix that curves along the corpus 
callosum and branches to the supramammillary nucleus (SuM) of the hypothalamus, anterior 
thalamic nuclei, and basal forebrain (reviewed in Nowrangi and Rosenberg, 2015). The 
hippocampus is composed of the dentate gyrus and the hippocampal proper or Cornu Ammonis 
with 3 subsectors: CA1-3. A summarizing schematic of major hippocampal circuitry is shown in 
Figure 1.4 with descriptions in the legend. Its memory function was first revealed by anterograde 
amnesia caused by the bilateral damage in the hippocampus. Numerous studies further proved 
its roles in episodic memory, spatial navigation, and context-dependent memory. The 






Figure 1.4 – A schematic of rodent hippocampal circuitry 
(Original drawing) The major glutamatergic afferents to the hippocampus are from the EC. Axons from 
the EC layer II and III travel through the perforant path to all sectors of the hippocampus. Pyramidal 
neurons of the medial and lateral EC layer II (orange) innervate the DG especially dendrites of the dentate 
granule neurons (DGC) along the middle (MML) and outer molecular layer (OML) respectively and extend 
further to innervate pyramidal neurons of the CA3 and CA2. Axons from the EC layer III on the other hand 
innervate the CA1 and subiculum. The DG also receives extrahippocampal afferents via fimbriae/fornix 
from various sources such as the cholinergic and GABAergic neurons of the MS/DB (reddish brown), 
dopaminergic and noradrenergic neurons of the locus coeruleus, and serotonergic neurons of the dorsal 
raphe, which innervate other hippocampal sectors as well (reviewed in Scharfman, 2016). Long axons of 
the DGCs (green) called mossy fibres converge into a large bundle in the CA4 or hilus, extend along the 
CA3 to the CA2, and finally travel longitudinally to the more ventral part of the hippocampus (reviewed in 
Dudek et al., 2016). Mossy cells of the CA4 (red), one of the major postsynaptic targets of the mossy fibres, 
locally innervate DGCs and inhibitory interneurons (not shown). Mossy cells in the ventral hippocampus 
send distal axons to the inner molecular layer (IML) of the ipsilateral dorsal and contralateral ventral 
hippocampus. Pyramidal neurons of the CA2 (blue) and CA3 (purple) mainly target the CA1 (light blue), 
but also possess extensive network of axons with multiple other shared targets including contralateral 
CA2 and CA3 and subcortical lateral septal nuclei (LSD). Nonetheless, CA2 also projects to the MS/DB and 
only CA3 project back to the DG. The CA1 and subiculum (pale light blue) then relay the information to 





1.2.2 Dentate gyrus 
1.2.2.1    Local cell types and architectures 
The DG is composed of the molecular layer (ML), granule cell layer (GCL), subgranular zone (SGZ), 
and the hilus or CA4. The dentate granule cells (DGCs) are glutamatergic excitatory neurons 
lining up in a dense band of the GCL. Some DGCs, however, are not in the GCL namely the 
semilunar DGCs in the inner molecular layer (IML) and the ectopic DGCs in the hilus. The DGCs 
receive major glutamatergic signals from entorhinal cortex (EC) layer II-III. Pyramidal neurons of 
the lateral and medial EC Layer II-III send axons along the performant path (PP) to the outer 
(OML) and middle molecular layer (MML) respectively (Figure 1.4). The inner molecular layer 
(IML) receives glutamatergic signals from mossy cells in the hilus, distant projections of the 
neurons in the SuM, and back-projection from the CA3 pyramidal neurons. The DG receives local 
GABAergic signals from different interneurons such as PV-positive basket cells, CR-positive 
neurons, axo-axonic cells, and diverse types of other GABAergic neurons with nomenclature 






Projections and Targets 
Glutamatergic Neurons 
Mature DGC GCL/ML Hilus and CA3/2; adult-born DGCs  
Adult-born DGC GCL/ML Hilus and CA3/2 
Semilunar DGC IML Hilus and CA3/2 
Ectopic DGC Hilus Hilus and CA3/2 
Mossy cells Hilus Hilus and IML 
GABAergic interneurons 
MOPP/NG ML OML/MML 
Axo-axonic cell GCL Axon initial segments of DGCs 
PV+ Basket cell GCL Around DGCs; the contralateral DG 
HICAP Hilus IML 
HIL Hilus Hilus and MS/VDB 
HIPP Hilus OML/MML 
CR+ cells Hilus DG interneurons except PV+ basket and axo-axonic cells  
Table 1.1 – Cell types in the DG  
(Reviewed in Scharfman, 2016) DGCs are mostly in the GCL, but there are also semilunar DGCs in the IML 
and ectopic DGCs in the hilus. Some mossy cells may extend their axons to the ML as well. Besides the PV-
positive basket cells in the GCL, small calretinin (CR)+ interneurons, and axo-axonic cells, GABAergic 
neurons in the DG are classified by the locations of their somas and axon terminals. Interneurons with a 
molecular layer cell body that projects to the terminal zone of the perforant path (MOPP)/neuroglia form 
(NG) have a cell body in the ML and send axons to the perforant path (PP). Both hilar cells that projects to 
the terminal zone in the PP (HIPP) and interneurons with a hilar cell body with axon targeting the 
commissural/association pathway (HICAP) have cell bodies in the hilus but send their axons to the 
OML/MML where the terminal zone in the PP located and IML where the commissural/association 
pathway located respectively. SST-positive GABAergic interneurons with cell body and axon in the hilus 




Mossy cells are glutamatergic neurons in the hilus that are capable of directly stimulating DGCs 
and disynaptically inhibiting DGCs by stimulating DGCs-innervating GABAergic interneurons 
(reviewed in Scharfman, 2017; Scharfman, 2016). In mice, mossy cells have been demonstrated 
to have dorso-ventral specialisation. While dorsal mossy cells do not express CR and mainly 
innervate locally, ventral mossy cells are CR-positive, and they send distant axons to the 
contralateral ventral and ipsilateral dorsal hippocampus. On the other hand, human mossy cells 
in both the dorsal and ventral hippocampus do not contain CR but instead express cocaine-
amphetamine regulating transcript (CART) protein (Seress et al., 2008).    
The DGCs send their axons namely mossy fibres to innervate mossy cells and pyramidal neurons 
of the CA2 and CA3 with massive en passant mossy terminals along the axon (Acsady et al., 
1998). These large mossy boutons form multiple asymmetric synaptic contacts with specialised 
postsynaptic spines called thorny excrescences. The density and complexity of thorny 
excrescences of the hilar mossy cells are higher than that of pyramidal neurons in the CA3 
(reviewed in Dudek et al., 2016). Mossy fibres also travel along the hippocampal longitudinal to 
innervate the CA2 of the more ventral coordinate. However, the length is approximately half of 
the hippocampal length so the dorsal DGCs can send their axons down to the intermediate CA2 
and the intermediate DGCs to the ventral CA2. DGCs also innervate GABAergic interneurons with 
asymmetric synaptic contacts from filopodia extended from the mossy boutons and small 
boutons. The number of filopodia and small boutons together is approximately 10 times the 
number of mossy boutons.  
1.2.2.2    Functions    
The DG is involved in the pattern separation and possesses several characteristics befitting such 
function (reviewed in Deng et al., 2010; Petrantonakis and Poirazi, 2015). Pattern separation is 
a computational process that convert overlapping or similar inputs into less similar outputs. 
There are a higher number of neurons in the DGs than in the EC or the CA3. This is reminiscent 
of kernel methods in the support vector machine (SVM) that map given inputs to a higher 
dimensional space for better separation. In addition, lateral inhibition from the GABAergic 
interneurons, which are activated by either direct monosynaptic or mossy cell-dependent 
disynaptic inputs from the DGCs, facilitate sparse coding scheme such that only few DGCs can 
be activated at a given time. Mossy cells provide excitatory inputs to both DGCs and GABAergic 
interneurons especially PV-positive basket cells, but activation of mossy cells usually result in 
net inhibition for sparse activation of the DGCs (Jinde et al., 2012). A process inspired by mossy 
cell-mediated lateral inhibition has been shown to improve the performance of sparse 
approximation algorithm “Iterative Soft Thresholding” (Petrantonakis and Poirazi, 2015). These 
features together allow similar inputs to be encoded into distinct populations of DGCs. The firing 
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of DGCs is associated with stress (Snyder et al., 2011) and discrimination of spatial and temporal 
contextual information but is not related to speed or reward (Danielson et al., 2016).    
          
1.2.3 CA3  
1.2.3.1    Local cell types and architectures 
CA3 pyramidal neurons receive direct excitatory inputs and indirect interneuron-dependent 
disynaptic inhibitory inputs by mossy fibres of the DGCs (reviewed in Prince et al., 2016). CA3 
pyramidal neurons are large pyramidal neurons and exhibit vast and complex networks of 
intrahippocampal projections. Approximately 80% of all intrahippocampal presynaptic terminals 
are from the CA3 pyramidal neurons (Amaral and Witter, 1989). The majority 70% of axon 
terminals expectedly lie within the CA1 region; 28% of them are in the CA3 for recurrent 
signalling; and the remaining 2% for back projection to the DGCs and innervation to other 
neurons in the hilus (Wittner et al., 2007).   
GABAergic interneuron population in the CA3 are composed of numerous subtypes. Both basket 
and chandelier axo-axonic cells express PV but axo-axonic cells are SATB1- and SST-negative and 
some basket cells are also SST-positive (Viney et al., 2013).           
1.2.3.2    Functions    
Pattern completion is a process by which a network retrieves the whole memory patterns when 
triggered with partial inputs. Extensive network of recurrent synapses of CA3 enables a partial 
pattern that initially activate a subset of an ensemble of interconnected CA3 pyramidal neurons 
to recruit the remaining cells of the ensemble of which recurrent synapses have been 
potentiated by a more complete stimulus pattern (Lisman, 1999; Bush et al., 2010; reviewed in 
Rolls, 2018). Despite superficial similarity to the neocortical pyramidal cell network, CA3 
pyramidal cell network has lower connection probability (more sparse), more spatially uniform 
synapses, more enriched in disynaptic connectivity motifs, and smaller number of more effective 
functional synaptic contacts between individual CA3 pyramidal neurons (Guzman et al., 2016). 
These characteristics increase efficiency and precision of encoding especially by a relatively small 





1.2.4.1    Local cell types and architectures 
Among hippocampal neurons, CA2 pyramidal neurons exclusively express IgG-domain 
containing adhesion protein AMIGO2, plasticity-suppressing protein Regulator of G-protein 
signalling 14 (RGS14), Purkinje cell protein-4 (PCP4), and striatum-enriched protein-tyrosine 
phosphatase (STEP) (Hitti and Siegelbaum, 2014). Unlike CA3 pyramidal neurons that project to 
different CA1 sublayers equally, CA2 pyramidal neurons preferentially innervate deep layer 
calbindin-negative CA1 pyramidal neurons (Kohara et al., 2014). CA2 pyramidal neurons receive 
bilateral yet weak inputs from the CA3. Furthermore, CA2 pyramidal neurons send subcortical 
innervation to the MS/DB, dorsal part of the lateral septum (LSD), and SuM. Besides the MS/DB 
and SuM, the CA2 is also innervated by the paraventricular nucleus. While CA2 pyramidal 
neurons are also innervated by mossy fibres, unlike CA3 pyramidal neurons, they do not possess 
conspicuous thorny excrescences.        
1.2.4.2    Functions    
Optogenetic inhibition of CA2 pyramidal neurons has been demonstrated to completely impair 
social memory (Hitti and Siegelbaum, 2014). Perineuronal nets, high calcium buffering, and 
expression of RGS14 contribute to the restriction of LTP in the CA2 (reviewed in Benoy et al., 
2018). As a result, plasticity in the CA2 is tightly regulated by CA2-exclusive mechanisms. For 
example, both vasopressin from the paraventricular nucleus (Pagani et al., 2015) and substance-
P from the SuM (Dasgupta et al., 2017) mediate potentiation of social memory in the CA2.    
1.2.5 CA1 
1.2.5.1    Local cell types and architectures 
The CA1 has two layers of pyramidal neurons with distinct functionalities (reviewed in Soltesz 
and Losonczy, 2018). The early-born (E14) deep layer pyramidal neurons lack calbindin and 
receive stronger excitatory inputs from the MEC and CA2. Conversely, the late-born (E17) 
superficial pyramidal neurons express calbindin and receive excitatory inputs predominantly 
from the LEC and CA3. Multiplexed barcode scheme sequential fluorescence in-situ 
hybridisation (seqFISH) has provided an evidence of spatial heterogeneity in the CA1 pyramidal 
neuron population and demonstrated that the degree of heterogeneity increases along the 
dorsoventral axis (Shah et al., 2016). It was confirmed that seqFISH of the barcoded genes of low 
average abundance, excluding the genes of high expression, are sufficient to provide the same 
map of spatial heterogeneity (Shah et al., 2017).      
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CA1 is connected to the subiculum, both of which together serve as the main hippocampal 
output structures that convey information to the cortex and other parts of the brain. In addition, 
the activity of different subcortical systems is also linked through the CA1-subiculum path. For 
example, stimulation of dopaminergic neurons in the ventral tegmental area (VTA) but inhibition 
of dopaminergic neurons in the substantia nigra pars compacta (SNpc) in the midbrain by MS 
stimulation requires the ventral subiculum (Bortz and Grace, 2018).   
1.2.5.2    Functions    
Theta oscillations in the CA1 correspond to the separate phases of encoding and retrieval such 
that encoding occurs during the theta trough, but retrieval happens during the peak (reviewed 
in Hasselmo and Stern, 2014). During the encoding phase, both the CA3 and CA1 receive strong 
inputs from the EC but provide weak outputs to the CA1 and the cortex respectively. 
Transmission of the signals is low, but plasticity is upregulated for potentiation at several 
connections especially the CA3-CA1 synapse. During the retrieval phase, because of the prior 
potentiation, weak input can induce strong recurrent activation of the CA3 pyramidal neurons 
to intensely stimulate the CA1 pyramidal neurons to provide strong inputs to the entorhinal and 
frontal cortices.      
 
1.2.6 Distant projection from other brain regions 
The hippocampus receives considerable innervation from distant regions and can be considered 
on an anatomical and neurochemical basis. This innervation is summarised in Figure 1.5 and 
described in detail below.   
1.2.6.1    Glutamatergic innervation 
Glutamatergic neurons of the MS/DB innervate the CA1 to control locomotion, theta oscillation, 
and speed-correlated firing of CA1 pyramidal neurons (Fuhrmann et al., 2015). Locomotion-
dependent signals of these MS/DB glutamatergic neurons stimulate disinhibitory GABAergic 
interneurons of the alveus/oriens regions, likely the O-LM interneurons to suppress GABAergic 
interneurons of the SR and SLM that feedforward inhibit inputs from the Schaffer collateral 
(CA2/3) and perforant path (MEC LIII) to the CA1.  In short, elevated activity of MS/DB 
glutamatergic projection neurons increases firing rates of CA1 pyramidal neurons during faster 
locomotion.  
Glutamatergic neurons of the SuM in the hypothalamus innervate the CA2 and the IML of the 
DG (Pedersen et al., 2017). There are two types of hippocampal-projecting glutamatergic 
neurons in the SuM: GABA-coreleasing neurons and NOS1-expressing neurons. While GABA-
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coreleasing axons account for the majority of SuM-hippocampal tracts, NOS1-expressing 
innervation is more potent at inducing wakefulness than the GABA-coreleasing counterpart.  
Interestingly, ventral tegmental area (VTA) also contains projection neurons that express both 
VGluT2 and GAD65 and corelease glutamate and GABA in the DG and CA2 (Ntamati and Luscher, 
2016). However, unlike the band of SuM axons in the IML, VTA axons are dense in the outer 
layer of the GCL beneath the IML. Overall activation of VTA glutamatergic neurons decreases 
firing rates of the DGCs.  
The basolateral amygdala (BLA) also sends glutamatergic projections to the ventral 
hippocampus to modulate social behaviours and anxiety. Glutamatergic neurons of the BLA 
provide direct excitatory inputs to CA1 pyramidal neurons in the ventral hippocampus to induce 
anxiety (Felix-Ortiz et al., 2013). Nonetheless, glutamatergic inputs from the BLA also have 
indirect inhibitory effects by stimulating local GABAergic interneurons. Furthermore, 
optogenetic stimulation and inhibition of these glutamatergic projection neurons of the BLA has 
been shown to repress and enhance social behaviours respectively (Felix-Ortiz and Tye, 2014).   
1.2.6.2    GABAergic innervation 
All hippocampal sectors including the DG receive distant GABAergic innervation from the 
MS/DB. While all GABAergic projection neurons in the MS rhythmically fire action potential, 
their burst duration and rhythmicity are diverse across different subpopulations. PV-positive 
Teevra cells exhibit short burst duration but Komal cells exhibit long burst duration (Joshi et al., 
2017). During locomotion, firing rate of the Teevra cells increases, but that of Komal cells 
decreases. Interestingly, several subtypes of GABAergic neurons project to specific sectors of 
the hippocampus. For example, Teevra cells mainly project to cholecystokinin-positive 
interneurons and axo-axonic interneurons of the CA3. Inhibition of CA3 interneurons by the 
Teevra cells at the peak of the theta trough corresponds to the high signal transmission and 
firing probability of the CA1 pyramidal neurons.          
1.2.6.3    Cholinergic innervation 
The majority of cholinergic axons in the hippocampus arise from the Ch1 and Ch2 or the MS and 
VDB but some of the axons in the DG have cell bodies in the Ch3 or the HDB (Zhu et al., 2017). 
Cholinergic signalling has been shown to enhance theta wave (Vandecasteele et al., 2014). 
Activation of only BFCNs in the MS/DB induced frequency-dependent effects on non-cholinergic 
neurons of the MS/DB and hippocampal interneurons during behavioural inactive state but was 
not sufficient to significantly regulate hippocampal function during explorative behaviours 




1.2.6.4    Dopaminergic and noradrenergic innervation 
While the cortices are predominantly innervated by the dopaminergic neurons of the ventral 
tegmental area (VTA) in the midbrain (Hosp et al., 2011; Mingote et al., 2015; Popescu et al., 
2016), the hippocampus is mainly innervated by dopamine-coreleasing noradrenergic axons 
from the LC (Smith and Greene, 2012; Ermine et al., 2016; Takeuchi et al., 2016). These neurons 
express tyrosine hydroxylase (TH) but, unlike midbrain dopaminergic neurons, also contain 
dopamine-β-hydroxylase (DBH) and only have norepinephrine transporter (NET) instead of 
dopamine transporter (DAT) for taking up both noradrenaline and dopamine into presynaptic 
cytosol. Expectedly, noradrenergic axons from LC neurons in the cortex also corelease dopamine 
(reviewed in Devoto and Flore, 2006). The hippocampus is still innervated by VTA dopaminergic 
axons: sparsely in the DG and CA1, and more densely in the CA2 (Takeuchi et al., 2016). 
Interestingly, the distribution of VTA dopaminergic axons is similar to that of VTA glutamatergic 
axons (Ntamati and Luscher, 2016). This is congruent with the findings that approximately half 
of the VTA dopaminergic neurons also corelease glutamate (Taylor et al., 2014; Mingote et al., 
2015). Nonetheless, it should be noted that VTA dopaminergic neurons preferentially project to 
the ventral hippocampus (Kempadoo et al., 2016). Rabies virus propagation studies in the 
hippocampus (Ohara et al., 2013) and specifically in the DGCs (Vivar et al., 2012) show that 
dopaminergic and noradrenergic signalling in the hippocampus is prevalently mediated by 
volume transmission as it has been described in other brain regions (reviewed in Rice and Cragg, 
2008).   
1.2.6.5    Serotonergic innervation 
The dorsal and median raphe nuclei send serotonergic innervation to the hippocampus (Vertes 
et al., 1999; Teixeira et al., 2018). The density of serotonin (5-HT) terminals in the hippocampus 
is roughly half of that in the cortex but the most striking difference is that the cortical 5-HT 
synaptic incidence is approximately 30-40% but the synaptic incidence of 5-HT terminals in the 
hippocampus is lower from 0.5% (Descarries et al., 1990) to 8% (Umbriaco et al., 1995) in a single 
section. The evidence of volume transmission as a prominent mode of 5-HT signalling includes 
the very low number of serotonergic neurons that send monosynaptic inputs to the 




Figure 1.5 – Schematics of connectivity and functional inputs/outputs of the DG 
(Taken from Yun et al., 2016 with permission from Springer Nature, Appendix Table A.11) The DG is 
innervated (black lines) by the entorhinal cortex via PP and perirhinal cortex, medial septum, contralateral 
DG (not shown), recurrent CA3, and VTA/SN, LC, DR of the mid/hindbrain. The DG is also probably affected 
by multiple indirect circuitries (grey line). The hippocampus receives direct stress-associated inputs from 
the HPA (red lines) and indirect stress-related inputs from the HPA-innervated entorhinal cortex (dotted 
red line). DR – dorsal raphe; Ent – entorhinal cortex; LC – locus coeruleus; NAc – nucleus accumbens; PFC 
– prefrontal cortex; PP – perforant path; PRH – perirhinal cortex; SN – substantia nigra; VTA – ventral 
tegmental area.  
 
  
1.2.7 Comparative hippocampal features between human and mouse 
Antero-posterior longitudinal axis of the human hippocampus, unlike the dorso-ventral axis in a 
rodent, possibly results as an evolutionary adaptation to bipedal posture of human and primate 
(Figure 1.6). Human anterior DG has several folds while mouse DG consistently has a single fold 
along its longitudinal axis. While hilar mossy cells of the anterior/ventral hippocampus are the 
primary source of commissural axons between the two contralateral DGs in both primate and 
rodent, the density of DG commissural fibres in monkeys was much lower and mainly restricted 
to the anterior/ventral DG (Amaral et al., 1984). Commissural projections from the CA3-CA1 
were also found only in the anterior/ventral hippocampus of monkeys but more extensive in 
rodents. Limited functional commissural projections in humans were also reported as maximal 
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single pulse stimulation did not evoke detectable responses in the contralateral hippocampus 
(Wilson et al., 1990).   
Spatial representations in the primate hippocampus are different from that of rodents because 
of their different modes of vision.  Rodents have no fovea and up to 320° of visual field with 
limited eye movement control. Primates, on the other hand, have highly developed fovea and 
narrow fields of vision with flexible eye movement control to explore the environment. 
Therefore, rodents have neuronal representations of their locations namely place cells in the 
hippocampus whereas primates have spatial view representations namely spatial view cells 
(reviewed in Rolls and Wirth, 2018).   
Expression of some genes/proteins in hippocampal cells may be different across species 
including human and rodents. For example, mouse ventral mossy cells are CR-positive, but 
human mossy cells in both the dorsal and ventral hippocampi do not contain CR but instead 
express cocaine-amphetamine regulating transcript (CART) protein (Seress et al., 2008).    
 
Figure 1.6 – Comparison of hippocampal anatomy between human and mouse 
(Modified from Strange et al., 2014 with permission from Springer Nature, Appendix Table A.12) The 
longitudinal axes in human and mouse are anteroposterior and ventrodorsal respectively.   Scale bar = 1 






1.3.1 Background and epidemiology 
Dementia or the code 6D8_ by the 11th revision of the International Classification of Disease 
(ICD-11) (WHO, 2018) or major neurocognitive disorder by the 5th Diagnostic and Statistical 
Manual on Mental Disorders (DSM-V) (Association, 2013)  is a syndrome characterised by 
progressive decline in cognitive performance with impairment in at least two of the following 
cognitive domains: memory, executive functions, attention, language, social cognition and 
judgment, psychomotor speed, and visuospatial abilities. Aging alone cannot account for the 
impairments and these impairments have to debilitate daily life activities.  
Dementia due to Alzheimer’s disease (AD) or 6D80 by ICD-11 (WHO, 2018) is a progressive 
neurodegenerative disease and the most prevalent type of dementia. The current number of 
patients worldwide is around 35.6 million and it is predicted to increase up to 65.7 million in 
2030 (Wortmann, 2012). The causes of the disease remain elusive, but the major consistent 
characteristics include the following; gross cerebral atrophy; cell and synapse loss; amyloid 
depositions of misfolded proteins including extracellular plaques of β-amyloid protein (Aβ) and 
intracellular neurofibrillary tangles of hyperphosphorylated tau. 
Lewy body dementias consist of Dementia with Lewy bodies (DLB) and Parkinson’s disease with 
dementia (PDD), which share similar pathology but different clinical progression. In ICD-11, DLB 
or 6D82 is considered a separate type of dementia from PDD or 6D85.0, which belongs to the 
type of dementia due to other classified diseases (WHO, 2018). DLB is the second most prevalent 
type of dementia, estimated to account up to 15% of all dementia cases (Aarsland et al., 2008). 
For PDD, a systematic review of prevalence studies conservatively estimates the dementia 
frequency of 24% in all PD patients (Aarsland et al., 2005). On the contrary, prospective studies 
over a period of 8 (Aarsland et al., 2003) and 20 years (Hely et al., 2008) reported that 75% and 
80% of PD patients developed dementia respectively. Pathological hallmarks of both DLB and 
PDD are intracellular inclusions predominantly composed of α-synuclein in neuronal cell bodies 
namely Lewy bodies and dystrophic neurites that contain α-synuclein-rich inclusion namely 
Lewy neurites (Spillantini et al., 1998). DLB and PDD patients may also have AD-associated 
pathological features such as Aβ neuritic plaques and tau neurofibrillary tangles albeit generally 
in milder extents (Duda, 2004; Howlett et al., 2014). Atrophy in the medial temporal lobe (MTL) 
(Burton et al., 2009) may also be present, especially in the hippocampus and amygdala (Burton 
et al., 2012) of DLB/PDD patients, but to a lesser degree compared with those of AD patients.  
As DLB and PDD share multiple similarities, they are distinguished from each other by the onset 
of dementia relative to Parkinsonism. According to this ‘1-year rule’, DLB is diagnosed if 
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dementia manifests earlier than Parkinsonism or after Parkinsonism for at most 1 year (McKeith 
et al., 2005; McKeith et al., 2017).  
   
1.3.2 Symptoms 
1.3.2.1    AD overview 
Typical AD symptoms include progressive loss of memory together with visuospatial and 
executive functions and eventually impaired functional independence. Other important non-
amnestic symptoms in language domains include deficits in word finding and category naming 
(reviewed in Stilwell et al., 2016).  Declarative memory, in which implicated by the temporal lobe 
including hippocampal and parahippocampal structures, is significantly affected. Patients may 
forget the locations of objects, conversations, time-related elements such as appointments 
(Erkkinen et al., 2018). Procedural memory, however, is less impaired. In addition to these 
cognitive symptoms, a range of non-cognitive changes, including changes in behaviour and 
mood, form parts of the syndrome of dementia (reviewed in Kratz, 2017). The most prominent 
and most frequently occurring of these symptoms are depression and apathy (reviewed in 
Ballard et al., 2009). Less common but particularly troublesome symptoms include agitation, 
aggressive behaviour, night-time wandering, and psychosis  
The original criteria from the National Institute of Neurological and Communitive Disorders and 
Stroke and Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) has low 
specificity and sensitivity of 70% because it strictly required amnestic symptoms (McKhann et 
al., 2011). Atypical symptoms were later included to improve the criteria. These non-amnestic 
variants are caused by degeneration of brain regions other than the medial temporal lobe.  For 
example, damaged frontal cortex is associated with impaired executive functions and abnormal 
behaviours such as apathy and disinhibition. Atrophy of posterior cortical areas leads to occipito-
temporal-associated visuospatial deficits such as face and word recognition and parietal-
associated visuospatial impairment. In terms of language skills, word retrieval and sentence 
repetition become significantly difficult despite relatively normal motor speech programming 
and semantic knowledge (McKhann et al., 2011).    
1.3.2.2    Mild cognitive impairment (MCI) overview 
Mild cognitive impairment (MCI) describes a condition with cognitive deficits that are not 
sufficiently severe to be diagnosed as dementia. Core clinical criteria for diagnosis of MCI have 
been established by the National Institute on Aging and the Alzheimer’s Association (NIA-AA) 
(Albert et al., 2011). Patients should have concerns over their cognitive changes and exhibit 
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evidence of deficits in at least one cognitive domain. These domains include memory, 
visuospatial skills, executive function, attention, and language. In this regard, AD-transitioning 
MCI patients commonly have impaired episodic memory. Importantly, MCI patients retain 
independence in activities of daily living. While not all MCI cases progress to dementia, most 
MCI cases develop dementia especially AD (Villemagne et al., 2011b).  
1.3.2.3    DLB and PDD overview 
Parkinsonism in DLB and PDD compared with cognitively healthy PD displays stronger degree of 
postural instability and gait difficulty, but less rest tremors (reviewed in Erkkinen et al., 2018). 
With respect to the above pattern, DLB exhibits poorer motor balance and less frequent tremor 
compared with PDD. DLB and PDD share most dementia-associated deficits in executive 
functions, visuospatial skills, memory retrieval, mood disturbance, REM sleep behavioural 
disorder, and neuroleptic sensitivity.  Fluctuation, delusions, and visual hallucination are more 
frequent in DLB and PDD than controls and AD. Fluctuation in DLB affects arousal, attention, and 
cognition. Visual hallucinations are also spontaneous in DLB but may be induced by levodopa 
treatment in PDD. PDD patients have high mortality rate of approximately 4 years after 
dementia manifestation while the survival time of DLB is slightly longer at 5-9 years. The recently 
revised (McKeith et al., 2017) and previous (McKeith et al., 2005) criteria advise that the 
dementia onset must be earlier than a year period after the parkinsonism onset for the diagnosis 
of DLB instead of PDD.    
 
1.3.3 Cognitive and behavioural tests 
A general cognitive assessment may include the follow procedures. Subjects are examined either 
at the neuropsychiatric memory department or clinic of the hospital or at home by experienced 
psychiatric nurses. The examination covers psychiatric symptoms, personality changes, 
executive functions, aphasia, ataxia, agnosia, and both short and long-term episodic memory. 
This may include interviews of key informants after consent especially for the information on 
family history of dementia, stroke, transient ischemia attack, and education. Final scorings of 
the examination are assigned by a geriatric psychiatrist or neurologist. Definite clinical 
characteristic in DLB and PDD that is not found in AD is spontaneous parkinsonism. Core features 
of parkinsonism are combination of bradykinesia, a decrease in movement amplitude or speed, 
and of either rest tremor or rigidity or both (Postuma et al., 2015; McKeith et al., 2017).     
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1.3.3.1    CDR 
The Clinical Dementia Rating (CDR) assesses the performances in six cognitive ad functional 
domains with a 5-point scale: 0 = normal, 0.5 = very mild, 1 = mild, 2 = moderate, 3 = severe 
(Morris, 1993). The six domains are memory, orientation, judgment & problem solving, 
community affairs, home & hobbies, and lastly personal care. Its fine scale allows this test to 
diagnose even patients with very mild cognitive impairment. Nonetheless, assessment protocol 
of the CDR, including patient interview and gathering data from collateral sources, can be time-
consuming. The test is subjective by nature and therefore reportedly less sensitive to 
longitudinal changes. Nonetheless, the sum of CDR six domains or boxes or CDR-SOB was shown 
to efficiently indicate progression of AD (O'Bryant et al., 2008).   
1.3.3.2    MMSE 
The Mini Mental State Examination (MMSE) is the most commonly used questionnaire that was 
first designed to provide fast numerical evaluation of cognitive performance (Folstein et al., 
1975). MMSE has a total score of 30 that can be divided into 3 ranges of cognitive performance 
levels: cognitively healthy [24-30], moderately impaired [11-23], and severely impaired [0-11].  
MMSE can be used to distinguish MCI from AD and healthy controls based on cut-off scores 
(Roalf et al., 2013) but it is still unsuitable for diagnosing DLB because it does not have criteria 
for DLB-relevant symptoms such as visual hallucinations or fluctuating cognition (McKeith et al., 
2005).       
1.3.3.3    ADAS-Cog 
The Alzheimer’s disease assessment scale-cognition sub-scale (ADAS-Cog) was primarily 
designed to measure 11 cognitive and 10 non-cognitive domains in dementia patients (Rosen et 
al., 1984). It has become the most widely used measure for the effectiveness of dementia clinical 
trials. The 11 cognitive items are as follows: 1) spoken language ability, 2) comprehension of 
spoken language, 3) recall of test instructions, 4) word-finding difficulty, 5) following commands, 
6) naming: objects, fingers, 7) constructions: drawing, 8) ideational praxis, 9) orientation, 10) 
word recall, and 11) word recognition. Despite its prediction capacity for AD, effectiveness of 
the classic ADAS-Cog for assessment in MCI patients seemed limited (Skinner et al., 2012). 
Multiple approaches have been tested to improve the assessment power of ADAS-Cog for MCI 
including the random forest-based         
1.3.3.4    NPI 
The Neuropsychiatric Inventory (NPI) questionnaire is a survey of non-cognitive behavioural and 
mood changes in dementia (Cummings, 1997). It is designed to be completed on a monthly basis 
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by an informant who takes care of the patient on 12 domains, night-time behaviour changes, 
appetite/eating changes, and 10 standard neuropsychiatric domains: hallucination, delusion, 
agitation/aggression, dysphoria/depression, anxiety, irritability, disinhibition, euphoria, apathy, 
and aberrant motor behaviour. The NPI is one of the most commonly used assessments of non-
cognitive behaviours and mood and It is relatively neither difficult to use nor time-consuming 
(Cummings, 1997). Moreover, some of its domains are specific to certain types of dementia and 
hence useful for dementia diagnosis, for example, euphoria is rare in AD. Nonetheless, the 
scoring is prone to personal bias of the caregiver and it cannot effectively rate the severity of 
dementia (de Medeiros et al., 2010).  
1.3.3.5    Differential cognitive diagnostic tests 
Impairment in attention, executive function, and visual processing are more severe relative to 
naming and memory deficits in DLB and PDD than in AD (McKeith et al., 2017). Trail-making tests 
and Stroop tasks are for attention and executive function assessment. Visual processing deficits 
can be detected by figure copy, visual assembly, spatial matching, size matching, and perceptual 
discrimination tasks. Story recall and confrontation naming tasks can be implemented to 
measure naming and memory performance. Patients generally have difficulties identifying their 
state of fluctuation themselves but a questionnaire on certain symptoms such as 
absentmindedness, daylight drowsiness, and disorganised speech can reflect the extents of 
fluctuation in DLB.     
  
1.3.4 In vivo Biomarkers and imaging 
1.3.4.1    Brain structural imaging  
Computed tomography or a CT scan produces cross-sectional images of a brain from a 
combination of X-ray results. According to the diagnostic guidelines by the National Institute on 
Aging-Alzheimer Association, medial temporal lobe atrophy visualised by structural imaging is 
an important marker to diagnose AD (McKhann et al., 2011). CT scan is cheaper and requires 
shorter procedure and assessment time. While CT scan alone cannot diagnose AD patients with 
relatively spared MTL volume, it still can improve the diagnostic ratios in combination with other 
procedures (Firbank et al., 2016).     
Magnetic resonance imaging (MRI) applies the concepts of nuclear magnetic resonance by 
detecting different frequencies of hydrogen atom-emitted resonant signals which are influenced 
by electronic environment surrounding those hydrogens within their respective molecules. Fat 
and water have different T1 and T2 relaxation phase properties. Therefore, MRI distinguishes a 
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composition of these molecules in each brain anatomical area i.e. signals in the lipid-enriched 
white matter are higher than in the cortex during T1-weighted visualisation. Fat loss and water 
composition gain from demyelination and lesions are detectable by MRI. Presymptomatic 
patients who later developed AD had progressive atrophy in the medial temporal lobe (Fox et 
al., 2001). Global sulcal index and the span of the lateral sulcus were more sensitive for detecting 
the early stages of AD than cortical thickness and subcortical volume (Cai et al., 2017). Relative 
preservation of the medial temporal lobe from CT or MRI scan is also a supportive biomarker of 
DLB diagnosis (McKeith et al., 2017).           
Higher static field strength allows visualisation with greater resolution. An increase from 1.5 
Tesla (T) to 3T facilitates detection of volume disparity of hippocampal subfields between 
disease groups (Chow et al., 2015). A 7T MRI offers a better imaging resolution but also impose 
a challenge of how to efficiently control field homogeneity and minimise distortion given a 
considerable increase in static field strength (reviewed in McKiernan and O'Brien, 2017). 
Notwithstanding, 7T-increased resolution has so far been sufficient to detect abnormalities 
which have not been observable in vivo but have been confirmed postmortem e.g. a significant 
decrease in the thickness of CA1 apical neuropil layer or stratum radiatum and stratum 
lacunosum-moleculare in mild AD patients compared with controls (Kerchner et al., 2010).   
 
1.3.4.2    Radiolabelled ligands neuroimaging with PET and SPECT 
Positron emission tomography (PET) and single photon emission compound tomography 
(SPECT) are nuclear medicine imaging techniques that measure gamma radiation from 
radioisotope-containing compounds often called tracer which had been injected into patients.  
One of the most well-known PET tools is radioactive glucose analogue [18F]fluorodeoxyglucose 
(FDG) which has been implemented to evaluate tissue metabolism in terms of glucose uptake. 
As 2-OH group is required for conversion to fructose in glycolysis, [18F]FDG of which 2-OH is 
substituted by 18F cannot be further metabolised. The uptake of glucose or [18F]FDG is recently 
demonstrated to be driven by GLT-1 (glutamate transporter 1)-dependent transport of 
astrocytic glutamate (Zimmer et al., 2017). The potential of FDG-PET in diagnosis will be 
reviewed further in the next section 1.1.4.3 on brain activity imaging.        
Pittsburgh compound B ([11C]PiB) was the first Aβ-selective ligand used in PET scan to visualise 
brain amyloid deposition (Klunk et al., 2004). Although [11C]PiB is a thioflavin analogue, it does 
not bind to amyloid fibrils of tau or α-synuclein. Retention of [11C]PiB is increased in specific 
regions of AD patient brains including frontal, parietal, temporal, occipital cortices, 
parahippocampal regions, anterior cingulate gyrus, and striatum (Klunk et al., 2004). Several 
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studies have confirmed the association between postmortem amyloid deposition and [11C]PiB 
results in human cases (Burack et al., 2010; Sojkova et al., 2011; Kantarci et al., 2012) especially 
in AD cases with region-matched analyses (Ikonomovic et al., 2008). High [11C]PiB may 
potentially predict conversion of MCI to AD as 67% (30/45) of high [11C]PiB MCI cases progressed 
to AD compared with only 5% (1/20) of low [11C]PiB MCI (Villemagne et al., 2011b). There was 
an inverse correlation between baseline episodic memory performance and Aβ burden 
especially in MCI patients. The increase in neocortical Aβ deposition is correlated with the 
number of ApoE ε4 alleles and the decline in MMSE score, but not the episodic memory 
performance deficits 
With a short radioactive half-life of 20 mins, long scanning time of 30 min, and limited 
production of 11C, [11C]PiB is deemed impractical for clinical purposes (Yeo et al., 2015). This 
results in the development and practical investigation of the following three novel compounds 
that contain a 110-min long half-life radioisotope 18F with reliable diagnostic odds-ratio: 
[18F]florbetapir, [18F]florbetaben, and [18F]flutemetamol (Villemagne et al., 2011a; Clark et al., 
2012; Yeo et al., 2015).    
Challenges in tau imaging stem from diversity in strains of tau aggregates (e.g. AD neurofibrillary 
tangles, Pick bodies, astrocytic plaques, tufted astrocytes, argyrophilic grains), maturity of tau 
deposits (e.g. pre-, mature-, ghost-tangles), and splicing isoform ratio (3R: 4R) in different 
tauopathies (reviewed in Leuzy et al., 2019). Regardless, development of tau PET tracer has been 
steadily progressing with promise. The first-generation ligands are [18F]THK5317, [18F]THK5351, 
[18F]AV1451 (or [18F]flortacipir), and [11C]PBB3. The second-generation ligands – [18F]MK-6240, 
[18F]RO-948, [18F]PI-2620, [18F]GTP1, [18F]PM-PBB3, [18F]JNJ64349311, and [18F]JNJ-067 – were 
developed since first-generation ligands have off-target binding affinity to dense Aβ plaques or 
MAO-B (monoamine oxidase B). Furthermore, imaging of tau does not always follow the 
pathological Braak staging (reviewed in Leuzy et al., 2019). Taken together these concerns mean 
that further research is needed before these ligands can become part of routine clinical workup 
of dementia diagnosis.  
It can be difficult to differentiate DLB from AD especially prior to the manifestation of motor 
symptoms and hence the development of supporting diagnostic tests has been a priority. 
Autoradiography imaging on cryostat sections with a D2 receptor specific ligand [3H]raclopride 
showed significantly reduced D2 binding in the caudal putamen in DLB cases compared with 
controls and in all levels of the basal ganglia compared with PD; and there was no change 
between AD and controls (Piggott et al., 1999). SPECT for a presynaptic dopamine transporter 
ligand [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (FP-CIT) a cocaine 
analogue has been implemented for imaging for dopaminergic system and it has demonstrated 
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significantly reduced retention in the DLB patients compared with AD and controls (Walker et 
al., 2007; Walker and Walker, 2009). Neuropathological autopsy following the [123I]FP-CIT scan 
within a 10 year period confirmed the promising specificity and sensitivity of 88% and 100% 
respectively (Walker et al., 2007). PET imaging for VMAT2-specific ligand [18F]AV-133 showed 
significantly decreased retention in DLB and PD cases compared with controls and no difference 
between AD and controls (Villemagne et al., 2012). 
1.3.4.3    Functional brain imaging: FDG-PET, 99mTc-HMPAO SPECT, and fMRI 
Glucose hypometabolism detected by  [18F]FDG-PET  in AD is prevalently found in the medial 
temporal cortices, the posterior lateral part of the temporal lobe, the posterior cingulate gyrus, 
the inferior parietal lobule, and the precuneus (De Santi et al., 2001). In the parietal region, 
[18F]FDG retention is also negatively correlated with amyloid burden measured by [11C]PiB 
(Edison et al., 2007). Optimisation of single-subject statistical parametric mapping [18F]FDG-PET 
enables significant prediction of MCI conversion to either AD and FTLD in each individual 
(Caminiti et al., 2018). The DLB- and AD-like patterns of hypometabolism have been 
demonstrated as best predictors for dementia progression in PD cases (Pilotto et al., 2018). 
Benefits of in vivo imaging include an opportunity of a longitudinal study. A study on 8 AD 
patients showed that signal of [11C]-(R)-PK11195, a ligand of neuroinflammatory microglial 
activation marker TSPO (18-kDa translocator protein), is inversely correlated with [18F]FDG-PET 
signal but positively correlated with [11C]PiB over disease progression (Fan et al., 2015).       
Regional cerebral blood flow is measured by SPECT imaging of 99mTc-HMPAO in the brain and is 
correlated with brain regional metabolism. The general gradient of cerebral perfusion is the 
same for both AD and control groups with low perfusion in the hippocampus and the highest in 
the striatum, thalamus, and cerebellum; and there is no difference between AD and controls in 
those mentioned regions (Trollor et al., 2005). In the prefrontal cortex, AD cases exhibit bilateral 
reduction of blood flow in the frontal pole and unilateral reduction in the left dorsolateral 
region. Cerebral perfusion SPECT helps improve the specificity of episodic memory score to 
predict MCI-AD progression (Quaranta et al., 2018). Combination of EEG-biomarkers and 99mTc-
HMPAO SPECT with machine learning technique also show potentials for diagnosis of amnestic 
disorders: AD, MCI, DCI, and SCC (Höller et al., 2017).    
PET imaging is a potentially invaluable tool to observe in vivo cholinergic degeneration. 
Degeneration of the cholinergic system in AD was one of the earliest neurochemical changes 
discovered in AD (Bowen et al., 1976). Vesamicol is a high-affinity binding ligand to vesicular 
acetylcholine transporter (VAChT) and multiple derivatives/analogues have been developed as 
potential PET ligands. Benzovesamicol was found to have higher affinity than vesamicol (Rogers 
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et al., 1989) and several analogues of benzovesamicol such as [123I]-iodobenzovesamicol and 
[18F]-Fluoro-ethoxybenzovesamicol (FEOBV) have been widely in multiple human brain imaging 
studies (Aghourian et al., 2017; Mazère et al., 2017; Nejad-Davarani et al., 2018). For CHT-1, only 
[3H]-hemicholinium has been used in several research studies on animal models and human 
autopsy but not human in vivo screening (Bissette et al., 1996; Noshita et al., 2015).                
 
1.3.4.4    Cerebrospinal fluid and blood-based biomarkers   
Cerebrospinal fluid (CSF) is generally collected from the lumbar spinal cord by lumbar puncture. 
The use of CSF biomarkers as an adjunct to the differential diagnosis of dementia has been 
increasingly popular, especially in Scandinavian countries (Simonsen et al., 2017). While there is 
not enough evidence to evaluate cost effectiveness of CSF biomarker procedure, complications 
of lumbar puncture are not significant and are considered by many outweighed by its diagnostic 
benefits. To date the focus of these biomarkers has been two of the neuropathological hallmarks 
of AD, Aβ and hyperphosphorylated tau. There are currently no definite diagnostic cut-offs for 
Aβ (AD ~ 50% of control), total tau (AD ~ 250% of control), and p-tau (AD ~ 200% of control) but 
the sensitivity for AD and prodromal AD can be higher than 90% (reviewed in Blennow, 2017).   
Linear scaling values of [11C]PiB is also negatively correlated with the level of Aβ42 in the CSF 
(Leuzy et al., 2016). Reduction in CSF Aβ42 level even without detectable amyloid burden PET is 
correlated with abnormal connectivity in the default mode network (DMN) (Pereira et al., 2018). 
DMN refers to connected brain regions with highly correlated activity as follow: the medial 
temporal lobes, the medial prefrontal cortex, the posterior cingulate and precuneus, and the 
bilateral angular gyri. However, it was also demonstrated that Aβ burden PET outperformed CSF 
Aβ42 and phosphorylated tau in predicting MCI progression to dementia (Caminiti et al., 2018). 
While CSF Aβ42 with a cut-off of 507.5 pg/ml could differentiate AD from stable MCI and that 
reduction in CSF Aβ42 was correlated with the hippocampal atrophy, lateral ventricle volume, 
and white matter lesion, CSF Aβ42 alone is still not a biomarker to efficiently diagnose AD from 
PDD or DLB (Janelidze et al., 2016). On the other hand, decreased CSF Aβ42/Aβ40 and 
Aβ42/Aβ38 ratios with cut-offs of 0.10 and 0.29 respectively were demonstrated to be 
diagnostic biomarkers of AD not DLB/PDD. The same study also reported that patients with 
DLB/PDD or vascular dementia had lower levels of the three Aβ isoforms in the CSF, supporting 
an idea that an exclusive decrease in CSF Aβ42 is specific to AD.  
Screening for blood biomarkers have been continuously investigated in the hope that a test that 
was less invasive than those based on CSF could be developed for diagnosis. One definite 
diagnostic factor has not yet been discovered as most studies showed diagnostic power only 
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from multivariate analysis combining multiple blood factors together (reviewed in Henriksen et 
al., 2014; O'Bryant et al., 2015). Several caveats of these studies include unclear effects of 
demographic variables on these factors, unstandardised methodologies, difference among 
cohorts, and model overfitting.       
 
1.1.4.5    Biological definition of AD 
Definite AD can only be confirmed by the evidence of Aβ and tau pathology after brain autopsy. 
Amnestic multidomain dementia was historically a diagnostic feature for “probable AD”, which 
was often referred to as “AD”. However, amnestic multidomain dementia does not guarantee 
postmortem AD characteristics or vice versa. These observed inconsistent sensitivity and 
specificity led to an establishment of biological definition of AD based on in vivo biomarkers by 
the NIA-AA (Jack et al., 2018). This system allows an individual to be categorised as AD patient 
for exhibiting biomarkers despite not having clinical features. The AT(N) system consists 3 
categories of biomarkers: A for aggregated Aβ including high amyloid PET burden, low CSF Aβ42, 
or CSF Aβ42/Aβ40 ratio; T for aggregated tau including [18F]flortaucipir PET burden or CSF 
phosphorylated tau especially pThr181; and N for neurodegeneration including MRI, low FGD-
PET, or high CSF total tau. The criteria of each category can be satisfied by either CSF biomarker 
or brain imaging. Biological definitions of AD based on the combinations of the AT(N) system are 






Syndromal cognitive stages 












A- T- (N)-           normal AD biomarkers 
A+ T- (N)-             Alzheimer’s pathologic change 
A+ T- (N)+ Alzheimer’s and concomitant suspected non-Alzheimer’s pathologic change 
A+ T+ (N)-          Alzheimer’s disease 
       Preclinical AD                            Prodromal AD                    AD with dementia A+ T+ (N)+ 
A- T+ (N)-          non-Alzheimer’s pathologic change 
A- T- (N)- 
A- T+ (N)- 
Table 1.2 – Biomarker profiles combined with syndromal cognitive staging 
(Modified from Jack et al., 2018) There are 3 general groups of AT(N) biomarker profiles: 1) normal AD 
biomarkers (no colour), 2) Alzheimer’s continuum (grey), 3) non-Alzheimer’s pathologic (dark grey). In the 
grey shading gradient area, darker gradient indicates higher rate of short-term clinical progression. Non-
Alzheimer’s pathologic change groups are not included because their rates of cognitive decline have not 
been well characterised.      
 
In support of the concept shown in Table 1.2 that biological AD patients with neurodegenerative 
markers have higher predisposition to cognitive decline, a recent study found that preclinical AD 
patients (A+T+N±) had significantly lower (N) markers specifically CSF neurofilament and total 
tau than both prodromal and demented AD together (Merluzzi et al., 2018). These cognitive 
deficit-associated markers of neuronal damage seem to be independent of glial activation and 
synaptic dysfunction as well.               
 
1.3.5 Pathology 
At postmortem the brains of AD patients have marked reduction in cortical gyrification and 
widening of sulci except the intraparietal sulcus, both of which were significantly correlated with 
MMSE score (Liu et al., 2012b). During the early stage of AD, atrophy occurs in the entorhinal 
cortex (EC), inferior and middle temporal gyrus, fusiform gyrus, and precuneus (Braak and Braak, 
1991; Parker et al., 2018). At a microscopic level, AD is characterised by the presence of Aβ 
deposition, some in the form of neuritic plaques and intracellular inclusions of 
hyperphosphorylated tau. The pattern and extent of these changes has formed the basis of 
various diagnostic classifications ADD Thal and Braak references.  Postmortem neuropatho-
logical studies also found cognitive deficit-correlated synaptic loss and dendritic degeneration 




In 2012, the NIA-AA established a practical guide (Montine et al., 2012) for the revised 
neuropathological assessment criteria for AD (Hyman et al., 2012). The 2012 NIA-AA guidelines 
measure the extent of neuropathology in a composite ABC score system: Thal phases of amyloid 
deposition (A), Braak stages of NFT (B), and Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) neuritic plaque score (C).  
A common characteristic of several neurodegenerative disease proteins such as Aβ, tau, and α-
synuclein is their ability to form a cross-β rich amyloid fibril aggregate (reviewed in Knowles et 
al., 2014). In an amyloid fibril, each monomer is linked to one another by a hydrogen-bond rich 
β-sheet interaction. A segment that forms a β-sheet is called a β-strand and is naturally oriented 
perpendicular to the longitudinal axis of the fibril. Interestingly, these proteins also form smaller 
oligomeric aggregates that may have different conformations and β-sheet configurations among 
monomers than fibrils but also possess capacity to transform into fibril seeds. Theoretically, 
there are 3 ways of new aggregate unit formation: 1) primary nucleation where monomers 
aggregate into an oligomer; 2) secondary nucleation where amyloid fibril catalysed the 
oligomerisation of monomers; and 3) fragmentation where a fibril is broken down into several 
smaller ones and more fibril ends are exposed for elongation.                  
1.3.5.1    Tau 
Tau protein is encoded by MAPT (microtubule-associated protein tau) gene on human 
chromosome 17q21. The longest isoform htau40 or 2N4R contains two 29-residue-long N-
terminal (N) regions and four 31-residue almost-identically repeated (R) sequences. There are 6 
isoforms of tau generated by alternative splicing combination at N-sequence (no exon2-3, only 
exon2, or both) and R-sequence (having or lacking R2 encoded by exon10). The repeated R 
sequences together with the second proline-rich region constitute a microtubule assembly 
domain. The PHF6* motif (VQIINK) and PHF6 motif (VQIVYK) on the R2 and R3 sequences 
respectively play an important role in aggregate seeding and oligomer formation (Li and Lee, 
2006). Hyperphosphorylation has been implicated in aggregation and pathogenicity of tau, but 
the exact order and interaction of these phosphorylation sites still require further investigation. 
Phospho-S262 (pS262) has been found in both age-matched healthy controls and AD patients 
(Seubert et al., 1995), but also shown to induce separation from microtubule (Drewes et al., 
1995). It also has been shown that phosphorylation sites recognised by AT8 and AT100 were 
preceded by phosphorylation at S231 (Luna-Munoz et al., 2007). On the other hand, a study has 
shown that most tau aggregates in AD patient – including those with conformational changes 
recognised by Alz50, pS262, and C-terminal truncation at E391 and D421 – contain pS396 and 
pS404 (Mondragón-Rodríguez et al., 2014).  
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Both pS199 of the AT8 epitope and pS396 of the PHF-1 epitope, highly associated with AD, 
belong to the same motif sequence of Y-X-pS-P that are stabilised in a β-strand conformation 
(Chukwu et al., 2018). Under the amyloid configuration, Tyrosine residue of the motif (Y197, 
Y394) also partially hinders the phosphatase PP2A from dephosphorylating the phosphor-serine 
residue of the motif.  
Soluble high molecular weight (HMW) phosphorylated oligomeric tau species, classified by a 
minimum size of 669 kDa with size-exclusion chromatography, have been found in the brains of 
AD patients and have been demonstrated to be actively taken up by neurons, transported along 
the axon, and transferred to other neurons via synapses (Takeda et al., 2015). Phosphorylation 
of HMW tau promoted its neuronal uptake but there was no immediate cytotoxic effect from 
neuronal uptake and subsequent intracellular aggregation of tau. These HWM tau species have 
high seeding activity and are detectable in the ventricular and lumbar CSF from the AD patients 
(Takeda et al., 2016).      
Native disordered tau proteins have been demonstrated to accumulate and form droplets with 
different liquid phase from the cytoplasm (Wegmann et al., 2018). Hyperphosphorylation was 
shown to accelerate droplet formation that in turn seeded aggregation. Although neuronal 
uptake of tau proteins mediates propagation of pathological tau aggregates during disease 
progression, a recent study showed that healthy neurons efficiently endocytosed monomeric 
and aggregated tau via dynamin-dependent mechanism (Evans et al., 2018). This finding 
suggested that tau neuronal uptake is a physiological process.      
Braak staging of tau pathology was first based on spatiotemporal pattern of Gallyas advanced 
silver-iodate staining on polyethylene glycol-embedded 100-µm thick sections (Braak and Braak, 
1991), which are inconvenient for routine diagnostic procedures. Braak staging was later revised 
to employ immunohistochemical staining of AT8 antibody (pS199, pS202, and pT205) that can 
be applied to conventional samples especially thin paraffin-embedded sections (Braak et al., 
2006). NFTs first appear in the transentorhinal region and entorhinal cortex, then spread to the 
hippocampus starting from CA1, CA2-3, CA4, to lastly DG (Figure 1.7) and subiculum. In the 
isocortical domains, NFTs propagate from the occipito-temporal gyrus, insular cortex, isocortical 
association areas, to occipital peristriate and striate areas (Table 1.3). In the subcortical domains, 
NFTs are first developed in the locus coeruleus, antero-dorsal nucleus of the thalamus, basal 
magnocellular complex or Ch3 (MCPO/HDB)-Ch4 (nbM/SI) of the basal forebrain, and amygdala. 
They are later spread to other parts of the thalamus, hypothalamus, and later basal ganglia.  
































         
I 0, + 0, + 0, + 0, + 0, + +, +++ 0, + 0, + 
II 0, + 0, + 0, + 0, + +, +++ ++, +++ 0, + +, +++ 
III 0, + 0, + 0, + ++, +++ ++, +++ ++, +++ ++, +++ ++, +++ 
IV 0, + 0, + ++, +++ ++, +++ ++, +++ ++, +++ ++, +++ ++, +++ 
V 0, + ++, +++ ++, +++ ++, +++ ++, +++ ++, +++ ++, +++ ++, +++ 
VI ++, +++ ++, +++ ++, +++ ++, +++ ++, +++ ++, +++ ++, +++ ++, +++ 
Table 1.3 – Four brain regions stained with AT8 for Braak stage assessment 
(Modified from Alafuzoff et al., 2008) Whole cross-sectional views of 4 brain regions dissected into blocks 
for AT8 immunohistochemistry: 1 – the occipital cortex with calcarine fissure; 2 – the temporal cortex 
with the middle and superior temporal gyri; 3 – the anterior hippocampus at the level of uncus; and 4 – 
the posterior hippocampus at the level of the lateral geniculate nucleus.  
 
Gallyas silver-iodate technique and AT8 staining are mostly matched and either is valid for Braak 
staging. Nonetheless, some cells and their neurites contain “pretangle” tau aggregates which 
are not dense enough to be detected by silver staining. For examples, AT8 staining detects 
numerous CA3 pyramidal neurons and CA4 hilar mossy cells at Braak III but a large number of 
these cells are detectable by the silver staining only after Braak IV (Figure 1.7). DG granule 
neurons start to develop argyrophilic or silver-stained NFTs only at Braak V, but they have been 
shown to express AT8 immunoreactive pretangle since Braak III. Neurons of the locus 
coeruleus/subcoeruleus may also express pretangle tau aggregate even as early as in teenagers 





Figure 1.7 – A graph showing approximate tau pathology severity in different hippocampal 
regions 
(Modified data from Braak and Braak, 1991 and Braak et al., 2006) The data described in these papers 
provided the extent and pattern of the staining in each hippocampal sector by silver technique (Ag) Braak 
and Braak, 1991 and AT8 antibody Braak et al., 2006. These data have been interpolated as the above 
graphical smooth curves with respect to the Braak stages. Plateaus are commonly present in this graph 
between consecutive Braak stages because of overlapping staining intensity score and not necessarily the 
actual steady rate of tau propagation. The striking contrasts between the two methods manifest in the 
CA3 and the DG, where AT8-positive tau structures develop much earlier than argyrophilic dense NFT.    
 
Despite the presence of early AT8-positive tau in the LC, the pathogenicity of these pretangles 
was not measured. A procedure to measure and compare seeding and propagation capacity of 
tau aggregates in different brain regions would be beneficial to exploring critical brain regions 
in the progression of tau pathology.  Cell culture "biosensor" has been recently developed to 
detect tau seeding activity in diverse types of biological samples (Holmes et al., 2014) including 
archived paraffin-embedded PFA-fixed human brain tissues (Kaufman et al., 2018). This HEK293 
cell line has stable expression of tau-RD(P301S)-CFP and tau-RD(P301S)-YFP such that the 
seeding can be measured by FRET activity. Transduction with PFA-fixed section homogenates of 
the transentorhinal/entorhinal cortices (TRE/EC) and LC from both AD (biological definition) and 
primary age-related tauopathy patients into the biosensor cells showed generally higher seeding 
activity in the TRE/EC than the LC especially in many cases with observable seeding activity in 
the TRE/EC but non-observable in the LC (Kaufman et al., 2018). In congruence, there is also 
higher proportion of biologically classified AD cases with AT8-positive but seeding-negative LC 
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than those with AT8-positive but seeding-negative TRE/EC. This finding supports the notion that 
early tau aggregation in the LC even in the pre-tangle stages is seeded by tau from the TRE/EC.  
     
1.3.5.2    Aβ 
Aβ is generated by proteolytic processing from a precursor protein, amyloid precursor protein 
(APP) (Glenner and Wong, 1984). APP is a type I integral protein encoded by APP gene in the 
chromosome 21 in human (Tanzi et al., 1987). There are 3 major APP isoforms generated via 
alternative splicing: APP695, APP751, and APP770. APP is first excised either by α-secretase 
ADAM10 into a luminal sAPP-α and a non-amyloidogenic substrate α-C terminal fragment (CTF) 
or by β-secretase BACE1 into a luminal sAPP-β and an amyloidogenic substrate β-CTF. The 
segment β-CTF then is cleaved into AICD and different Aβ fragments by γ-secretase complex that 
comprises 4 protein subunits: PEN-2, APH-1, substrate-recruiting nicastrin, and catalytic 
presenilin (reviewed in De Strooper et al., 2012). 
Aβ protein has a natively unfolded conformation instead of a globular structure. The hierarchy 
of aggregation follows from an oligomer to a fibril. Different forms of Aβ oligomers have been 
observed and artificially reproduced but they can be categorised based on their binding affinity 
to a conformation-specific antibody A11: A11-recognisable prefibrillar oligomer and A11-
unrecognisable fibrillar oligomer (reviewed in Glabe, 2008). A11-positive prefibrillar oligomers 
of Aβ42 have been reported by several articles to be the main toxic species (Cerf et al., 2009; 
Stroud et al., 2012). One type of prefibrillar oligomer contains a stack of 4 β-sheets, each of 
which connect four Aβ42 monomers together through their three intramolecular antiparallel 
equally segmented β-strands (Gu et al., 2014). These oligomers may undergo strand rotation 
conversion to become fibril seeds that have continuous cross-β sheets along the fibril 
longitudinal axis and do not contain an intramolecular β-sheet. Several studies have shown Aβ42 
fibril structures containing a monomer with a relatively disordered N-terminus and three β-
strand turns (Xiao et al., 2015), but one recent study found a fibril that contains monomers with 
four β-strand turns including the N-terminus (Gremer et al., 2017). These findings pointed out 
the strain diversity in multiple hierarchies of Aβ aggregates even in systems with wild-type APP.  
It has been shown that secondary nucleation plays a significant role in proliferation of Aβ42 
fibrils (Cohen et al., 2013; Cohen et al., 2018). This is also consistent with the finding that neuritic 
plaques were surrounded by a diffusing halo of oligomers and the density of glutamatergic 
synapses is correlated with the distance from the plaque circumference (Koffie et al., 2009). The 
rate constant for primary nucleation of Aβ42 is 100 times of the primary nucleation rate constant 
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of Aβ40, but the Aβ42 secondary nucleation rate constant is only 3 times as high as that of Aβ40 
(Meisl et al., 2014).                    
The early established assessment of Aβ deposition recommended by CERAD was histochemical 
procedure using thioflavin S or modified Bielschowsky silver staining to detect dense core 
neuritic plaques (Mirra et al., 1991).  This was later known as CERAD neuritic plaque (NP) score. 
The CERAD NP score is required to be assessed in the middle frontal gyrus, superior and middle 
temporal gyri, and inferior parietal lobule (Montine et al., 2012). The hippocampus, entorhinal 
cortex, and occipital cortex can be considered for NP score evaluation. Staging of amyloid 
deposition progression according to Aβ immunohistochemical profiles has been described (Thal 
et al., 2002) as follows: isocortical (1), limbic (2), basal ganglia (3), basal forebrain and midbrain 
(4), and cerebellum and brainstem (5) (Table 1.4). It must be noted that Thal phases measure 
both dense core plaques and diffuse plaques. In addition, Thal scores reflect distribution of 
amyloid deposition according to a specific progression pattern whereas CERAD scores evaluate 
the abundance of neuritic plaques in the frontal, parietal, and temporal isocortices. 
Dementia entails higher antemortem cognitive impairment score the Clinical Dementia Rating 
Sum of Boxes (CDR-SOB) and lower cognitive performance score the Mini Mental State 
Examination (MMSE). Overall ABC score and specifically Braak NFT score are associated with 
higher CDR-SOB and lower MMSE While CERAD neuritic plaque score is correlated with CDR-
SOB, Thal score is not associated with any cognitive measurements (Serrano-Pozo et al., 2016).   
  
Brain regions Phase 1 Phase 2 Phase 3 Phase 4 Phase 5   
Neocortex 100.0% 100.0% 100.0% 100.0% 100.0%  
CA1 0.0% 100.0% 100.0% 100.0% 100.0%  76%-100% 
Entorhinal region 0.0% 83.3% 100.0% 100.0% 100.0%   
Cingulate gyrus 0.0% 50.0% 88.9% 100.0% 100.0%  51%-75% 
Presubiculum 0.0% 33.3% 100.0% 100.0% 100.0%   
Amygdala 0.0% 33.3% 88.9% 100.0% 100.0%  26%-50% 
Dentate gyrus 0.0% 33.3% 77.8% 100.0% 100.0%   
Nucleus Basalis of Meynert 0.0% 0.0% 55.6% 100.0% 100.0%  1%-25% 
CA4/Hilus 0.0% 16.7% 22.2% 100.0% 100.0%   
Substantia nigra 0.0% 0.0% 0.0% 60.0% 66.7%  0% 
Anterior/Central Raphe nuclei  0.0% 0.0% 0.0% 0.0% 62.5%   
Locus coeruleus 0.0% 0.0% 0.0% 0.0% 62.5%  
Table 1.4 – Percentage of cases with Aβ deposition in each listed region at a given phase 
(Modified from Thal et al., 2002). Neocortical areas develop Aβ deposition earlier than other regions. The 




1.3.5.3    α-synuclein 
Both Lewy bodies and Lewy neurites are majorly composed of α-synuclein amyloid fibrils 
(Spillantini et al., 1998). Other reported components of Lewy bodies and neurites include 
ubiquitin (Kuzuhara et al., 1988; Lowe et al., 1988a) and neurofilament (Goldman et al., 1983). 
Braak staging of PD-associated Lewy pathology showed an ascending course of progression from 
the brainstem to the neocortex (Braak et al., 2003) (Table 1.4). Cortical Lewy bodies and Lewy 
neurites are characteristics of Lewy body dementia especially DLB and PDD (Spillantini et al., 
1998). Cortical Lewy bodies are similar to subcortical Lewy bodies commonly found in idiopathic 
PD except that they have less defined core and halo. Consistently, most DLB and PDD patients 
have LB Braak stages 4-6 (reviewed in Jellinger and Korczyn, 2018).       
Braak - PD  Regional distribution of Lewy bodies 
1 Dorsal motor nucleus of the vagus nerve in the medulla, anterior olfactory 
nucleus 
2 Caudal raphe nuclei, reticular nucleus, locus coeruleus-subcoeruleus  
3 Substantia nigra pars compacta, nbM  
4 Transentorhinal region, CA2/CA3 sector 
5 Multimodal association cortices, prefrontal cortex 
6 Unimodal association cortices, primary sensory areas 
Table 1.5 – Braak stages for anatomical distribution of Lewy bodies in the progression of PD 
(Modified from Braak et al., 2003) Progression of α-synuclein aggregation follows an ascending pattern 
from the brainstem to the cortex.  
 
Human α-synuclein is a 140 amino-acid presynaptic protein encoded by a gene SNCA on 
chromosome 4 and mainly expressed in brain neurons Kim et al., 2014. This intrinsically 
disordered protein has 3 domains: amphipathic N-terminal that contains KTKEGV-including 11-
residue repeats [1:60], central hydrophobic region [61:95], and acidic proline-rich C-terminal 
[96:140] (Clayton and George, 1998). The hierarchy of α-synuclein assembly is as follows: 
protofilaments → protofibrils → mature fibrils (Qin et al., 2007). Cross-β rich core of the 
protofilaments and fibrils is composed of the residues 32-102. While the C-terminal is not 
incorporated into the cross-β sheet architecture, it facilitates fibril maturation via interaction 
between protofilaments.      
The major localisation of α-synuclein proteins is in presynaptic terminals. Nonetheless, it has no 
significant role in synaptic development. Preferential localisation of α-synuclein to the synaptic 
vesicles is mediated by its interaction with synaptobrevin-2/VAMP-2 (reviewed in Burre et al., 
2018).     
Amyloid fibrils of α-synuclein grow by monomer addition but they assemble into a higher-order 
aggregate, further reducing the available free ends for elongation (Buell et al., 2014). At neutral 
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pH, rates of primary nucleation, fragmentation, and secondary nucleation are negligible. 
However, mildly acidic environment such as in endosome or lysosome substantially increases 
the rate of secondary nucleation. Presence of metal ions such as Cu2+ also affects α-synuclein 
aggregation and characteristics of the resulting aggregates (Villar-Pique et al., 2016). Addition 
of Cu2+ enhances aggregate formation in neurites and perikarya. Nuclear α-synuclein aggregates 
are also observed only under Cu2+ treatment. While neuritic and perikaryal inclusions mainly 
comprise of added recombinant α-synuclein, nuclear inclusions are strictly composed of 
endogenous α-synuclein.      
Despite varying sizes, β-sheet contents, and hydrophobicity, all oligomers of α-synuclein share 
hollow cylindrical architectures (Chen et al., 2015b). While monomers have no effects on ROS 
production in rat midbrain neuronal culture, oligomers facilitate higher ROS production than 
fibrils do. Oligomers effectively disrupt the membrane with high content of acidic phospholipids 
and low content of proteins. Interestingly, the mechanism may not directly involve pore 
formation despite the hollow structure of the oligomer. While oligomers exhibit greater toxicity 
than fibrils in neuronal cultures, inoculation of various aggregate species (oligomers, ribbons, 
and fibrils) demonstrated that fibrils are the most toxic species in vivo as indicated by loss of TH-
positive neurons and striatal axon volume, impaired motor function, and long persistence in the 
brain (Peelaerts et al., 2015).   
The most prevalent posttranslational modification of α-synuclein is phosphorylation. In the brain 
of DLB patients, phosphorylation at S129 is found in 90% of the deposited α-synucleins but only 
in 4% of the soluble population Anderson et al., 2006. Fibrils of phosphorylated S129 α-synuclein 
injected into the mouse striatum have higher capacity to seed inclusions in both SNpc and cortex 
than wild-type fibrils (Karampetsou et al., 2017). Neuronal uptake of phosphorylated S129 fibrils 
is also greater than that of wild-type fibrils. Ubiquitination at K12, K21, and K23 are only found 
on Lewy body-incorporated α-synuclein and the majority of these α-synuclein have 
phosphorylated S129 (Anderson et al., 2006). Less common sites of phosphorylation are S87, 
Y125, Y133, and Y135 (Okochi et al., 2000). 
Both PDD and DLB have been proposed to be characterised by ascending propagation of α-
synuclein-associated pathology from the medulla to the cortex (Braak et al., 2003; Jellinger, 
2008). Lewy body pathologies were extensive in the substantia nigra, ventral tegmental area, 
raphe nuclei, pedunculopontine nuclei, locus coeruleus, reticular formation, and dorsal motor 
vagal nucleus (Seidel et al., 2015). Coiled bodies are α-synuclein aggregates in oligodendrocytes 
and they were present in most brainstem nuclei. Lewy bodies are also present in the cerebellar 
nuclei and adjacent white matter of both PDD and DLB patients (Seidel et al., 2017). Within the 
hippocampal formation of DLB patients, α-synuclein pathology is highest in the CA2 and the 
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entorhinal cortex but the decline in cognitive performance is more correlated with Lewy 
pathology in the CA1 than that in the CA2 (Adamowicz et al., 2017). DLB and PDD, nonetheless, 
have pathological dissimilarities (reviewed in Jellinger and Korczyn, 2018). Lewy body load in the 
temporal and parietal cortex is higher in DLB than in PDD and this burden is also correlated to 
cognitive decline only in DLB but not PDD (Howlett et al., 2014).  
 
1.3.5.4    Mixed pathologies 
A cross-sectional community-based study in Brazil reported that 20% among 480 subjects that 
met the criteria for neuropathological diagnosis had mixed pathologies (Suemoto et al., 2017). 
AD pathology of at least Braak III and CERAD 2 in combination with other pathologies namely 
vascular disease (7.7%), Lewy body disease with Braak PD stage of at least 3 (5.2%), or others 
including TDP-43 (4.4%) were the most common types of mixed pathologies. Another 
community-based study in Mayo Clinic Study of Aging in Minnesota on neuropathology with 
similar NFT tau criteria but more flexible Aβ and synuclein pathological criteria found that up to 
16%, 10%, and 8% of 161 clinically normal subjects had AD pathology mixed with vascular 
disease, synuclein, and TDP-43 respectively (Wennberg et al., 2019). Both studies also reported 
that tau pathology was the best predictor of cognitive decline. 
DLB generally have higher AD-associated pathologies namely tau and Aβ loads in the cortex and 
striatum than PDD (reviewed in Jellinger and Korczyn, 2018). Aβ40 burden and Aβ42:Aβ40 ratio 
in the prefrontal cortex were correlated with MMSE decline in PDD but not DLB (Howlett et al., 
2014). AD patients also developed multiple patterns of Lewy body pathology. A study 
categorised 146 AD cases with Lewy bodies into 3 major types: amygdala (62), transitional (32), 
and diffuse (52) (Uchikado et al., 2006). While most (92%) of the amygdala type did not fit the 
PD Braak staging, only 19% and 6% of the transitional and diffuse did not fit the standard Lewy 
pathology Braak scheme. Furthermore, Lewy body density in the amygdala was also correlated 
with Lewy body density in the EC and with NFT in the amygdala, but there was no difference in 
clinical features between AD cases with amygdala Lewy bodies and AD cases without 
synucleinopathy.   
Tar-DNA binding protein-43 (TDP-43) is a major protein in an inclusion commonly found in 
frontotemporal lobar degeneration (FTLD) TDP subtype and amyotrophic lateral sclerosis 
(reviewed in Rahimi and Kovacs, 2014). TDP-43 inclusion in the hippocampus was significantly 
associated with higher rates of hippocampal atrophy in subjects with Braak III-IV and to a slightly 
lesser extent in those with Braak V-VI (Josephs et al., 2017). A recent study demonstrated that 
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APOE ε4 allele was associated with higher TDP-43 burden that in turn mediated higher odds of 
hippocampal sclerosis through AD pathology-independent mechanisms (Yang et al., 2018). 
Different neuropathological proteins can facilitate progression of one another through various 
mechanisms (reviewed in Spires-Jones et al., 2017). Insoluble and soluble pS129 α-synuclein 
levels were differentially correlated with insoluble and soluble Aβ in different brain regions and 
the insoluble pS129 α-synuclein in the midfrontal cortex was also correlated with Braak stages 
in a PD/DLB cohort (Swirski et al., 2014). The same study also demonstrated that Aβ42 aggregate 
significantly induced S129 phosphorylation in SH-SY5Y cells and more effectively than Aβ40 did. 
Overexpression of α-synuclein in J20 transgenic AD mouse model by crossing with human α-syn 
overexpressing mouse line significantly reduced Aβ deposition but aggravated apoptosis-
associated cell-cycle re-entry, production of Aβ oligomers, and memory impairment (Khan et al., 
2018). Conversely, knock-out of SNCA by crossing J20 with SNCA-null mice increased amyloid 
burden but also significantly decreased all of the above synuclein overexpression-associated 
deleterious effects. Another study also showed that reducing endogenous α-synuclein 
expression in APPSwe/Lon transgenic mice rescued reduction in hippocampal ChAT-positive axons, 
degeneration of CA3 pyramidal neurons, and memory deficits (Spencer et al., 2016). On the 
other hand, α-synuclein could stimulate GSK-3β-mediated tau phosphorylation by directly 
forming a heterotrimeric complex (Kawakami et al., 2011). Another important mechanism is 
called cross-seeding where a misfolded aggregate of one protein can incorporate different 
proteins with aggregation propensity and similar potential conformation into a heterologous 
aggregate (reviewed in Soto and Pritzkow, 2018). For example, it was recently demonstrated 
that α-synuclein can cross-seed tau into a unique and stable toxic tau oligomeric strain that does 
not naturally undergo fibrillization (Castillo-Carranza et al., 2018).   
 
 
1.3.6 Genetic risk factors 
It was estimated by studies on twin and families that genetic inheritance is likely to contribute 
in up to 80% of AD cases (Gatz et al., 2006). Early onset AD (EOAD) is defined by the age onset 
below 65 years. Multiple rare mutations in APP, PSEN1, and PSEN2 have autosomal dominant 
effects to cause early-onset familial AD (FAD), which constitute about 5% of AD patients 
(reviewed in Tanzi, 2012). A population-based study calculated the prevalence of EOAD and FAD-
caused EOAD to be 41.2 and 5.3 per 100,000 persons at risk respectively; FAD hence account for 
12.9% of EOAD (Campion et al., 1999). Late-onset AD (LOAD) is the most common form. 
Polymorphisms in ApoE gene have the greatest influence on the risk of LOAD: ε3/ε4 and ε4/ε4 
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genotypes increase the risk of AD compared with the most common genotype ε3/ε3 by 3 and 8 
folds respectively and approximately 30-50% of AD patients are ε4-carriers Pericak-Vance et al., 
2000(reviewed in Loy et al., 2014). Additional AD-risk genes have been increasingly identified 
over these past years by genome-wide association studies (GWAS), in which genetic markers 
especially single-nucleotide polymorphisms are tested for association with the disease risk, age-
onsets, biomarkers, and other disease-related features (reviewed in Hardy and Singleton, 2009).       
 
1.3.6.1    Familial AD (FAD) and early onset AD (EOAD) 
The gene APP is located on the chromosome 21q21. The first amino acid residue of the Aβ 
peptide and β-CTF is the 672nd residue of the APP770 variant (Tanzi, 2012). The first EOAD-
causing mutation – the London mutation V717I or β-CTF V46I – was also first identified by (Goate 
et al., 1991) on the gene APP. Most of the APP mutations have autosomal dominant EOAD-
causing phenotype. Biochemical effects of the mutations can be categorised as elevating total 
Aβ levels, increasing Aβ42/Aβ40 ratio, or altering aggregation behaviours (summarised in Table 
1.6)(reviewed in Alzforum, 2018a).   
The genes PSEN1 and PSEN2 encode presenilin-1 and -2 respectively. Most mutations in these 
two genes  cause FAD or autosomal dominant EOAD (reviewed in Tanzi, 2012). Interestingly, a 
genetic screening study also found 7 novel PSEN1 missense mutations in sporadic EOAD patients 
whose parents lack that corresponding mutation (Lanoiselee et al., 2017). Most mutations in 
PSEN1 except M149V generally decrease the overall APP cleavage activity but do not 
consistently affect the cleavage activity on other substrates (Chavez-Gutierrez et al., 2012). 
Importantly, all PSEN1 mutations were demonstrated to reduce the activity of the 4th cleavage 
reaction on any Aβ chains – namely Aβ42 → Aβ38 and Aβ43 → Aβ40, and therefore effectively 
increase Aβ42/Aβ40 ratio. Dominant negative effects of the mutant PSEN1 have recently been 
attributed to the hetero-oligomer formation among γ-secretase complexes with WT and mutant 
PS1 that suppresses the activity of WT PS1-containing γ-secretase in this hetero-oligomer (Zhou 
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Table 1.6 – List of some notable mutations and polymorphisms that cause AD or increases the 
risk of the disease 
(Reviewed in Alzforum, 2018a) Shown in this table are selected AD-pathogenic PSEN1 mutations, notable 
pathogenic APP mutations with names, AD-pathogenic PSEN2 mutations, and TREM2 and ADAM10 
variants that potentially increase the risks of AD. CY – cytosolic domain; TM – transmembrane domain; LU 
– luminal domain; PRO – prodomain; Ex – exon; In – intron; T – total level of Aβ; R – Aβ42/Aβ40 ratio; A – 
aggregation propensity; B – ligand binding affinity; S – shedding; P – downstream pathway activation; .. – 
unknown mechanisms. Pink highlight denotes that the mutation causes both AD and CAA while dark red 
highlight with white texts indicate that the mutation mainly causes CAA. Grey highlight corresponds to 
LOAD. Green highlight refers to the protective effect. Mutations in red are overexpressed in 5XFAD mice. 




1.3.6.2    Late-onset AD (LOAD)  
The APOE gene is located on chromosome 19q13.2 and encodes 299-amino acid protein 
apolipoprotein E (apoE). The 3 major alleles ε2, ε3, and ε4 encode the 3 isoforms: apoE2 (Cys112, 
Cys158), apoE3 (Cys112, Arg158), and apoE4 (Arg112, Arg158) respectively (reviewed in 
Kanekiyo et al., 2014). The residues 136-150 and 244-272 of apoE are binding regions for Aβ and 
heparin. ApoE4 with R112 and R158 has a specific conformation that allows a strong interaction 
between R61 and E255, rendering it more prone to aggregation. A meta-analysis found that 50% 
of AD patient had at least a copy of APOE ε4 and that the presence of ε4 allele increases the risk 
of developing AD by 12 fold (Farrer et al., 1997). Patients lacking ε4 allele have low probability 
of AD progression regardless of their Aβ deposition by PET imaging and Bdnf V66M mutation 
(Lim et al., 2015).   
Since the discovery of the linkage between ApoE and BDNF in the context of AD, this has been a 
subject of extensive research. This is in part because it provides a mechanistic link between Aβ 
pathology, cholinergic function, and adult neurogenesis (Lim et al., 2015; Sen et al., 2015). 
Each ApoE isoform has different effects upon astrocytic production of BDNF protein (Sen et al., 
2017). Compared with ApoE3-treated astrocytes, ApoE2 treatment increased production of pre-
pro-BDNF only by 19% but interestingly elevated mature BDNF production by 3 folds and 
decreased pro-BDNF secretion by 43%. ApoE4, on the other hand, completely diminished 
secretion of any BDNF forms. ApoE4 was also shown to potentiate Aβ seeding and lengthen 
brain Aβ half-life (Liu et al., 2017). Treatment with antisense oligonucleotide for APOE in 
APP/PS1 APOE-ε4 homozygous reduced the levels of both oligomeric and plaque Aβ species 
when conducted at birth and also decreased neuritic degeneration despite enlarging the plaques 
when conducted during initial amyloid seeding stage at 6 weeks of age (Huynh et al., 2017).  
ApoE4 is more susceptible to cleavage by serine protease into 12-20 kDa smaller toxic N-terminal 
fragments specifically in neurons but not astrocytes (Harris et al., 2004). Homozygous APOE-ε4 
also increased multiple tau phosphorylation sites and both Aβ42 and Aβ40 levels in iPSC-
differentiated neurons especially GABAergic interneurons (Wang et al., 2018).     
In addition to increasing the risk of AD, the presence of APOE-ε4 allele has been shown to 
increase the risk of dementia in Lewy body diseases specifically DLB and PDD (Tsuang et al., 
2013). A recent study supported this notion by showing that the APOE-ε4 allele is associated 
with higher severity of Lewy pathology regardless of tau or Aβ burden (Dickson et al., 2018).    
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1.3.6.3    LOAD – others  
Genome-wide association studies (GWAS) (reviewed in Hardy and Singleton, 2009; Harold et al., 
2009; Lambert et al., 2009; Seshadri et al., 2010; Hollingworth et al., 2011; Naj et al., 2011) have 
identified 9 genes, besides APOE, with AD-associated single nucleotide polymorphisms (SNPs) 
namely: CR1, BIN1, CD2AP, EPHA1, CLU, MS4A6A, PICALM, ABCA7, and CD33. Two-stage large 
meta-analysis on the above GWAS studies identified 11 additional genes with SNPs of significant 
AD risk: (stage 1) HLA-DRB5-HLA-DRB1, PTK2B, SORL1, and SLC24A4-RIN3; (stage 1 and 2 
combined) ZCWPW1, CELF1, NME8, FERMT2, CASS4, INPP5D, and MEF2C (Lambert et al., 2013).                
Some mutations of PSEN1 and PSEN2 cause LOAD instead of EOAD such as PSEN1-I168T, PSEN2-
A237V (Sassi et al., 2014), and PSEN2-N141I (Rogaev et al., 1995). The non-amyloidogenic α-
secretase ADAM10, encoded by the gene ADAM10 on the chromosome 15q22, has also been 
reported to have at least 2 mutations that significantly increase the risk of LOAD: Q170H and 
R181G (Kim et al., 2009) that have been demonstrated to impair chaperone function of the 
prodomain, and hence induce misfolding and decrease enzymatic activity (Suh et al., 2013).  
Two examples of LOAD-associated circulatory protein transport genes are CLU and PICALM 
which encode clusterin or apolipoprotein J and phosphoinositol binding clathrin assembly 
protein respectively (Harold et al., 2009). Clusterin reduces transport of Aβ from the vascular 
system to the brain (DeMattos et al., 2004) and PICALM facilitates clathrin-endocytosis of Aβ for 
degradation (reviewed in Tanzi, 2012).   
TREM2 is a transmembrane protein of immunoglobulin family expressed in microglia. Its 
interaction with an adaptor protein DAP12 transduces the signalling by recruiting tyrosine kinase 
SYK to activate mTOR pathway (reviewed in Ulland and Colonna, 2018). TREM2 ectodomain can 
also be cleaved by ADAM10 or ADAM17, the enzymes also responsible for shedding of APP and 
p75NTR. After shedding, its intramembrane domain is later digested by γ-secretase and later 
separated from the DAP12. R47H is one of the several rare variants associated with an increased 
risk in AD (Guerreiro et al., 2013). TREM2-mutant and TREM2-deficient microglia, due to their 
defects in mTOR pathway, undergo excessive autophagy and eventually apoptosis in response 
to Aβ plaque exposure (Ulland et al., 2017). Elevated soluble TREM2 ectodomain in the CSF was 
correlated with increased white matter diffusivity, which preceded symptom onset, in 
autosomal dominant AD patients (Araque Caballero et al., 2018).          
1.3.6.4    DLB/PDD  
Mutations in the LRRK2 gene, which encodes a large 2527-residued multidomain protein 
Leucine-rich repeat kinase 2 (LRRK2), are important risk factors for PD. Postmortem 
investigation revealed different neuropathology associated with different LRRK2 mutations 
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(reviewed in Li et al., 2014). For example, R1441C, Y1699C, and G2019S polymorphisms were 
associated with Lewy bodies, neurofibrillary tangles, ubiquitin accumulation, and substantia 
nigra neuronal loss. Some mutations/polymorphisms are not associated with Lewy bodies and 
the neuropathological features of some others remain unclear. Major LRRK2 mutations are 
located in the highly conserved ROC and COR domains and kinase domain.         
The gene GBA1 on chromosome 1q21 encodes for a lysosomal enzyme glucocerebrosidase 
(GCase) (reviewed in Creese et al., 2017). GBA1 is highly susceptible to genetic recombination 
because it is located only 16 bp upstream to its 96%-exonic homologous pseudogene 
counterpart GBAP Hruska et al., 2008. A subject with homozygous GBA1 mutations may develop 
Gaucher’s disease (GD) a lysosomal storage disorder. There are 4 main GD-associated mutations 
of GBA1: three missense mutations N370S, D443N, and L444P; and one splicing mutation 
IVS10+1G>T (Asselta et al., 2014). N370S and L444P are the most common GD-associated 
mutations and they are categorised as non-neuropathic and neuropathic respectively such that 
the former and the latter correspond to the type 1 and type 2-3 GD. Type 1 GD involves mild 
CNS damage but also higher chance of developing parkinsonism, but type 2-3 is marked by 
severe damage and fast progression in the CNS.  
Importantly, heterozygous GBA1 mutations are the most prevalent genetic risk for PD and DLB, 
but their aetiological mechanisms remain unclear (Nalls et al., 2013). A study (Aharon-Peretz et 
al., 2004) has shown that in the populations of Ashkenazi Jews, 31.3% of PD patients but only 
4% of AD patients and 6.2% of healthy controls have GBA1 mutations. Other studies have 
demonstrated that the frequencies of GBA1 mutations are ethnic-specific with the range of 
3.21% (Choi et al., 2012) to 21% (Lwin et al., 2004) in non-Ashkenazi PD patients. Among all 2,766 
cases with primary degenerative Parkinsonism from Parkinson Institute Biobank, DLB and 
PD/PDD patients have the high frequencies of all 4 GD-associated GBA1 mutations of 13.8% and 
4.5% respectively but other parkisonisms show insignificant frequencies of the pathogenic 
mutations Asselta et al., 2014. E326K and T369M are two GBA1 variants of which homozygosity 
do not lead to GD but their encoded GCase have lower enzymatic activity (Mallett et al., 2016). 
E326K is associated with DLB and PDD (Gámez-Valero et al., 2016). An association between 
T369M and PD requires further investigation. PD patients with GBA1 mutation are as 3 times 
and 2 times at risk for dementia and death as non-carrier PD patients (Cilia et al., 2016). In 
addition, GBA1 mutations are also disproportionately found in males (Gámez-Valero et al., 
2016). 
The mechanisms of the effects of GBA1 mutations on parkinsonism are still unclear. One study 
(Mazzulli et al., 2011) first demonstrated a positive feedback loop between α-synuclein 
pathology and GCase dysfunction. Accumulation of glucosylceramide (GlcCer) from the 
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depletion of GCase increases the level of α-synuclein by inhibiting lysosomal protein degradation 
and further promoting toxicity by stabilizing α-synuclein oligomers. Patients homozygous or 
heterozygous for GBA1 mutation also have higher levels of α-synuclein oligomers. Higher levels 
of α-synuclein from overexpression in cell culture in turn induced GCase retention within the 
endoplasmic reticulum and hence reduced enzymatic activity. This finding is further supported 
by a 40% decrease in GCase activity of PD patients without GBA1 mutations compared with 
controls (Mazzulli et al., 2011). It was later demonstrated that GlcCer converted a soluble non-
toxic non-seeding α-synuclein oligomer into a more compact soluble toxic fibril-seeding 
oligomer (Zunke et al., 2017). This study also showed that GlcCer-associated oligomers were 
resistant to both SDS and proteinase-K, but the physiological oligomers are not. Furthermore, 
reduction of GlcCer shifts the equilibrium and decreases the level of toxic α-synuclein oligomers.  
Although GCase is ubiquitously expressed in the brain, the following specific neurons in the non-
human primate have been reported to have high levels of GCase: cholinergic neurons of the 
nbM, dopaminergic neurons of the SNpc, serotoninergic neurons of the raphe nuclei, and 
noradrenergic neurons of the locus coeruleus (Dopeso-Reyes et al., 2018). The significance of 
this distribution is not fully understood but it is of particular interest given the vulnerability of 
these cellular populations in DLB/PDD. 
1.3.6.5    Transgenic mouse models 
The discovery of autosomal dominant mutations in APP and PSEN1 has provided the opportunity 
for the development of transgenic mouse models. The most widely used models are summarised 
in Figure 1.8. While these models have provided significant mechanistic information of the 
disease, there are significant limitations. A major limitation of these mice, unlike humans, is that 
they do not develop NFT without the presence of non-AD mutations in tau (Kitazawa et al., 





Figure 1.8 – Characteristics of AD mouse models  
(Taken from Alzforum, 2018b) 3xTg – APP (K670N/M671L: Swedish) and MAPT (P301L) mutants under 
Thy1.2 regulatory element and have PSEN1 (M146V) knock-in.  5XFAD – APP (K670N/M671L + I716V + 
V717I) and PSEN1 (M146L + L286V) expression are driven by Thy1 promoter. APP23 – APP (K670N/M671L: 
Swedish) is driven by Thy1 promoter. APPswe/PSEN1dE9 – APP (K670N/M671L: Swedish) and PSEN1 
(deletion of exon 9) are driven by mouse prion protein (PrP) promoter. J20 – APP (K670N/M671L: Swedish) 
and (V717F: Indiana) driven by a PDGF promoter. PS/APP or APPswe/PSEN1(M146L) – generated by 
crossing between Tg2576 and PDGF-driven PSEN1 (M146L).   PDAPP – APP (V717F: Indiana) driven by 
PDGF promoter. TASTPM (TAS10 x TPM) – APP (K670N/M671L: Swedish) and PSEN1 (M146L) are driven 
by Thy1 promoter. Tg2576 – APP695 mutants (K670N/M671L: Swedish) under hamster prion protein 
promoter.  
 
1.3.7 Cholinergic deficits in dementia 
1.3.7.1    Alzheimer’s disease 
One of the seminal neurochemical findings in postmortem brains of people with AD was a 
reduction in the enzyme responsible for the synthesis of acetylcholine, choline acetyltransferase 
(Bowen et al., 1976; Davies and Maloney, 1976). Since these discoveries and the link to the 
cognitive decline, these changes have formed the basis of the most successful symptomatic 
treatment to date (Francis et al., 1985; Francis et al., 1999). In AD, loss of cortical cholinergic 
innervation is most severe in the temporal lobe, especially the entorhinal cortex or Brodmann 
area 28 (BA28) and association areas (BA20, 21, and 22) (Geula and Mesulam, 1996). These 
regions are also one of the earliest parahippocampal and neocortical regions respectively to 
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develop NFTs (Braak et al., 2006). Depletion of cholinergic innervation in a specific cortical area 
is associated with degeneration of cholinergic neurons in a corresponding projecting sector of 
the Ch4 NbM/SI (Mufson et al., 1989; Geula and Mesulam, 1996). While ChAT activity and M1-
mAChR/G-protein coupling were reduced more in the frontal than in the temporal cortex, M2-
mAChR and α4β2-nAChR density were decreased more in the frontal cortex (Lai et al., 2006). 
Relative preservation of cholinergic fibres in the cingulate cortex, of which most cholinergic 
axons are from the MS/DB and Ch4am (Mesulam et al., 1983a), is congruent with the notion 
that Ch4am has the lowest neuronal loss (35%) compared with Ch4i (62%), Ch4al (76%), and 
Ch4p (77%). Although loss of cholinergic innervation in the hippocampus especially CA1 can be 
up to 53%, the remaining cholinergic axon density in the hippocampus was still relatively higher 
than in other brain regions and neuronal loss (17%) in the MS/DB in AD patients was not 
significant reduced compared with controls (Mesulam et al., 1983a). Decline in ChAT-positive 
cholinergic axon density in different hippocampal sectors has also been observed: CA4, CA3-2, 
and CA1 Kooi et al., 2011; and DG (Perry et al., 2012). This may be associated with a decrease in 
the size of MS/DB BFCNs (Fujishiro et al., 2006).  
Nonetheless, multiple pieces of evidence suggested relative preservation or compensation of 
hippocampal innervation and MS/DB cholinergic neurons. ChAT activity in the hippocampus was 
upregulated in MCI patients compared with controls and AD patients (DeKosky et al., 2002) 
especially among cases with NFT Braak stage 3-4 (Ikonomovic et al., 2003). Hippocampal ChAT 
activity was also significantly correlated with the density of neuritic plaques in the entorhinal 
cortex (Ikonomovic et al., 2003) which is congruent with the findings that entorhinal cortex 
lesion can induce cholinergic axon sprouting in the rat hippocampus and that some individual 
AD cases had more dense cholinergic innervation in the OML of the DG, where axons from the 
entorhinal cortex connect to the dendrites of DG granule neurons, than did controls (Geddes et 
al., 1985). Surprisingly, one AD case with extensive cholinergic axon sprouting in the dentate 
OML and CA1 stratum moleculare had severe loss of BFCNs in the MS/DB unlike the majority of 
AD cases (Hyman et al., 1987). However, two AD cases from the above study exhibited massive 
loss of cholinergic axons, visualised by AChE histochemical assay, in the DG and subiculum. 
Similarly, another study showed that AD cases with NFT Braak stages IV-VI had a significant 
decrease in ChAT immunoreactivity in the DG (Perry et al., 2012). Both in-vivo PET imaging 
(Aghourian et al., 2017) and postmortem autoradiography (Parent et al., 2013) of a novel VAChT 
tracer [18F]fluoroethoxybenzovesamicol (FEOBV) showed severe reduction in many cortical 
regions but no difference in the hippocampus, thalamus, and cerebellum. This observed 
plasticity of VAChT in the hippocampus was possibly associated with upregulation in 
hippocampal ChAT activity during MCI (DeKosky et al., 2002). Higher levels of CHT1 and choline 
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uptake activity were reported from the autopsy of AD patients compared with controls (Bissette 
et al., 1996). These pieces of evidence appear to confirm the plasticity of cholinergic innervation 
to the hippocampal-parahippocampal circuitry.  
1.3.7.2    Lewy body dementia 
The cholinergic basal forebrain system, especially the nbM demonstrates considerable damage 
in both DLB and PDD (reviewed in Liu et al., 2015). Since diagnostic criteria of differentiating DLB 
and PDD were established only recently (McKeith et al., 2005), most of the studies before on 
Lewy body dementia, if not specified as PDD, before the 3rd consortium in 2005 include both DLB 
and PDD. Cases with Lewy body dementia had consistently greater loss of BFCNs in the NbM 
than AD cases and lower ChAT level in the parietal cortex that was associated with higher cortical 
Lewy body content (Lippa et al., 1999). Cases with Lewy body dementia also had lower nAChR 
density but higher mAChR density in the parietal cortex (Perry et al., 1993). DLB has been 
reported to have significantly lower density of ChAT-positive axons in the hippocampus including 
DG (Johnson et al., 2011). This is consistent with a finding of loss and shrinkage of BFCNs in the 
MS/DB (Fujishiro et al., 2006). A previous study found significant reduction in AChE 
histochemical staining but non-significant decrease in ChAT activity in the entorhinal cortex, 
subiculum, and CA2-3 in the DLB cases (Ballard et al., 2000). The same study also reported higher 
M1 mAChR binding affinity measured with pirenzepine binding autoradiography and impaired 
cholinergic innervation in the temporal cortices BA20 and BA36. Decreased ChAT activity in the 
visual association cortex or BA36 was also significantly associated with visual hallucinations in 
the DLB patients (Cuello, 2006; Francis and Perry, 2006). An imaging study in DLB patients with 
VAChT ligand [123I]-iodobenzovesamicol found significantly lower VAChT binding potential in the 
BA24 or the anterior cingulate cortex specifically in DLB patients with apathy (Mazere et al., 
2017). This study also showed loss of VAChT binding, which theoretically marks cholinergic 
innervation, in the Ch5-innervated thalamus and the cholinergic interneuron-containing 
striatum in DLB patients. A more recent study with another vesamicol analogue [18F]-FEOBV in 
DLB patients confirmed extensive cholinergic denervation not only in the cortex, but also in the 





1.3.8 Abnormalities in other neurotransmitter systems 
1.3.8.1    Glutamatergic system 
In AD patients, presynaptic glutamate reuptake and vesicular glutamate transport are 
significantly downregulated in accordance with the severe reduction in cortical synapses 
(reviewed in Francis, 2009). These changes have been suggested to lead to higher extrasynaptic 
glutamate concentration and less synaptic glutamate signal transmission, hence resulting in 
lower signal-to-noise ratio. Several studies found that Aβ42 oligomers stimulated astrocytic 
glutamate release to activate extrasynaptic NMDAR (Talantova et al., 2013), decreased neuronal 
glutamate uptake (Li et al., 2009b), and impeded astrocytic glutamate reuptake by internalising 
the transporter (Scimemi et al., 2013). These findings are in agreement with the notion that LTD 
is induced by Aβ42 and activation of perisynaptic NMDAR by leaking glutamate (reviewed in 
Palop and Mucke, 2010).          
1.3.8.2    GABAergic system 
Early studies indicated that GABA was reduced in AD towards the end of the disease while being 
relatively preserved early on (Lowe et al., 1988b). Relative preservation of GABAergic 
neurotransmission has provided an attractive therapeutic target although such an approach 
would not be without problems in disrupting the circuitry. The approach of using a partial 
agonist or inverse-agonist has been considered (reviewed in Nava-Mesa et al., 2014). In addition, 
there may be mechanistic links between preserved GABA function in AD and the function of 
hippocampal circuitry. For example, astrocytes in the DG of AD patients and AD mouse models 
produced abnormally high level of GABA, which induced tonic inhibition in the DG circuitry and 
subsequently memory impairment in the mouse models, with two potential mechanisms either 
through canonical GAD67-dependent pathway (Wu et al., 2014b) or monoamine oxidase B-
catalysed synthesis from putrescine (Jo et al., 2014). Physical brain injury was also demonstrated 
to transform resting astrocytes into inhibitory GABA-producing hypertrophic astrocyte in 
contrast to enriched environment that increases the number of proBDNF-positive but GABA-
negative hypertrophic astrocytes (Chun et al., 2018). Patients with amnestic MCI exhibited fMRI-
measured hyperactivity at the hippocampal DG/CA3 connections (Yassa et al., 2010; Bakker et 
al., 2012) and APOE-ε4 carriers also had fMRI-hyperactivity in the hippocampus (Bookheimer et 
al., 2000; Dickerson et al., 2005; Filippini et al., 2009). Loss of hilar GABAergic interneurons in 
apoE4 knock-in mice and rescue of cognitive deficits in this model by transplantation lend 
support to the notion that apoE4-associated hippocampal hyperactivity in human is attributed 
to aberrant GABAergic system (Tong et al., 2014).   
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1.3.8.3    Monoaminergic systems 
The serotonergic raphe nuclei also contain a high level of NFTs (Chen et al., 2000; Šimić et al., 
2017) and Aβ deposition (Thal et al., 2002). However, serotonergic nuclei were still not one of 
the recommended regions to be investigated for diagnosis (Hyman et al., 2012). AD patients also 
experienced severe denervation of neocortical and hippocampal serotonergic axons and loss of 
serotonergic neurons in the raphe nuclei (Chen et al., 2000; Lyness et al., 2003; reviewed in Trillo 
et al., 2013). Several postmortem studies unanimously showed the reduction in 5-HT in the AD 
temporal cortex compared with the controls (Palmer et al., 1987; Garcia-Alloza et al., 2005). 
Patients with severe AD also had lower 5-HT in the hippocampus, a part of the temporal gyrus 
BA22, and cerebellum (Vermeiren et al., 2014). PET with a selective ligand for 5-HT1A receptor 
revealed a decrease in binding densities in the AD hippocampus and this binding decrease was 
correlated with MMSE decline and lower glucose metabolism measured by FDG-PET (Kepe et 
al., 2006).  Serotonergic system-related symptoms observed in AD patients include sleep 
fragmentation, depression, and agitation (reviewed in Šimić et al., 2017). 
The LC is the major if not the only source of noradrenergic innervation to the cortex and 
hippocampus (Foote and Morrison, 1987) and one of the most vulnerable regions to AD 
pathology. The severe loss of adrenergic neurons in the LC was also correlated with earlier onset 
and duration of dementia (Zarow et al., 2003). Loss of neurons in the LC was significantly 
correlated with that in the nbM in both AD and PD patients. The proportion of LC neurons 
containing AT8-positive NFT was significantly higher in cases with cognitive impairment than in 
cognitively healthy controls (Grudzien et al., 2007). Noradrenaline has also been demonstrated 
to protect hippocampal neurons from Aβ42 possibly via stimulation of autocrine or paracrine 
release of NGF or BDNF (Counts and Mufson, 2010). AD patients were shown to have lower 
levels of noradrenaline in the temporal cortex (Nazarali and Reynolds, 1992). Connectivity 
between the left LC and the left parahippocampal gyrus was correlated with memory 
performance and was impaired in prodromal AD patients (Jacobs et al., 2015). Interestingly, 
among prodromal AD group, patients with higher cognitive performance had higher 
compensatory connectivity between the right LC and the left parahippocampal gyrus. A 
combination of significant neuronal loss in the LC and relative sparing of neurons in the nbM 
was also associated with depression in AD (Förstl et al., 1994).   
The two major dopaminergic pathways of interest here are the nigrostriatal tract from the SNpc 
to the striatum and the mesocorticolimbic tract from the ventral tegmental area to the 
neocortex, hippocampus, subcortical areas and nucleus accumbens. There have been 
contradicting results on dopaminergic changes in AD. Some found decreased level of 
homovanillic acid in the CSF in vivo (Blennow et al., 1992) and reduced dopamine in postmortem 
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AD brains (reviewed in Trillo et al., 2013) whereas others found increased homovanillic acid in 
the CSF in vivo (van der Cammen et al., 2006) and postmortem frontal cortex (Palmer et al., 
1987) of AD patients.  
        
   
1.3.9 Therapeutic options in dementia 
1.3.9.1    Cholinesterase inhibitors 
The consistent reduction in cholinergic markers in AD coupled with the correlation of these 
changes with symptoms provided the main target for treatment of cognitive symptoms (Francis 
et al., 1999). Of the possible approaches, inhibition of the breakdown of acetylcholine by 
acetylcholinesterase has proved the most reliable and effective mechanism. Tacrine was the first 
approved AChEI for patient treatment (Knapp et al., 1994) but its adverse effects on the liver led 
to its discontinuation (Watkins et al., 1994). There are currently 3 licensed AChEIs for AD in UK: 
galantamine (Razadyne™ and Reminyl™), donepezil (Aricept™), and rivastigmine (Exelon™) 
(reviewed in O'Brien et al., 2017). Galantamine is a reversible competitive inhibitor but 
donepezil is a non-competitive inhibitor as it decreases Vmax but not Km of the enzyme (Barnes 
et al., 2000). Galantamine is also an α7-nAChR allosteric modulator and its long-term treatment 
preserve cognitive performance for at least a year (Lilienfeld and Kurz, 2002). Several studies 
with small (Moraes et al., 2008) and large patient cohorts (Rogers et al., 1998) reported 
significant cognitive improvement assessed by a lower ADAS-Cog score or higher MMSE score. 
Donepezil was demonstrated to decrease dementia progression rate in MCI patients only within 
the first 12 months of treatment but not after 3 years (Petersen et al., 2005). Rivastigmine is a 
slowly-reversible non-competitive inhibitor of AChE and also Butyryl cholinesterase (BuChE); this 
dual inhibition was beneficial as BuChE activity was progressively increased in dementia 
especially in the hippocampus and temporal cortex and BuChE also increases neurotoxicity of 
associated Aβ plaques (reviewed in Ballard, 2002). Rivastigmine has selectively higher efficacy 
in the hippocampus and neocortex than other regions (Weinstock et al., 1994). This is possibly 
due to its preferential binding to the mostly cytoplasmic monomeric G1 form of both AChE and 
BuChE rather than their mostly membrane-bound tetrameric G4 form; activities of G4 forms of 
AChE and BuChE are reduced in AD by 50-70% and 20% respectively, but BuChE G1 activity is 
elevated by 30-60% despite a stable activity of AChE G1 (reviewed in Giacobini, 2006). 
Rivastigmine is also a potential substitute for donepezil in AChEI treatment switching (reviewed 
in Blesa et al., 2018).  Donepezil and Rivastigmine are also prescribed for DLB/PDD (reviewed in 
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O'Brien et al., 2017). Overall, these drugs provide modest symptomatic benefit in many AD 
patients.   
1.1.9.2    NMDAR antagonists 
The second class of drug to be approved for symptomatic treatment of AD was memantine, a 
moderate affinity NMDA antagonist. Clinical trials indicated some efficacy (Reisberg et al., 2003) 
before the mechanism of action was clearly understood. It was proposed that prolonged 
extrasynaptic NMDAR-dependent Ca2+ influx decreased signal-to-noise ratio and eventually this 
may lead to a form of excitotoxicity (reviewed in Francis, 2005). Memantine, NMDAR antagonist 
with characteristics similar to Mg2+, reduces aberrant NMDA receptor activation together with 
baseline Ca2+ concentration and hence has the potential to improve signal sensitivity of neurons 
in AD patients. A meta-analysis found that memantine monotherapy without ChEIs significantly 
improved cognitive performance and global functions (Matsunaga et al., 2015). A later meta-
analysis from the same group also showed a benefit of memantine in reducing behavioural 
disturbances when cotreated with ChEIs (Kishi et al., 2017). In addition, memantine-induced 
delay in cognitive decline was associated with slower rate of FDG-PET reduction in AD-
susceptible brain regions but not with any CSF protein markers (Wang et al., 2013). 
Nevertheless, another meta-analysis study did find a significant effect of memantine on AD 
symptoms (Blanco-Silvente et al., 2018).  Memantine, together with cholinesterase inhibitors, 
form the frontline treatment for the symptoms of AD in the absence of disease-modifying 
treatments.                 
1.1.9.3    Antidepressants/SSRI  
The dysfunction of the serotonergic system in AD and the clear links to changes in mood 
provided a rationale for treatment by this route. Selective serotonin reuptake inhibitors (SSRIs) 
are a commonly used class of antidepressant drugs that are considered to increase the level of 
serotonin in the synapse by decreasing its presynaptic reuptake. Nonetheless, each SSRI may 
also act upon distinct cellular mechanisms that contribute to its antidepressant effects. The best 
evidence from the DIASDS-II (Rosenberg et al., 2010) and the SADD studies (Banerjee et al., 
2011) suggests that this class of drug has very limited benefit against depressive symptoms in 
AD. A meta-analysis found only few studies that reported cognitive improvement after SSRI 
treatment (Jones et al., 2016). Aside from possible symptomatic treatments, some studies 
suggest potential impacts on disease progression. Treatment with an SSRI citalopram decreased 
Aβ production without affecting clearance in patients and halted amyloid formation in 
APPswe/PS1dE9 transgenic mice (Sheline et al., 2014). In contrast, treatment with another SSRI 
paroxetine also in APPswe/PS1dE9 transgenic mice had no effect on Aβ pathology. A 2-year follow-
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up study after SSRI treatment in MCI and AD patients did not alter PET-measured Aβ burden but 
significantly delay cognitive decline (Brendel et al., 2018). Interestingly, different serotonin 
receptor subtypes may have opposing effects (Klempin et al., 2010). Therefore, some non-SSRI 
antidepressants alleviate the symptoms by suppressing specific serotonin receptors.   
Pimavanserin, an inverse agonist of serotonin receptor 5-HTR2A, has been prescribed mainly to 
alleviate PD-associated hallucination and delusion with caveats for higher mortality risk on 
dementia patients with psychosis (Cruz, 2017). However, recent clinical trials showed 
significantly higher efficacy of Pimavanserin than placebo in AD patients with psychosis (Ballard 
et al., 2018; Ballard et al., 2019). The potential role of 5-HTR2 inverse agonist in promoting adult 
hippocampal neurogenesis will be discussed in section 1.4.6.4. 
 
1.1.9.4    Disease-modifying approaches 
The proceeding approaches are based on treating symptoms and do not alter the underlying 
causes of the disease. Disease-modifying approaches refer to therapeutic measures that change 
pathological processes which contribute to a lasting effect, especially cell death, during the 
disease progression (reviewed in Cummings and Fox, 2017). Cell death-contributing factors 
include Aβ-related toxicity, tau-related toxicity, membrane disruption, inflammation, oxidative 
stress, synaptic loss, mitochondrial dysfunction, demyelination, etc. As a molecular 
neuropathology of AD has become clearer, approaches that target Aβ and tau have been the 
major focus. Tackling the overproduction and deposition of Aβ was the first focus, partly due to 
the genetic links and the availability of transgenic mice (Kitazawa et al., 2012). Only more 
recently has tau become a significant therapeutic target largely in a response to the successive 
clinical failures of Aβ-based approaches. The main classes of Aβ agents that went through to late 
stage clinical trials were inhibitors of the Aβ production including inhibitors of β-secretase and 
those based on antibodies directed against Aβ (reviewed in Cline et al., 2018).     
BACE inhibitors are promising therapeutic candidates since β-secretase cleavage of APP by 
BACE1 or BACE2 is a key process in Aβ production. Most of the ongoing drugs were developed 
to inhibit BACE1 but they usually inhibit both BACE1 and BACE2. MK-8931 or Verubecestat is 
currently in Phase III clinical trial and has been demonstrated to dose-dependently reduce Aβ 
levels but it still could not improve cognitive performance in prodromal AD patients (reviewed 
in Zhu et al., 2018b). However, BACE1 has diverse substrates and excessive inhibition of BACE1 




Tau-associated cytotoxicity can be targeted from various pathways (reviewed in Congdon and 
Sigurdsson, 2018). Memantine and sodium selenate can enhance PP2A phosphatase activity by 
blocking its natural inhibitor (Chohan et al., 2006) and by activating regulatory subunit (van 
Eersel et al., 2010) respectively. Tideglusib, an irreversible inhibitor of GSK-3β, successfully 
improved cognitive performance in a pilot study (del Ser et al., 2013) but its phase II trial did  not 
show significant result (Lovestone et al., 2015). Lithium chloride, another GSK-3β inhibitor, also 
significantly reduced CSF phospho-tau and improved cognitive performance of MCI patients 
(Forlenza et al., 2011). Tau acetylation inhibitor such as Salsalate is also currently in an 
unpublished early trial for progressive nuclear palsy (PSP) (ClinicalTrials.gov, 2015) after its 
remedial outcomes in tau P301S transgenic mice including lowered tau level and acetylation, 
preserved cognitive performance and less hippocampal atrophy (Min et al., 2015). Inhibitors of 
tau deglycosylation and truncation are also gaining medical interests. Both methylene blue and 
associated derivatives (reviewed in Congdon and Sigurdsson, 2018) and curcumin (reviewed in 
Hu et al., 2015) are potent tau aggregation inhibitors in vitro and in mouse models in vivo with 
history of safe uses in humans, but there has been no record of cognitive improvement in clinical 
trials 
Neuroinflammation exacerbates neuronal damage through excessive activation of astrocytes 
and microglia (reviewed in Ahmad et al., 2019). Significant increase in the levels of 
proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 impairs clearance of tau and Aβ, 
induces abnormal synaptic pruning, and contributed to dysregulation of brain insulin signalling 
(reviewed in Frozza et al., 2018). Regardless of their theoretical potentials, anti-inflammatory 
drugs such as TNF-α pathway inhibitor, PPAR-γ activator, or NSAIDs (non-steroidal anti-
inflammatory drugs) have not produced significant improvement in any trials. 
Enhancement of mitochondrial homeostasis such as unfolded protein responses and mitophagy 
by NAD+ booster nicotinamide riboside (NR) and translation inhibitor doxycycline significantly 
reduces Aβ aggregation and improves memory in APP/PSEN1 mice and decreased Aβ staining in 
APPswe-expressing neuroblastoma respectively (Sorrentino et al., 2017). Another independent 
study also showed that nicotinamide riboside (NR) rescued DNA damage, neuroinflammation, 
hippocampal neurons apoptosis, and cognitive impairment in 3xTg mice (Hou et al., 2018). A 
clinical trial of chronic NR supplementation to produce calorie restriction-like anti-aging effects 
found a significant increase in NAD+ level in middle-aged and older adults without side-effects 
(Martens et al., 2018). Mitochondrial homeostasis-promoting compounds are promising 




1.1.9.5    Antibodies and anti-aggregation drugs 
Passive immunotherapy by administration of antibodies against Aβ has been garnering clinical 
and research interests. Antibodies with higher specificity for Aβ aggregates than monomers are 
still under clinical trials while half of those without preferential binding affinity to the aggregates 
have been discontinued (reviewed in Arndt et al., 2018)(Table 1.7). This is congruent with the 
finding that Aβ monomers may have physiological neuroprotective effects (Giuffrida et al., 
2012). Specificity of an antibody for oligomers or amyloid fibrils is possibly associated with its 
innate low binding affinity or shallow binding cleft to a monomer that allows fast dissociation 
from the monomer and higher binding probability to the multiple epitope-containing 
(multivalent) aggregate species (Brännström et al., 2014; Arndt et al., 2018).  
      
Candidates Mouse 
analogues 
Clinical stage Aβ selectivity Epitopes (residues) 
aducanumab chaducanumab Ph III A >> M 3-7 
gantenerumab chgantenerumab Ph III A > M 3-11, 18-27 
BAN2401 mAb158 Ph II A >> M 1-16 
bapineuzumab 3D6 discontinued A ~ M 1-5 
crenezumab MABT5102A Ph III A ~ M 13-24 
solanezumab M266 Ph III, halted A << M 16-26 
ponezumab 2H6 discontinued A << M 30-40 
Table 1.7 – Information on selected antibody candidates for clinical purposes 
(Taken from Arndt et al., 2018) A – aggregates; M – monomers; ch – murine chimeric analogues.  
 
Anti-aggregation compounds such as scyllo-inositol and epigallocatechin-3-gallate have showed 
promising effects and are currently in phase-2 and 3 trials with AD patients respectively 
(reviewed in Jia et al., 2014). One of the potent metal-chelator classes – 8-hydroxyquinolines 
such as PBT2 and clioquinol – have been demonstrated to inhibit Zn2+/Cu2+-dependent Aβ 
aggregation and oxidative damage (reviewed in Ayton et al., 2013). Interestingly, there have 
been several studies suggesting the notion of direct metal-Aβ complex degradation-accelerating 
mechanisms of these compounds besides their conspicuous ionophore or ion-sequestering 
activity (Adlard et al., 2008; Matlack et al., 2014). PBT2 is currently in phase-II clinical trial 
(Lannfelt et al., 2008).  
Active immunisation with Aβ fragments is also a promising therapeutic alternative (reviewed in 
Wisniewski and Drummond, 2016). A pioneering study discovered that immunisation with Aβ42 
in PDAPP mouse model (see Figure for details) even as late as at 11-mo significantly prevented 
Aβ pathology up to 18-mo in the neocortex (Schenk et al., 1999). Later studies confirmed 
cognitive protection effects of Aβ42 immunisation in other AD mouse models (Janus et al., 2000; 
Morgan et al., 2000). The first proof of concept in postmortem human brain from the first clinical 
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trial of immunisation with Aβ 42 plus QS-21 adjuvant or AN-1792 showed that AN-1792 
immunisation was capable of clearing Aβ plaques with evidence of microglia association but had 
minimal effect on tau pathology and cerebral amyloid angiopathy (CAA) (Nicoll et al., 2003). T-
cell meningoencephalitis and white matter infiltration of macrophages were also observed. The 
trial of AN-1792was later terminated in phase-II after the evidence of autoimmune-associated 
aseptic meningoencephalitis and cerebral haemorrhage (Orgogozo et al., 2003). Regardless, a 
later postmortem study found a case that exhibited effective clearance of both Aβ and tau 
pathologies in the absence of meningoencephalitis (Nicoll et al., 2006). CAD106, an Aβ1-6 
fragment conjugated to a Qβ particle, has passed the phase 2b trial and showed inverse 
correlation between Aβ-IgG titres and PET amyloid burden (Vandenberghe et al., 2017). 
However, albeit not statistically significant, strong serological responding patients elicit higher 
rates of MMSE decline and grey matter volume loss.      
A variety of approaches targeting tau have been tried including inhibitors of phosphorylation of 
tau and more recently antibodies directed at conformational isoforms of tau (reviewed in 
Sigurdsson, 2018). Immunotherapies against tau are now in early stage clinical trials (Table 1.8). 
Tau antibodies that are not readily transported into the cytoplasm can inhibit extracellular 
assembly and promote microglial phagocytosis via sequestration of tau aggregates (reviewed in 
Congdon and Sigurdsson, 2018). Antibodies that are easily transported into neurons can induce 
tau disassembly to promote lysosomal digestion or enhance proteosomal degradation via 
binding of E3 ubiquitin-protein ligase.    
      
Candidates Clinical stage Subjects Fragments / Epitopes  
Active immunisation    
AADvac-1 Ph II AD 294-305 
ACI-35 Ph I AD pS396, pS404 
Passive (antibodies)    
BIIB092 (BMS-986168) Ph I-II Healthy, PSP 8-19 
ABBV-8E12 (CN2-8E12) Ph II AD, PSP 25-30 
RO7105705 Ph II Healthy, PSP pS409? 
LY3303560 Ph I Healthy, MCI, AD 7-9, 312-342 (conformation) 
RG7345 (RO6926496) discontinued Healthy pS422 
JNJ-63733657 Ph I Healthy, AD Middle region 
UCB0107 Ph I Healthy 235-246 
Table 1.8 – Information on selected tau immunisation therapy candidates for clinical purposes 
(Taken from Sigurdsson, 2018) PSP – progressive supranuclear palsy.  
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1.4 Adult Hippocampal Neurogenesis 
1.4.1 Background 
Mammalian adult neurogenesis in the hippocampal dentate gyrus (DG) and olfactory 
bulb/subventricular zone was first discovered by the use of [3H]-thymidine incorporation into 
newly synthesised DNA and autoradiography (Altman and Das, 1965; Altman, 1969; Kaplan and 
Hinds, 1977). Injection with bromodeoxyuridine (BrdU) a thymidine analogue was later 
introduced as an alternative method to detect cell proliferation in the brain because BrdU is 
incorporated into the DNA during replication (Miller and Nowakowski, 1988). This led to 
compelling evidence of adult neurogenesis in rat (Kuhn et al., 1996) and was quickly followed by 
the first report of adult hippocampal neurogenesis in the human brain where BrdU had been 
administered for cancer diagnosis (Eriksson et al., 1998). The first stage of investigation to 
understand adult neurogenesis was the discovery of asymmetric cell division, which helps 
sustain self-renewing population while producing new differentiating cells, and fate 
specification in cerebral cortex development by combining the lineage marker BAC retrovirus 
and keeping track of new neurons generated at specific date by BrdU injection at said time 
(Mione et al., 1997). Soon afterwards, multipotent neural progenitors were first isolated from 
the rat hippocampus and induced to proliferate and differentiate into neural cells both in vitro 
and in vivo after transplantation (Gage et al., 1998). Asymmetric division was later confirmed by 
live-cell imaging and found to involve asymmetric cellular distribution of Numb (Shen et al., 
2002).  
Postnatal renewal of human hippocampal neurons was confirmed by correspondence between 
the 14C concentration in neuronal genomic DNA and the atmospheric 14C concentration after the 
date of birth of the subject (Spalding et al., 2013). Specifically, genomic DNA of hippocampal 
neurons of individuals born before the nuclear bomb testing during the Cold War had higher 14C 
concentration than the atmosphere and that of individuals born after the tests had lower 14C 
concentration than the bomb curve. The observed genomic 14C data was best fitted by a model 
where there are two subpopulations, one of which is renewing but the other is not. From this 
model, annual turnover rate of human adult hippocampal granule neurons was estimated at 
1.75% which is comparable to that of middle-aged mice. This turnover rate corresponds to 
approximately 700 newly born granule neurons in each hippocampus. Interestingly, 
approximately 35% of hippocampal neurons constituted a homogeneous subgroup of neurons 
undergoing a single mode of turnover. Since the proportion of DGCs among hippocampal 
neurons is slightly more than 35%, the above finding supported the notion that most DGCs are 
subject to turnover.  
81 
 
1.4.2 Adult neurogenesis in the hippocampus 
In the hippocampus, there are two types of slowly-dividing neural stem cells (NSC) which can 
switch between quiescent and active states. Type-1 cells have radial-glia-like morphology with 
their cell bodies in the subgranular zone (SGZ) and their radial processes through the granular 
cell layer (GCL). Type-1 NSCs express glial fibrillary acidic protein (GFAP), Sox2, and nestin (Figure 
1.9). NG2-expressing oligodendrocyte precursors (Encinas et al., 2011) and astrocytes (Steiner 
et al., 2004) may also serve as actively proliferating progenitors similar to NSCs in the DG under 
specific conditions. Type-1 cells once activated can produce rapidly-dividing intermediate 
progenitor cells with limited self-renewability or type-2a via asymmetric cell division. Type-2a 
cells lack glial features as they neither have radial process nor express GFAP but still express 
Sox2 and nestin. Interestingly, Type-2b cells, produced by type-2a cells, are committed to the 
neuronal fate as indicated by their expression of doublecortin (DCX), NeuroD, and Prospero 
homeobox protein-1 (Prox1). Type-2b cells rapidly divide for only several cycles and eventually 
asymmetrically divide into type-3 cells or neuroblasts, which express neuronal markers MAP2ab 
and βIII-tubulin but still can proliferate. Neuroblasts migrate tangentially along the blood 
vessels, then migrate a short distance radially into the GCL before completely exiting a mitotic 
stage and starting to express NeuN (Sun et al., 2015). Postmitotic granule neurons express 





Figure 1.9 – Overview of the adult hippocampal neurogenesis and markers of the DGCs  
(Original drawing based on the references included below and the results from Chapter 3 and 4) Type-1 
cells have radial glia-like characteristics with expression of GFAP and RNA-binding protein Musashi 
homolog 1 or Musashi-1 (Msi-1). Type-2a or early neuroblast no longer express radial glial markers but 
retain Nestin and Sox2. Neuronally-determined type-2b cells start express DGC lineage-specific markers 
Prox1 and NeuroD1. DCX and PSA/NCAM are expressed throughout type-2b and immature neuron or 
type-3 phases. MAP2A/B and βIII-tubulin are expressed by type-3 and more matured cells. High-
molecular-weight 200kDa neurofilament (NF) is specific to immature neurons (Tartt et al., 2018). 
Postmitotic neurons express NeuN. They first express calretinin which is later replaced by calbindin. 
Calbindin-positive neurons also express tryptophan 2,3-dioxygenase (TDO), desmoplakin (Dsp), type-1 
interleukin-1 receptor (IL1-R) (Kobayashi et al., 2010) and tetradecanoyl phorbol acetate-inducible 
sequence (Tis21). Tis21 (mouse analogue of human B-cell translocation gene anti-proliferation factor 2, 
BTG2) expression fades as DGCs become more mature and integrated in the circuitry (Attardo et al., 2010). 
Mouse HuB/C/D is expressed in early stages whereas human HuB/C/D is expressed in neuronally-
determined immature populations. Ki67 and PCNA are highly expressed in dividing cells but PCNA has 
longer half-life. Human Sox2 was also demonstrated to colocalise with NeuN (Briley et al., 2016). Studies 
in rodent showed that immature populations have high NKCC1 but low KCC2 but this relative expression 
profiles are reversed in more mature neurons. The present study found a few neurons with or without 




1.4.3 Adult neurogenesis in the subventricular zone 
The subventricular zone (SVZ) along the wall of the lateral ventricle is an adult neurogenic niche 
(Figure 1.12). GFAP-positive astrocytic NSC is attached to a blood vessel and may remain 
quiescent (Lim and Alvarez-Buylla, 2016). Around 20 % of GFAP-positive NSCs sustain the 
population via repeated symmetric self-renewing division, but the rest majority undergo 
symmetric consuming division into transiently amplifying cells (Obernier et al., 2018). 
Transiently amplifying cells usually divide few times before they produce migratory neuroblasts. 
Migratory neuroblast of the SVZ, similar to that of the DG, starts expressing DCX and PSA-NCAM. 
These neuroblasts migrate using each other as their platform and forming a path structure called 
rostral migratory stream toward the olfactory bulb to differentiate into GABAergic neurons. The 
fates of these progenitors are innately determined by their original positions on the lateral 
ventricle (Merkle et al., 2007). NSCs from the dorsal wall produce olfactory granule cells of the 
superficial layer and TH-positive calretinin-positive calbindin-negative periglomerular cells. On 
the other hand, NSCs from the ventral wall produce calretinin-positive GABAergic granule cells 
of the deep layer and TH-negative calbindin-positive periglomerular cells. Moreover, 
heterotopic transplantation of ventral NSCs into the dorsal wall does not change their fate.      
Humans, however, have very few neurogenic cells in the SVZ and the SVZ itself is also instead 
filled with a ribbon layer populated by astrocytes and ependymal cells followed by a thick gap 
layer filled by dense interconnected processes from those cells (Sanai et al., 2004). Chain 
migration to the olfactory bulb similar to rodent RMS has also never been observed in humans 
(Bergmann et al., 2015). A recent study found evidence of adult-born neurons in the human 
striatum (Ernst et al., 2014). However, a later study argued that almost all striatal interneurons 
in humans and rhesus monkeys are Sp8-negative unlike neurons differentiated from the NSCs 
of the SVZ (Wang et al., 2014b).  
The neurogenic niche of the SVZ also has various unique characteristics such as distinct subtypes 
of microglia that lack ATP-induced chemotaxis and exhibit low phagocytic activity (Ribeiro Xavier 
et al., 2015). Local ablation of the specific microglia significantly disrupts survival and migration 





1.4.4 Neurogenic markers 
1.4.4.1    Proliferative markers  
Proliferating cell nuclear antigen (PCNA) and Ki-67 have been used as endogenous cell cycle 
marker to detect adult neurogenesis. PCNA is a critical DNA polymerase cofactor of which 
expression is activated during G1 and S phase (Moldovan et al., 2007). The functions of Ki-67 are 
much less understood. Ki-67 has been reported to be involved in ribosomal RNA transcription 
but the mechanisms still remain unclear (Bullwinkel et al., 2006). Ki67 also binds to chromatin 
surface directly to prevent different chromosomes from aggregating (Cuylen et al., 2016). Ki67 
plays a direct crucial role during mitotic exit by specifically recruiting protein phosphatase 1γ for 
histone dephosphorylation, chromatin reorganisation, and nuclear membrane assembly (Kumar 
et al., 2016).  
As PCNA and Ki67 have different functions and characteristics, they cannot be used as 
endogenous proliferation markers equivalently or interchangeably. PCNA has a half-life of 
approximately 20 times as long as that of Ki67 (Khoshyomn et al., 1993) and this has been 
demonstrated by the presence of PCNA even in postmitotic cells (Mandyam et al., 2007). 
Furthermore, PCNA plays a role in DNA repair (Yin et al., 2015) and can be upregulated in dying 
immature neurons as indicated by cellular colocalisation with caspase-3 (Knoth et al., 2010).    
1.4.4.2    Doublecortin  
DCX is a microtubule-stabilizing protein in the brain. Its functions remain elusive but several 
pieces of evidence suggest its contribution to migration (Gleeson et al., 1998; Gleeson et al., 
1999; Koizumi et al., 2011) and neurite development (Friocourt et al., 2003). While DCX is mostly 
expressed in rapidly dividing intermediate progenitors and migrating neuroblasts of both SVZ 
and SGZ, DCX can also be found in mature astrocytes of adult human neocortex and astrocytes 
(Verwer et al., 2007) in the vicinity of mouse ischemic infarcts (Kunze et al., 2015).   
Another neurogenic marker which closely overlaps with DCX in both rodents and human brain 
is polysialylated form of the neural cell adhesion molecule (PSA-NCAM). PSA-NCAM is a 
membrane glycoprotein that also plays a role in neuronal migration and neurite extension. 
However, level and distribution of PSA-NCAM and DCX may differ in several pathological 
conditions (Johnson et al., 2011; Perry et al., 2012). 
1.4.4.3    Hu 
Hu proteins are neuron-specific RNA-binding proteins which have been identified as target 
antigens in a paraneoplastic neurological syndrome. There are 4 main Hu family members: A, B, 
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C, and D. According to  in-situ hybrization experiments on the adult mouse hippocampus, HuC 
is the major Hu member expressed by granule neurons where HuB and HuD are almost absent 
(Okano and Darnell, 1997). Nevertheless, HuD plays a role in axon outgrowth of immature 
granule neurons by stabilizing GAP-43 mRNA (Bolognani et al., 2007). This finding was further 
confirmed by an increased length of DG-CA3 mossy fibres in HuD-overexpressing transgenic 
mice (Perrone-Bizzozero et al., 2011). In mouse DG, Hu proteins are also expressed in a wide 
range of neurogenic populations from GFAP-positive type-1 cells to DCX-positive neuroblasts 
(Liu et al., 2010). This is complementary to the findings in human that HuC/D-positive cells 
consist of both mitotic and post-mitotic cells and that their density in the DG is higher than of 
DCX-positive cells (Ekonomou et al., 2015). 
1.4.4.4    NeuroD and Prox1 
Expressions of NeuroD1 and Prox1 start in type-2b cells and determine the fate of DG granule 
neuron lineage (Steiner et al., 2006; Hodge et al., 2008; Beckervordersandforth et al., 2015). 
Expression of NeuroD1 and Prox1 are activated by canonical Wnt pathway and overexpression 
of both transcription factors induces neuronal differentiation of NSCs in vitro (Gao et al., 2009; 
Karalay et al., 2011). Furthermore, both NeuroD1 (Gao et al., 2009) and Prox1 (Lavado et al., 
2010) are necessary to survival of immature granule neurons.    
1.4.4.5    Calretinin 
Calretinin or also known as calbindin D-29k is a calcium-binding protein of the troponin C 
superfamily. As a calcium modulator, Calretinin regulates neuronal excitability. Calretinin is 
expressed in retinal neurons, cortical and hippocampal GABAergic interneurons, and immature 
DG granule neurons. After exiting mitotic phase and starting to express NeuN, immature granule 
neurons transiently express calretinin for about 3-4 weeks before calretinin is completely 
replaced by calbindin (Brandt et al., 2003).  
1.4.4.6    GABA signalling-associated transporters: NKCC1 and KCC2 
Electrophysiological effect of GABA signalling either depolarising or hyperpolarising depends on 
the concentration of Cl- in the target cell (Ben-Ari, 2002). High level of Na+-K+-2Cl- cotransporter 
NKCC1, a Cl- importer, elevates intracellular Cl- concentration and hence induces depolarising Cl- 
efflux when GABAA receptor is activated. Conversely, high level of K+-Cl- cotransporter KCC2 
decreases intracellular Cl- level and induces hyperpolarising Cl- influx upon GABA signalling. For 
development of young neurons, excitatory GABA signal and eventual transition to inhibitory 




1.4.5 Functional roles of the DG granule neurons  
1.4.5.1    The roles of DGC in a computational model of pattern separation 
Several findings have confirmed an important role of adult hippocampal neurogenesis in pattern 
separation (Clelland et al., 2009; Sahay et al., 2011; Zhu et al., 2017). There are 3 modes of 
mechanisms that may explain the enhancing effects of adult neurogenesis on pattern separation 
(reviewed in Aimone, 2016) (Figure 1.10). First, new neurons help encode novel information and 
allow higher number of possible distinct subsets of neurons to encode non-overlapping signals 
while preserving old memory. Neurons generated at a different time likely code for event 
occurring at a separate time as well (reviewed in Deng et al., 2010). Second, new-born DGCs are 
hyperexcitable and suppress the network by activating local interneurons in the DG. Higher 
inhibition induces sparser and more decorrelated signals. Third, new-born DGCs could 
preferentially activate CA3 interneurons to stimulate feedforward inhibition which reduce 
interference by decreasing the density of recruited CA3 pyramidal neurons. 
              
  
Figure 1.10 – Potential mechanisms of how AHN in the DG improves pattern separation 
(Taken from Aimone, 2016 with permission from Cold Spring Harbor Laboratory Press, Appendix Table 
A.13) Adult neurogenesis may enhance DG pattern separation with 3 potential mechanisms. Note that 




1.4.5.2    Functional characteristics of the DGCs 
Young adult-born granule neurons integrate into the circuitry when they are 3-4 weeks old. 
However, all of them fully change electrophysiological behaviours before they reach 10 weeks 
old. The young granule neurons are referred to as S-group for their high sensitivity to a specific 
range of input and the fully matured ones are called L-group for exhibiting incremental and less 
sensitive response (Brunner et al., 2014). It has been demonstrated that young neurons switch 
their electrophysiological nature independently to their ages and potentially according to their 
experience. Therefore, two granule neurons of at most 9 weeks old which were born on the 
same day may have two distinct functions. Two-photon Ca2+ imaging in awake mice also revealed 
young DGCs of 3-6 weeks of age have higher firing rates but convey less spatial information than 
mature DGCs (Danielson et al., 2016).         
Young DGCs was demonstrated to have net inhibitory effects on the circuitry because X-
irradiation to destroy young adult-born neurons also increased gamma burst amplitude in the 
DG (Lacefield et al., 2012 1755). One possible mechanism is that these highly sensitive young 
neurons preferentially target local GABAergic interneurons (reviewed in Aimone, 2016). This 
would induce sparser and more orthogonal activity of mature DGCs and hence enhance pattern 
separation.      
Adult neurogenesis also induces forgetting (Akers et al., 2014) and facilitates reversal learning 
by decreasing proactive interference, a process where old memory interferes with learning new 
similar information (Epp et al., 2016). For example, mice with running-enhanced neurogenesis 
stay in the target quadrant shorter than controls during the retention session but they swim to 
the hidden platform of Morris water maze (MWM) faster than controls after platform position 
is switched to the opposite quadrant. Neurogenesis-induced forgetting has been speculated 
through computational modelling (Weisz and Argibay, 2012).  Adult-born neurons also influence 
excitability of the existing mature granule neurons (Adlaf et al., 2017). Conditional knockout of 
apoptotic protein Bax only in new-born neurons through Nestin expression enhances survival of 
adult-born neurons and reduce EPSPs and spine density of mature neurons. In accordance, 
ablation of new-born neurons increases excitability. Surprisingly, Bax in a mature neuron is also 




1.4.6 Effects of neurotransmitters and signalling peptides on adult hippocampal 
neurogenesis 
1.4.6.1    Cholinergic inputs 
Hippocampus is innervated by cholinergic axons from MS/VDB. Loss of Msi-1, a marker of radial-
glia like type-1 cells, in both DLB and AD was correlated with loss of hippocampal ChAT 
immunohistochemical signal (Ziabreva et al., 2007; Perry et al., 2012). Furthermore, lesion of 
the basal forebrain with 192IgG-saporin decreased the number of adult-born neurons identified 
with BrdU and NeuN and increased cell death in the DG (Cooper-Kuhn et al., 2004). Granule 
neuron precursors also express both m1 and m4 cholinergic receptors (Mohapel et al., 2005) 
and it has been demonstrated that BFCNs of the DB directly innervate immature granule neurons 
with m1-dependent signal transduction (Zhu et al., 2017). The density of direct cholinergic 
terminals on dendrites of the new-born granule neurons in Tg2576-APPswe mice was less than 
that in controls, and theta burst stimulation increased cholinergic terminal density in Tg2576-
APPswe mice to that in controls. Theta burst stimulation of the DB also activated immature 
granule neurons and improved only pattern separation behaviour task without affecting the 
performances of other hippocampal-associated cognitive tests including MWM and novel object 
recognition. Treatment with AChE inhibitor physostigmine promoted adult hippocampal 
neurogenesis in both proliferation and survival (Mohapel et al., 2005). Cholinergic signals also 
induced differentiation of granule neuron progenitors from expressing NKCC1 to expressing 
KCC2 via α7-nAChR-dependent pathway (Campbell et al., 2010).   
1.4.6.2    Glutamatergic inputs 
New-born DG granule neurons receive intrahippocampal glutamatergic inputs from mossy cells 
of the hilus, pyramidal neurons of the CA3, and mature granule neurons (Vivar et al., 2012). After 
the new-born neuron integrates into the circuitry, the inputs from mature granule neurons start 
to fade but the inputs from hilar mossy cells increase over time. The inputs from CA3 pyramidal 
neurons, similar to those from cholinergic septohippocampal tract, remain stable. Immature 
new-born neurons receive cortical glutamatergic innervation from the PRH and LEC, which 
induces paired-pulse facilitation and steadily increases after they reach 3 weeks old. These 
glutamatergic inputs have been shown to be received very early even by 1-week-old adult-born 
granule neurons (Sah et al., 2017). Mature granule neurons, on the other hand, receive inputs 
of paired-pulse depression plasticity from MEC. Lesions in the PRH and LEC impaired pattern 
separation but not MWM-associated spatial memory.  
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Under virtual enriched environment, activity from integrated adult-born granule neurons 
enhanced neurogenesis in both proliferation and maturation (Kirschen et al., 2017). By contrast, 
optogenetically silencing these active granule neurons with light-stimulated chloride channel 
halorhodopsin abolished beneficial effects of enriched environment on adult hippocampal 
neurogenesis. Mossy cells are the first glutamatergic neurons that provide synaptic input to the 
adult born neurons (Chancey et al., 2014). However, specific ablation of mossy cells with 
Cre/loxP-driven diphtheria toxin receptor system had no effect on the number of DCX- and 
PCNA-positive cells (Jinde et al., 2012).  
1.4.6.3    GABAergic inputs 
Depolarization by ambient GABA in the DG is necessary to maturation and synaptic integration 
of adult-born granule neurons as well (Ge et al., 2006). Additionally, direct synaptic signalling 
from PV-positive GABAergic neurons promoted survival and maturation of young adult-born 
neurons (Song et al., 2013). While SST-positive interneurons have been shown to innervate 
mature adult-born granule neurons (Vivar et al., 2012), suppression or activation of SST-positive 
interneurons did not affect survival of young granule neurons (Song et al., 2013). This is 
congruent with a recent finding that both PV-positive and PV-negative GABAergic projection 
neurons in the MS stimulate PV-positive interneurons in the DG to control NSC quiescence and 
ablation of MS GABAergic neurons induced excessive neurogenesis and exhaustion of NSC pool 
(Bao et al., 2017). Moreover, MS is not the only source of distant GABAergic projection to the 
DG. Glutamatergic neurons of the SuM also release GABA together with glutamate to the DG 
granule neurons and CA2 neurons but its effects on adult hippocampal neurogenesis still have 
not been discovered (Pedersen et al., 2017).        
           
1.4.6.3    Dopaminergic and noradrenergic inputs       
Dopaminergic neurons of the VTA were shown to be more resistant to 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) than those of the SNpc (Phani et al., 2010). Nonetheless, a 
study found that MPTP-administered mice also had significantly reduced level of dopamine in 
the hippocampus, accumulation of membrane-associated insoluble truncated α-synuclein in the 
hippocampus, elevated hippocampal calpain activity, and deficits in survival and maturation of 
adult-born DGCs (Schlachetzki et al., 2016). Depletion of dopamine reduced the number of NPCs 
in the SGZ which was congruent with the lower number of NPCs in PD cases (Höglinger et al., 
2004). Dopamine signal was also demonstrated to reduce input from the entorhinal cortex to 
hyperactive new-born DGCs and suppress LTP (Mu et al., 2011).  However, specific ablation of 
noradrenergic neurons in the LC or dopaminergic neurons in the SNpc/VTA using anti-dopamine-
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β-hydroxylase-saporin or desipramine-administration followed by 6-hydroxydopamine (6-
OHDA) respectively had no effect on proliferation or mutation of adult-born neurons despite 
successful lesion of noradrenergic or dopaminergic axons in the hippocampus (Ermine et al., 
2018).     
 
1.4.6.4    Serotonergic inputs 
Serotonin (5-HT) is a major monoamine neurotransmitter released from the raphe nuclei which 
regulates cognition, appetite, emotion, and sleep (Alenina and Klempin, 2015). Serotonin 
synthesis from tryptophan is catalysed by tryptophan hydroxylase (TPH2) and aromatic L-amino 
acid decarboxylase (AACD) respectively. Serotonin is transported into synaptic vesicles by 
vesicular monoamine transporter 2 (VMAT2). After being released, serotonin can be recycled 
back into the presynaptic cell by the serotonin transporter.  
Serotonergic system has been demonstrated to contribute to adult hippocampal neurogenesis. 
Raphe nuclei lesion by 5,7-dihydroxytryptamine administration reduced PSA-NCAM-positive 
cells and BrDU-positive cells and these aberrations were later reversed by natural reinnervation 
(Brezun and Daszuta, 2000). Another finding (Jha et al., 2006) conversely showed that 5,7-
dihydroxy-tryptamine, after pre-treatment with desipramine to protect noradrenergic terminals 
and therefore to render the lesion serotonergic-specific, was not sufficient to suppress adult 
hippocampal neurogenesis but p-chlorophenylalanine which inhibits both serotonin and 
noradrenaline synthesis can do so. Mice with innate lack of serotonin Tph2-/- showed an 
increased baseline number of Sox2-positive NSCs (Klempin et al., 2013). Nonetheless, the 
serotonin-devoid mice still have defects in exercise-induced serotonin-dependent adult 
neurogenesis. As Pet1 is specifically expressed in developing and mature serotonergic neurons 
and that Pet1 knockout induced up to 80% loss of serotonergic neurons (Hendricks et al., 2003), 
Pet1-/- mice also exhibits higher proliferation and survival of adult-born neurons, which can be 
reversed by serotonin receptor agonist (Diaz et al., 2013).  
Multiple types of serotonin receptors are expressed in the DG. DCX-positive type-2b cells and 
neuroblasts express 5-HTR1a that promotes self-renewal (Klempin et al., 2010). The 
hippocampus exhibits increasing gradient of 5-HTR1a expression along its dorsal to ventral axis 
(Tanaka et al., 2012). This is congruent with the finding that either 5-HTR1a agonist or selective 
serotonin reuptake inhibitor fluoxetine specifically stimulated rapid proliferation of type-2b cells 
and neuroblasts in the ventral hippocampus (Zhou et al., 2016). Another type of serotonin 
receptor is 5-HTR2. The hilus and mature granule neurons prevalently express 5-HTR2a and 5-
HTR2b/c respectively (Klempin et al., 2010). Unlike 5-HTR1a, 5-HTR2 agonists have opposing 
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effects of suppressing proliferation and specific agonist of 5-HTR2c was demonstrated to 
promote differentiation of dividing progenitors to DCX-positive neuroblasts. However, another 
finding showed that 5-HTR2c specific agonist is more effective than 5-HTR2 pan agonist in 
reducing the number of DCX-positive cells in mouse models with conditional ablation of 
serotonergic neurons (Song et al., 2016).  
Chronic fluoxetine treatment induced the dematuration of DG granule neurons by significantly 
reducing the level of mature granule neuron markers including calbindin, tryptophan 2,3-
dioxygenase (TDO), desmoplakin, and type-I interleukin-1 receptor via 5-HTR4-dependent 
mechanisms (Kobayashi et al., 2010). These neurons also exhibit immature characteristics 
including lower spike threshold and hypoactivity. This similar dematuration phenomenon also 
occurred in α-CaMKII+/- mice (Yamasaki et al., 2008). Fluoxetine also increased the level of 
dopamine D1-like receptor at the DG-CA3 mossy fibre synapse and thereby enhanced 
dopamine-induced potentiation (Kobayashi et al., 2012). Electroconvulsive therapy for 
depression also similarly induced dematuration of granule neurons by antagonising NMDAR 
signal (Imoto et al., 2017).   
  
1.4.6.5    Brain-derived neurotrophic factor (BDNF) 
BDNF is involved in various functions such as synaptic plasticity, neuronal survival, and circuitry 
development (Bekinschtein et al., 2014). There are multiple promoters that can drive 
transcription of BDNF (Aid et al., 2007) but any of them always produce two populations of 
mRNA via alternative polyadenylation: one with short 3'UTR and the other with long 3'UTR 
(Pruunsild et al., 2007). The additional sequence of the long 3'UTR allows transcripts with long 
3'UTR, but not short 3'UTR, to be targeted and regulated by various proteins or recruited to 
specific neuronal parts such as dendrites (Lau et al., 2010). RNA-binding protein HuD also 
stabilises the long 3'UTR BDNF transcripts and consequently promotes its translation Allen et al., 
2013. HuD-induced BDNF translation in the dendrite is also activity-dependent (Vanevski and 
Xu, 2015). BDNF has been shown to enhance consolidation of pattern-separated memory 
through adult-born immature granule neurons (Bekinschtein et al., 2013, 2014). It was first 
hypothesised that the acute improvement in pattern separation by BDNF was mainly due to 
direct plasticity induction on immature granule neurons Bekinschtein et al., 2014 but it was later 
reported that BDNF-induced LTP at the entorhinal-DG synapses can also rapidly stimulate adult 
neurogenesis via Arc/Arg3.1-associated mechanisms (Kuipers et al., 2016).   
BDNF is first translated into endoplasmic reticulum as prepro-BDNF. Its signal peptide is later 
excised leaving proBDNF. The proBDNF is cleaved into the N-terminal pro-peptide and C-
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terminal mature BDNF (mBDNF). This last cleavage may be carried out inside or outside the cells. 
Intracellular cleavage by furin/P3 plays a role in dendrite outgrowth, hippocampal adult 
neurogenesis, and LTP (Zhu et al., 2018a). Extracellular cleavage by tPA/plasmin is required for 
hippocampal LTP (Pang et al., 2004). Unlike mBDNF, proBDNF and pro-peptide can have adverse 
regulatory effects. An increase in proBDNF level in aged mouse hippocampus was correlated 
with cognitive deficits (Buhusi et al., 2017). BDNF pro-peptide also activates caspase-3, 
promotes mitochondria elongation, and reduces dendritic spine density (Guo et al., 2016). 
Furthermore, BDNF binds to TrkB but proBDNF binds to apoptosis-associated p75NTR. Normal 
aging in both mouse (Buhusi et al., 2017) and human (Costantini et al., 2006) was accompanied 
by elevation in p75NTR level. Interestingly, the level of p75NTRin the basal forebrain was 
decreased in MCI and AD patients. 
An important role for BDNF was demonstrated in a study where transplantation of NSCs into the 
hippocampus of 3xTg transgenic AD model rescued deficits in spatial memory and contextual-
dependent object recognition. This effect was shown to be BDNF-dependant by using lentiviral-
delivery of shRNA to stably knockdown BDNF which abolished the rescue (Blurton-Jones et al., 
2009). Interestingly, when a later study performed a similar stereotactic injection but with 
BDNF-overexpressing NSCs into Tg2576 APP-transgenic AD model, these NSCs differentiated 
into granule neurons instead (Wu et al., 2016).                                 
1.4.6.6    Nerve Growth Factor 
Continuous intracerebroventricular infusion of NGF enhanced cell proliferation evaluated by the 
number of BrdU-positive cells (Birch and Kelly, 2013). On the other hand, proNGF has been 
shown to reduce the number of DCX-positive and BrdU/DCX-double-positive cells but conversely 
activate astrocyte and microglia in the DG (Guo et al., 2013) possibly via p75NTR-dependent 
pathways (Bernabeu and Longo, 2010). Polarized distribution of p75NTR in adult-born DG 
neuroblast was necessary for axon development after cell-cycle exit (Zuccaro et al., 2014).     
 
1.4.7 Factors affecting adult hippocampal neurogenesis 
1.4.7.1    Aging  
Aged mice have significantly lower number of adult-born DGCs but higher number of astrocytes 
(van Praag et al., 2005). Measurement of nuclear bomb 14C incorporated in nuclei of human 
hippocampal neurons showed that the aging-induced relative decline in humans was smaller 
than that reported in mice (Spalding et al., 2013). A study focusing on DCX-positive cells also 
found a similar rate of aging-induced decline in this population of neuroblast or immature 
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neurons (Knoth et al., 2010). A recent thorough investigation on postmortem human brains also 
showed that only the anterior DG was susceptible to aging-induced adult neurogenesis decline 
accompanied by a significant decrease in capillary area and number  (Boldrini et al., 2018).  These 
above findings were in contrast with another recent article that claims the paucity or even lack 
of neurogenesis in adult human (Sorrells et al., 2018).  
1.4.7.2    Physical exercise 
Running has been demonstrated to increase proliferation, new-born functionally mature 
neurons, and MWM spatial learning and memory in mice (van Praag et al., 1999b). These 
neurogenic effects were strictly associated with voluntary exercise and enriched environment 
because neither forced swimming exercise nor maze learning induced significant changes in 
adult hippocampal neurogenesis (van Praag et al., 1999a). 
As angiogenesis and adult hippocampal neurogenesis are coordinated (Palmer et al., 2000; Jin 
et al., 2002), MRI-detectable cerebral blood volume (CBV) has been used to confirm the 
beneficial effects of exercise on mouse and human adult hippocampal neurogenesis, together 
with cognitive performance and aerobic fitness in vivo (Pereira et al., 2007). Exercise also 
increased CBV specifically in the DG and has no effect on CBV of the CA1, subiculum, or the 
entorhinal cortex. This is congruent with a later study that demonstrated the necessity of VEGF 
from skeletal muscle in acute treadmill exercise-induced adult hippocampal neurogenesis and 
exercise improvement in terms of both speed and endurance (Rich et al., 2017).   
Running reorganises the glutamatergic innervation to young 1-week-old adult-born neurons by 
reducing the inputs from CA1 pyramidal neurons and also enhances dendritic growth of these 
adult-born neurons (Sah et al., 2017).  
Exercise has been demonstrated to improve pathological conditions of several dementia mouse 
models. Voluntary wheel running in APPswe/PS1ΔE9 AD transgenic mice alleviated Aβ plaque 
burden and tau hyperphosphorylation, reduced neuronal loss in CA3, increased proliferation 
and development of neuroblasts, and slightly improved spatial memory performance (Tapia-
Rojas et al., 2016). Physical exercise significantly improved contextual fear memory and novel 
object recognition in the trisomic Ts65Dn mouse model of Down’s syndrome (Parrini et al., 
2017). This behavioural finding is in accordance with higher proliferation and maturation of 
adult-born neurons as indicated by the number of BrdU-positive and BrdU/NeuN-positive cells 
respectively. Exercise also increased glutamatergic/GABAergic synapses ratio and BDNF 
expression REF. To elucidate the mechanism of exercise-induced cognitive repair, BDNF mimetic 
drug 7,8-dihydroxyflavone was also shown to augment TrkB phosphorylation in the 
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hippocampus and replicate the cognitive improvement in this mouse model similar to the 
exercise.      
  
1.4.7.3    Vascular system 
Angiogenesis is a formation of new blood vessels from the existing vasculature and its purposes 
are to provide nutrients and remove metabolites from new tissues. It is therefore an important 
aspect of sustaining existing and new neuronal architectures. The major protein mediator 
between angiogenesis and neurogenesis is vascular endothelial growth factor (VEGF) that has 
been demonstrated to stimulate proliferation of neuronal precursors in primary cortical neuron 
cultures and DCX-positive neuroblasts in the DG through VEGF receptor-2 (VEGFR2) pathway 
(Jin et al., 2002) (Figure 1.14). The finding of a correlation between stable formation of vascular 
system and adult hippocampal neurogenesis in vivo (Pereira et al., 2007) is congruent with 
another discovery that neurogenesis-enhancing effects of VEGF require stable vasculature 
beforehand (Licht et al., 2016). VEGF preconditioning to increase vessel density promotes the 
neurogenic effects of subsequent short-term VEGF treatment to persist for several months 
without exhausting the NSC pool. Furthermore, VEGF induces type-1 neurogenic cells to change 
their apical processes from dense fine arbours ensheathing synapses and vasculatures in the IML 
(Moss et al., 2016) to long extensions that envelope around blood vessels along the whole range 
of the ML (Licht et al., 2016). One classic example of angiogenesis-neurogenesis coordination is 
in the adult songbird higher vocal centre (Louissaint et al., 2002). Testosterone induced release 
of BDNF from endothelial cells and VEGF from androgen receptor-expressing neurons to 
enhance adult neurogenesis and angiogenesis respectively. Inhibition of VEGFR2 tyrosine kinase 
negates testosterone-induced angiogenesis and neurogenesis. Overall perivascular interactions 
within the neurogenic niche are as follows (reviewed in Goldman and Chen, 2011). Perivascular 
astrocytes and potentially pericytes express CD39L1 that hydrolyse ATP into ADP to activate 
metabotropic purinergic P2Y receptor (P2YR) signalling for the self-renewal of type-I NSCs. Nitric 
oxide produced by endothelial nitric oxide synthase promotes both neurogenesis and 
angiogenesis. Type-I cells communicate with endothelial cells via CD24 P-selectin signalling. 
Endothelial cells also release BDNF and VEGF to stimulate neurogenesis and angiogenesis.  





1.4.7.4    AD and associated factors 
Aberrant AHN in AD was observed in multiple studies (reviewed in Martinez-Canabal, 2014) with 
a prevalent trend of higher number of immature neurons and neuroblasts with dementia (Jin et 
al., 2004a) and increasing Braak stages (Perry et al., 2012) (Table 1.9). The most recent study by 
our group (Ekonomou et al., 2015) supported the notion of maturation deficits previously 
reported (Li et al., 2008) by showing a reduction in HuC/D-positive postmitotic immature 
neurons in Braak V-VI. However, there have also been contradicting results of no changes in AHN 
(Boekhoorn et al., 2006), lower number of immature neurons (Crews et al., 2010) or 
upregulation in both proliferation and survival/maturation (Gomez-Nicola et al., 2014).    
The discovery of point mutation in APP and presenilin led to the construction and generation of 
APP/PSEN1 transgenic mice which have been extensively used in AD research (section 1.1.6.4). 
Such models have made considerable contributions to the understanding of the roles of Aβ and 
APP in AHN. The results of the main studies are summarised in Table 1.8. In general, the studies 
show that the presence of the transgenes and overproduction and deposition of Aβ have a 
negative impact on neurogenesis. In some cases, there can be a biphasic pattern of early 
enhancement of neurogenesis and subsequent decline or vice versa. A complication of many of 
these models is that they overexpress the transgenes which in most cases include the whole of 
the APP gene which result in the overexpression of APP protein. This protein has been shown to 
promote neurogenesis and therefore there may be potential pro- and anti-neurogenic effects in 
the same mouse (reviewed in Wirths, 2017). 
A study on APP knockout mice demonstrated that lack of APP increased survival of adult-born 
DGCs with no effect on proliferation, but at the same time also suppressed dendrite outgrowth 
and complexity (Wang et al., 2016). In congruence with the above study, APP has been shown 
to regulate the release of GABA by GABAergic interneurons to promote maintenance and 
dendrite development of the adult-born neurons (Wang et al., 2014a). Specific deletion of APP 
in GABAergic interneurons increases proliferation but induces maturation defects and impairs 
contextual discrimination behaviour.  
Regarding proteolytic cleavage products of APP, sAPP has been shown to inhibit growth of NSCs 
in the SVZ (Sato et al., 2017). On the other hand, another study demonstrated that both secreted 
extracellular fragments sAPPα and sAPPβ enhance proliferation of GFAP-positive type-1 cells in 
the DG and partially suppress neuronal differentiation (Baratchi et al., 2012).  
Overexpression of APP intracellular domain and its direct interactor Fe65 reduced proliferation 
in the DG without affecting maturation via an inflammation-associated but Aβ-independent, 
pathway (Ghosal et al., 2010). This overexpression impaired Y-maze-tested working memory, 
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and induced the DG to be more susceptible to excitotoxicity indicated by loss of granule neurons, 
NMDAR phosphorylation, and Neuropeptide Y upregulation (Ghosal et al., 2016). These APP 
intracellular domain-induced neurogenesis impairment effects are also exacerbated by tau 
overexpression and in turn prevented by tau knockout. It has also been reported in the SVZ that 
the neural recognition molecule TAG1 binds to APP as a ligand and stimulates intracellular 
production of the APP intracellular domain via Fe65-dependent pathway to suppress 
neurogenesis (Ma et al., 2008). However, this phenomenon has not been observed in the DG.   
Toxic oligomeric species of Aβ42 have been shown to induce senescence in adult hippocampal 
NSCs in vitro which was further confirmed in APPswe/PS1dE9 transgenic mice (He et al., 2013). Aβ-
induced senescence, marked by expression of the cyclin-dependent kinase inhibitor p16 and β-
galactosidase, required membrane-bound FRBP2 and ROS-p38 MAPK signalling. Injection of 
Aβ42 into the CA1 causes amyloid aggregation at the injection site, degeneration of CA3 
pyramidal neurons marked by condensed nuclei and cell shrinkage, and a reduction in the 
number of cells positive for BrdU and double positive for BrdU and DCX (Zheng et al., 2013). 
Overexpression of Aβ limited to CAMKII-expressing mature glutamatergic neurons, including DG 
granule neurons and CA pyramidal neurons, resulted in widespread amyloid deposition and 
inflammation indicated by proliferation of astrocytes and microglia in the hippocampus but did 
not affect maturation or proliferation of new-born neurons (Yetman and Jankowsky, 2013).  
Two copies of APOE-ε4 alleles as well as complete lack of APOE in mice did not affect 
proliferation or survival of adult-born neurons but significantly decreased dendritic complexity 
of these young adult-born DGCs (Tensaouti et al., 2018). On the other hand, earlier study on 
ApoE4-knockin mice did not only show defects in dendritic structures, but also an increase in 
proliferation and decrease in maturation measured by the number of BrdU/Nestin and 
BrdU/NeuN-positive cells respectively (Li et al., 2009a). Furthermore, this deficient neurogenesis 
was associated with loss of GABAergic interneurons and was successfully reversed with a GABAA 









DCX / PSA-NCAM DCX [=] in SGZ;  [↑] in GCL   
(AD vs ND; Braak IV vs II-III | V vs III)  
(Perry et al., 2012) 
(AD vs non) (Jin et al., 2004a)  
 
DCX [↑] cells in DG (AD vs ND; Fisher’s 
Exact) (Ekonomou et al., 2015) 
 
PSA-NCAM [↑] in SGZ;  [↑] in GCL   
(AD vs ND; Braak VI vs I-III)  
(Perry et al., 2012) 
 
PSA-NCAM [=] in SGZ;  [↑] in GCL   
(AD vs non) (Jin et al., 2004a) 
 
 
DCX [=] cells in DG (AD vs ND) 
evidence of degradation  
(Boekhoorn et al., 2006) 
 
DCX [↓] cells in DG (AD vs ND)  
(Crews et al., 2010) 
 
 
Proliferation Nestin [↑] in DG 
(AD vs ND) (Braak VI vs I-III)  
(Perry et al., 2012) 
 
SOX2 no NeuN [↑] cells in DG (MCI vs 
ctrl) (Briley et al., 2016) 
 
Ki67 [↑] cells in DG (AD vs ND)  
(Gomez-Nicola et al., 2014) 
 
 
Ki67 [=] cells in DG but [↑] in CA1-3 
gliogenesis+angiogenesis (AD vs ND) 
(Boekhoorn et al., 2006) 
 
Msi-1 [↓] in DG 
(AD vs non) (Braak VI vs I-III | IV vs I-II)  
(Perry et al., 2012) 
 
SOX2 no NeuN [↓] cells in DG (AD vs 
MCI, NDAN) (Briley et al., 2016) 
 
SOX2 [↓] staining in DG (AD vs ND) 






HuC/D [↑] cells in DG  (AD vs non)  
; Braak as covariate 




PCNA+HuC/D [=] cells in DG  (Braak 0-VI) 
HuC/D [↓] cells in DG  (Braak V-VI vs I-II, 
III-IV) ; Dementia as covariate  
(Ekonomou et al., 2015) 
 
MAP2a,b [↓]  but  MAP2a,b,c [=] in DG 
(AD vs non) (Li et al., 2008) 
 
βIII-tubulin [=] in DG  despite 
increase in Nestin, DCX, PSA-NCAM 
(AD vs non) (Braak VI vs I-III)  
(Perry et al., 2012) 
 
[↓] survival by [↑] Caspase-8 cleavage 
product in SGZ (AD vs non) (Jin et al., 
2004a) 














[↓] shrunken cytoplasm of DCX+ cells 
and condensed nuclei → apoptosis 
(Jin et al., 2004a) 
 
SOX2 no NeuN [↓] cells in DG (AD vs 
MCI, NDAN) (Briley et al., 2016) 
 
Calretinin [↑] cells in DG (AD vs ND) 
(Gomez-Nicola et al., 2014) 
 
Sprouting [↑] in IML (AD vs non) 





Axonal plexus [↓] in SGZ (AD vs non)  
(Bandopadhyay et al., 2014) 
  
Calbindin  [↓] staining in GCL (AD vs non)  
(Palop et al., 2003)  
(Bandopadhyay et al., 2014) 
 
[↓] cells in GCL 
(Braak V-VI vs Braak I-IV, CJD, AGD, 
FTLD-TDP) (Stefanits et al., 2014) 
Cholinergic 
markers in the 
DG/hippocampus 
 ChAT [↓] staining as Braak increases 
(Perry et al., 2012) 
 
Table 1.9 – Alterations in AHN in AD studies (ii) 
ND – no dementia; NDAN – no dementia with high AD pathology (Braak IV-VI); CJD – Creutzfeldt-Jakob 
diseases; AGD – Argyrophilic grain diseases; FTLD-TDP – Frontotemporal lobar degeneration with TDP 










DCX [↑] in SGZ   (3-mo, 12-mo J20)  
(Jin et al., 2004b)   
 
[↑] in DG   (9-mo APPswe/PS1-
M146L)  
(Yu et al., 2009) 
 
[↓] in SGZ;  [↑] in GCL (3-mo PDAPP)  
(Donovan et al., 2006) 
 
[↓] in 2-4-mo; [=] in 7-mo DG (5XFAD) 
(Moon et al., 2014) 
 
[↓] in 5-mo DG (5XFAD) (Choi et al., 
2018) 
 
[↓] in 5-mo;  [↑] in 25-mo DG   (APP23) 
(Ermini et al., 2008) 
 
[↓] in 11-mo DG    (3xTg)  
(Hamilton et al., 2010) 
  
Proliferation BrdU [↑] in DG   (3-mo, 12-mo J20)  
(Jin et al., 2004b)   
 
BrdU [↑] in 25-mo, but [=] in 5-mo DG 
(APP23) (Ermini et al., 2008) 
 
BrdU [↑] in 9-mo DG  
(APPswe/PS1 M146L) (Yu et al., 2009) 
 
Ki67 [=] in DG (5XFAD) 
(2-mo) (Zaletel et al., 2018) 
(4-mo) (Shin et al., 2018) 
 
Sox1 and Sox21 [↓] in DG (5XFAD) 
(2-mo) (Zaletel et al., 2018) 
 
HH3 [↓] in DG (5XFAD) 
(2-mo) (Moon et al., 2014) 
(7-mo) (Fiol-deRoque et al., 2013) 
 
BrdU [↓],  Ki67 [↓]  in DG 
(11-mo 3xTg) (Rodríguez et al., 2008) 
 
BrdU [↓] in DG (9-mo Tg2576) 
(Li et al., 2015) 
BrdU [↓] in 3-mo, [=] in 5-12-mo 
(Tg2576) 
(Krezymon et al., 2013) 
 
BrdU [↓] in SGZ (2-mo PDAPP) 





BrdU 28dpi [↑] in 9-mo DG  
(APPswe/PS1 M146L) (Yu et al., 2009) 
 
BrdU/NeuN 30dpi [↑] in 25-mo,  [=] 
in 5-mo DG (APP23) (Ermini et al., 
2008) 
 
Activated caspase-3 [↑] in SGZ, [=] in 
GCL (3-mo PDAPP) (Donovan et al., 
2006) 
 
BrdU 37dpi [↓] in 5-mo DG (5XFAD) 
(Zhu et al., 2017) 
 
BrdU/NeuN, BrdU/DCX 30 dpi [↓]in DG 
(6-mo APPswe/PS1dE9)  
(Verret et al., 2007) 
 
BrdU/NeuN 30dpi [↓] in DG  
(9-mo Tg2576) (Li et al., 2015) 
BrdU/NeuN 30dpi [↓] in 3-mo,  [=] in 5-
12-mo (Tg2576) (Krezymon et al., 2013) 
 












[↑] dendrite length, spine density, 
eIPSCs and eECSCs in 18dpi 
Retroviral-GFP DGCs (2-3-mo J20) 
(Sun et al., 2009) 
 
[↓] dendrite length, spine density, 
eIPSCs and eEPSCs in 28-122 dpi 
retroviral-GFP DGCs (2-3-mo J20) (Sun et 
al., 2009) 
 
Retroviral-GFP labelled adult-born  
28dpi: total and minimal dendrite length, 
dendrite branch, axonal growth, spine 
density [↓]  (3-mo Tg2576) 
(Krezymon et al., 2013) 
 
[↓] nuclear roundness of BrdU 28dpi 
DGCs  
[↓] punctate BrdU pattern 
[↓] paralleled orientation of cells 
(3-mo PDAPP) (Donovan et al., 2006)  
 
Calretinin  [↓] in DG (2-mo 5XFAD) 
(Moon et al., 2014) 
 
 [↓] in DG (3-, 12-mo APPswePS1dE9) 
(Verdaguer et al., 2015) 
 
Calbindin  [↓] expression in GCL (6-7-mo J20)  




 [↓] pattern separation (5-mo 5XFAD) 
(Zhu et al., 2017) 
 
Cholinergic 






[↑] hippocampal AChE (4-mo 5XFAD) 
(Zhen et al., 2017) 
[↓] cholinergic synaptic terminals on 
adult-born DGCs (5-mo 5XFAD) 
(Zhu et al., 2017) 
 
 [↓] Hippocampus ACh and ChAT (4-mo 
5XFAD) (Zhen et al., 2017) 
Table 1.10 – Changes in AHN in AD mouse models (ii) 
The abbreviations in the table for transgenic mice are referred to in Figure 1.2. An upward arrow indicates 
an increase in neurogenesis and downward arrow indicates a decrease. eIPSCs – evoked inhibitory 
postsynaptic currents; eEPSCs – evoked excitatory postsynaptic currents. 
 
In summary, Table 1.10 illustrated a diverse pattern of neurogenesis and associated processes 
in response to overexpression of various transgenes. In future, it will be important to address 
the inconsistencies observed and determine whether there are strain-specific or related to 
particular levels of expression or particular transgenes.   
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1.4.7.4    Dementia and neurogenesis 
Changes in adult neurogenesis in dementia have been of interest for a long time but the 
mechanisms have been unclear. A common finding that further complicated this area of study 
is the upregulation of adult hippocampal neurogenesis in several types of dementia including 
AD and DLB/PDD. This phenomenon could be compensatory for the dementia-induced abnormal 
hippocampal circuitry or even contribute to the defects of the system. At the same time, greater 
AHN after drug treatment were reportedly associated with higher cognitive performance (Gatt 
et al., 2018). To understand the difference between healthy neurogenesis and disease-induced 
neurogenesis, more thorough profiling of neurogenic population and deeper comprehension of 
fundamental human adult hippocampal neurogenesis mechanisms are necessary. In that regard, 
currently the only method to study neurogenesis in the DG is from postmortem samples. 
Biomarkers of dementia-sensitive subpopulation in vivo and super high-resolution live imaging 
could be crucial to future longitudinal studies and even diagnosis. 
Changes in AHN as a function of dementia progression have been unclear since there has not 
been a complete profile of relevant neurogenic markers and there are multiple interconnected 
disease-related pathways that affect the DG which have not been understood. One of these 
crucial factors is the septophippocampal cholinergic innervation.      
1.5 Hypotheses and Aims 
1.5.1 Overarching Hypothesis  
Cholinergic innervation in the hippocampus is associated with adult neurogenesis in the dentate 
gyrus.  
1.5.2 Human AD study: hypothesis and aims  
Background: Documented defects in adult hippocampal neurogenesis in AD patients include loss 
of type-1 cells and dysfunctional maturation that results in accumulated population of 
intermediate neurogenic populations. Cholinergic axons from the medial septum and vertical 
diagonal band of Broca (MS/VDB) innervate the hippocampus. MS/VDB have been shown to be 
resilient in AD as demonstrated by an elevation in hippocampal ChAT activity of Braak stage III 
and MCI patients. This compensatory increase in hippocampal ChAT activity is correlated with 
preserved cognitive functions. Septohippocampal cholinergic signals have also been reported to 
regulate adult hippocampal neurogenesis.    
Hypothesis: Upregulation of hippocampal cholinergic innervation is associated with specific 
changes in adult neurogenesis that potentially contributes to cognitive preservation. 
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The aims of the study are 
• To measure the extents of adult hippocampal neurogenesis, cholinergic innervation, and 
correlation between the two using immunohistochemistry on 8 pilot cases of 4 controls 
and 4 AD patients. 
• The pilot study provides the information of whether our markers of choice show 
interesting trend across Braak stages and dementia status. The number of cases 
required for the main study is calculated from the pilot data to give the power of 
approximately 80% for multiple comparison and correlation.      
• To measure the number of intermediate neurogenic population (DCX, HuB/D, PCNA) 
and extents of cholinergic innervation (ChAT, VAChT) using immunohistochemistry on a 
cohort of 36 cases with Braak 0 (4), I (2), II (8), III (6), IV (4), V (5), VI (7). 
The benefits of the study 
• It may provide better understanding of the relationships between changes in cholinergic 
systems and adult hippocampal neurogenesis in humans especially in AD patients, which 
have been difficult to replicate in animal models. 
• It may suggest potential markers of either cholinergic or hippocampal neurogenesis for 
future disease diagnosis.     
 
1.5.3 D427V/WT GBA1 mice study: hypothesis and aims 
Background: Similar to AD, DLB patients exhibit significant degeneration of hippocampal 
cholinergic innervation, loss of DG type-1 cells, and higher number of proliferative intermediate 
populations. However, compensatory biphasic regulation of septohippocampal cholinergic 
systems has not been found. Heterozygous GBA1 mutations are the most prevalent risk factors 
for DLB. D427V/WT GBA1 heterozygous mice have lower GBA activity and impaired 
hippocampal-associated cognitive performance.  
Hypothesis: D427V/WT mice have hippocampal cholinergic deficits that are associated with 
cognitive deficits and aberrant neurogenesis 
The aims of the study are:       
• To profile the changes of cholinergic innervation (ChAT, VAChT) in various parts of the 
brain in D427V/WT mice compared to WT/WT using immunohistochemistry. 
• To evaluate the changes of adult hippocampal neurogenesis (DCX, HuB/D, PCNA) 
between the D427V/WT and WT/WT mice.  
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• To confirm the immunohistochemical findings on cholinergic aberration with western 
blot analysis.      
The benefits of the study  
• This mouse model has not been extensively studied before. Profiles of its cholinergic 
and adult neurogenic will contribute to the evaluation of its potential as a DLB model. 
• A clean genetic model will help us understand mechanistic links between GCase 
functions, cholinergic basal forebrain systems, and adult hippocampal neurogenesis.  
 
1.5.4 5XFAD mice study: hypothesis and aims 
Background: 5XFAD mice develop early and extensive amyloid plaque burden, loss of BFCNs, 
impaired AHN, and cognitive deficits. Nonetheless, there has not been a study on changes in the 
density of cholinergic axons in the cortex or hippocampus or on HuB/D-positive cells in the DG. 
A previous study investigated AHN at earlier ages of up to 7 mo but not at later age of 11-12 mo 
Hypothesis: 5XFAD mice have hippocampal cholinergic deficits that are associated with AHN 
The aims of the study are:       
• To profile the changes of cholinergic innervation (ChAT, VAChT) in various parts of the 
brain in 5XFAD compared with WT using immunohistochemistry. 
• To evaluate the changes of adult hippocampal neurogenesis (DCX, HuB/D, PCNA) 
between the 5XFAD and WT mice.  
The benefits of the study  
• Since 5XFAD does not develop NFT pathology, abnormalities in cholinergic and AHN 






2 Materials and methods 
This section covers the two main methodological approaches used in this thesis namely 
immunohistochemistry and Western blotting. Details of the individual studies and the 
description the cases and materials used are provided at the beginning of the chapter.  
2.1 Immunohistochemistry (IHC) 
Paraffin-embedded 8-µm-thick sections were obtained at the level of the hippocampus. 
Sections were dewaxed with Histo-Clear (National Diagnostics) (2 x 3 min), subsequently 
rehydrated with graded dilutions of alcohol (100%, 2 x 3 min; 90%, 1 x 3 min; 70%, 1x 3 min), 
and washed under running tap water.  Antigen retrieval solution, 10 mM citric acid (pH 6.4), was 
pre-heated to boil in a pressure cooker for 10 min. Slides were immersed in the solution and the 
lid was sealed tight. The cooker was heated again for 5 min 30 sec and left to cool down until 
the pressure valve dropped (~ 10 min). The lid was removed and the cooker was placed under 
gently running tap water for 5 min. Excess water on slides was drained and sections were 
covered with PBS for at least 5 min. Sections were incubated in primary antibody solution for 
overnight at 4°C. Slides were washed with PBS (3 x 3 min). Sections were then incubated in Alexa 
Fluor secondary antibody solution for 1 hr 45 min at room temperature (RT). After the secondary 
antibody was discarded, DAPI solution (D3571, ThermoFisher Scientific) (300 nM, 1 µl of the 5 
mg/ml stock solution in 36.3 ml PBS) was applied to sections for 3 min.  Slides were washed in 
PBS (3 x 3 min) and incubated in Sudan Black B (0.1% in 70% ethanol) for 20 min at RT. Slides 





Level Antigen Host Conjugate Dilution Source 
Primary ChAT Goat  
1:400  - hu 
1:800  - ms 
Millipore :  AB144P 
Primary VAChT Rabbit  
1:3000  - hu 
1:5000  - ms 
Synaptic Systems :  #139 103 
Primary VAChT Goat  1:5000  - ms  Immunostar :  #24286 
Primary CHT1 Rabbit  
1:3000  - hu 
1:5000  - ms 
Millipore :  ABN458 
Primary Synaptophysin Mouse  
1:150  - hu 
1:200  - ms  
Abcam :  ab8049 
Primary DCX Goat  
1:400  - hu 
1:800  - ms 
Santa Cruz :  sc-8066  
(discontinued) 
Primary DCX Mouse  
1:800  - hu 
1:800  - ms 
Santa Cruz :  sc-271390 
Primary HuB/D Rabbit  
1:500    - hu 
1:1000  - ms 
Thermo Fisher :  PA5-38596 
Primary HuC/D Mouse  
1:2000  - hu 
1:2000  - ms 
Thermo Fisher :  PA5-38596 
Primary PCNA Mouse  1:1000  Dako :  M0879 
Primary Calretinin Goat  1:4000 Swant :  CG1 
Primary NKCC1 Mouse  1:1000 DSHB :  T4 
Primary KCC2 Rabbit  1:1000 Millipore :  #07-432 
Primary p-Tau  AT8 Mouse  1:200 Invitrogen : MN-1020  
Primary p-Tau  Ser396 Rabbit  1:1000 Santa Cruz: sc-101815 
      
Secondary Mouse IgG  
Goat 
Donkey 
Alexa 488 1:500 
Thermo Fisher :  A-11008 
Thermo Fisher :  A-21202 
Secondary Rabbit IgG  
Goat 
Donkey 
Alexa 568 1:500 
Thermo Fisher :  A-11011 
Thermo Fisher :  A-10042 




Thermo Fisher :  A-11057 
Thermo Fisher :  A-21447 
      
Secondary Mouse IgG  Horse Biotin 1:500 Vector Lab :  BA-2000  
Secondary Goat IgG   Rabbit Biotin 1:500 Vector Lab :  BA-5000 
      
Secondary Streptavidin  Alexa 488 1:500 Thermo Fisher :  S32354 
Secondary Streptavidin  Alexa 568 1:500 Thermo Fisher :  S11226 
Secondary Streptavidin  Alexa 647 1:500 Thermo Fisher :  S21374 
      
Secondary ABC Kit  HRP 1:200 Vector Lab :  PK-4000 
      





2.2 Western blotting 
Proteins from mouse brains were extracted with TRIzol reagent by Dr Emily Clarke. In brief, 1.5 
ml of TRIzol was added per 100 mg tissue. Tissues were homogenised using the IKA Ultra Turrax 
handheld homogeniser. Homogenates were centrifuged at 12,000 ×g for 5 min at 8 °C. 
Supernatant was transferred to new tube and incubated for 5 min at RT before 0.2 ml of 
chloroform was added per 1.5ml of TRIzol. After incubation for 2-3 min at RT, the mixture was 
centrifuged at 12,000 ×g for 15 min at 4°C. The mixture should be separated into 3 layers: RNA-
concentrated aqueous phase, thin interface, and red phenol-chloroform phase at the bottom. 
Aqueous phase was removed from the interface (for qPCR by Dr Emily Clarke) and 450 µl 100% 
ethanol was added before followed by several times of inversion. The mixture was incubated for 
2-3 min at RT and then centrifuged at 2,000 ×g for 5 min at 4°C. Protein-concentrated 
supernatant was transferred to a new tube and 2.25 ml isopropanol was added. The protein 
solution was incubated for 10 min at RT and then centrifuged at 12,000 ×g for 10 min at 4°C to 
precipitate the proteins and discard the supernatant. Pellets were resuspended and washed in 
3ml of 0.3M Guanidine HCl in 95% ethanol. The protein suspension was incubated for 20 min 
and centrifuged at 7,500 ×g for 5 min at 4°C. The washing process was repeated again before 
the last vigorous wash by vortexing with 2ml 100% ethanol. The same incubation and centrifuge 
were performed, and the pellets were air-dried for 5-10 min. Pellets were resuspended in 200ml 
1% SDS approximately for 15 min at 50°C to ensure that most proteins were solubilised. The 
solution was centrifuged at 10,000 ×g for 10min at 4°C and the supernatant was collected for 
protein assay.          
Protein concentration was determined using the ThermoScientific™ Pierce™ Coomassie 
(Bradford) Protein Assay (# 23200) exactly according to the provided user guide.    
For loading sample preparation, 5X bromophenol blue-containing Laemmli sample buffer for 
SDS-PAGE was added to the TRIzol-extracted protein solution. The sample were then either 
boiled at 95°C for 5 min and then stored at -20°C for SDS-PAGE of most proteins or simply stored 
at 4°C without heating for SDS-PAGE of hydrophobic residue-rich integral membrane proteins 
such as VAChT and VMAT2. 
Electrophoresis was run with a 10% SDS-polyacrylamide gel at 80 V for the first 30 min and at 
130 V for the latter 1 hr. On each gel, 2.5 µl of full range rainbow molecular weight (RPN800E, 
GE Healthcare) was loaded in a central lane and flanked by two lanes of mouse cortex crude 
homogenate as positive controls.   
Proteins in the gel were transferred to nitrocellulose membrane (10600001, GE Healthcare) by 
wet electroblotting at 60 V for 90 min. Membranes were treated with 10% non-fat dry milk in 
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PBS with 0.05% Tween-20 (PBS-T) for 30 min and then incubated in primary antibody solution in 
5% milk PBS-T overnight at 4 °C. After washes in PBS-T (3 x 5 min), membranes were incubated 
in secondary antibody solution in 5% milk PBS-T. Protein bands were visualised by Odyssey 
infrared scanner (LI-COR).       
Level Antigen Host Conjugate Dilution Source 
Primary ChAT Goat  1:1000 Millipore :  AB144P 
Primary ChAT Rabbit  1:1000 Abcam :  ab137349 
Primary VAChT Rabbit  1:3000 Synaptic Systems :  #139 103 
Primary Synaptophysin Mouse  1:10000 Abcam :  ab8049 
Primary βIII-tubulin Rabbit  1:10000 Abcam :  ab6046 
Primary DCX Goat  1:1000 Santa Crux :  sc-8066 
      
Secondary anti-mouse  Goat Alexa 680 1:5000 Thermo Fisher :  A-28183 
Secondary anti-rabbit  Goat Alexa 750 1:5000 Thermo Fisher :  A-21039 
Secondary anti-goat   Donkey IRDye 800 1:5000 LI-COR :  #925-32214 
      





3 Contribution of cholinergic innervation to adult hippocampal 
neurogenesis in Alzheimer’s disease patients: Pilot cases 
3.1 Background 
The study of neurogenesis in AD has become an increasing focus of research (Kempermann et 
al., 2018) see section 1.4. Apart from a deeper understanding of disease mechanisms the 
prospect of supporting neurogenesis as new therapeutic target in AD is attractive (Han et al., 
2016). The levels of neuroblast markers and neuronal fate-determined progenitor markers in 
the DG such as DCX, PSA-NCAM, and TUC-4 have been evaluated to be higher in AD patients 
than in controls by using immunohistochemistry and western bloting (Jin et al., 2004a; Perry et 
al., 2012). The number of DCX-positive neurons may vary among individuals from none to several 
cells, but AD patients still show higher incidence of possessing DCX-positive cells. Interestingly, 
the level of βIII-tubulin is not different between AD patients and controls. This result is 
congruent with the lower number of HuC/D-positive cells without PCNA expression in patients 
with Braak stage V-VI, which indicates defects in maturation past mitotic phase (Ekonomou et 
al., 2015). Interestingly, the number of calretinin-positive immature neurons is also increased in 
AD patients, which suggests that there is also a defect in late maturation step and circuitry 
integration (Gomez-Nicola et al., 2014). This notion is supported by the lower number of 
calbindin-positive neurons in the DG (Palop et al., 2003; Bandopadhyay et al., 2014; Stefanits et 
al., 2014). However, western blotting of the whole hippocampus shows a contradictory result of 
unchanged calbindin level across between AD and controls (Jin et al., 2004a). The level of type-
1 marker Msi-1 is reduced in AD patients but the level of type-2 marker nestin is increased Perry 
et al., 2012. The number of Sox2-positive cells is not different between AD and controls, but the 
number of Sox-2 positive postmitotic granule neurons is lower in AD than in controls and non-
demented individuals with high pathology scores (Briley et al., 2016).      
The overall hypothesis of this study is that there is a relationship between cholinergic 
innervation in the DG and changes in adult hippocampal neurogenesis across progressing Braak 
stage (section 1.5)    
The purposes of the pilot study were to find suitable markers that truthfully characterise 
cholinergic axons in the DG and subpopulation of neuroblasts or immature DGCs, to optimise 
IHC procedures and quantification methods for corresponding markers, to perform exploratory 
statistics that helped identifying appropriate statistical models and potential covariates, and 
lastly to provide approximate effect sizes of different markers of interest to estimate 80%-power 
sample size for the main study. 
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The hypotheses of this chapter were as follows. First, ChAT and VAChT staining would reflect 
overall morphology or enzyme capacity and punctate characteristics of cholinergic axons 
respectively. Second, immunoreactivity for DCX and HuC/D would represent two different but 
overlapping neurogenic subpopulations in the course of adult-born DGC development. Last, 
effect size calculated from this pilot data of various markers should be sufficiently large that an 
estimated sample size of approximately 35-40 could achieve 80% power in the main study.        
 
3.2 Materials and Methods  
 
3.2.1 Pilot human cohort and data management 
All brain sections were requested from London Neurodegenerative Diseases Brain Bank, part of 
the Brains for Dementia Research & the Medical Research Council networks (LNDBB, BDR & 
MRC). Originally, 5 cases of control and dementia each were selected, but sections from one of 
the non-demented cases with Braak IV did not contain the DG. Therefore, there were 9 cases in 
total available for study. Demographic variables together PMI and pH are shown in the Table 
3.1. The only Braak IV ND case also had no reported pH data and had to be excluded from the 
regression analyses. To account for the effect of different longitudinal parts of the hippocampus, 
the distance in cm of each coronal section from the front of the brain was estimated from the 
shape of the hippocampus and parahippocampal gyrus with reference to high resolution Nissl-
stained sections provided in Virtual Microscopy page of TheHumanBrain.info 
(TheHumanBrain.info, 2018a). We planned to examine cm from front, sex, age, PMI, and pH as 
covariates for this study and also for the main study. Amyloid angiopathy was not included since 
we intended to minimize the number of cases with vascular pathology.  Student’s t-test with 
Welch’s correction showed that none of the selected covariates was significantly different 
























1 A319/14 BBN_24371 II ND - 22.0 F 90 44.0 5.79 
2 A345/12 BBN_11086 II ND Mod 29.0 M 85 55.0 6.62 
3 A133/12 BBN_16198 III ND - 18.0 F 88 39.0 6.64 
4 A282/11 BBN_9960 IV ND - 28.0 F 93 13.5 -- 
5 A223/12 BBN_9977 IV AD/VD Mod-High 18.0 F 83 22.0 6.46 
6 A323/11 BBN_9964 V D High 21.0 F 85 40.0 6.56 
7 A201/13 BBN_16191 V AD Mod 28.0 M 88 33.0 7.80 
-1 A110/13 BBN_16202 VI CBD mild 19.0 M 67 22.0 6.58 
8 A166/12 BBN_4244 VI AD - 35.0 F 88 25.0 6.47 
Table 3.1 – Clinical and demographic data of the pilot cases 
BBN-ID of each case can be used to look up further information on MRC UK brain bank network. Cm_front 
– Position of each coronal section in terms of cm from the front of the brain was estimated from the shape 
of the hippocampus and adjacent parahippocampal gyrus. There was no pH data available for the Braak 
IV ND case. Mod – moderate; VD – vascular dementia; ND – no dementia; D – dementia; CBD – 
corticobasal degeneration; AA – amyloid angiopathy; PMI – postmortem interval. 
 
Covariates Diagnosis N Mean SEM p-value 
Cm_front 
No dementia 4 24.25 2.59 
0.795 
Dementia 4 25.50 3.80 
Sex 
No dementia 4 0.25 0.25 
1.000 
Dementia 4 0.25 0.25 
Age 
No dementia 4 89.00 1.68 
0.127 
Dementia 4 85.50 1.04 
PMI 
No dementia 4 37.88 8.79 
0.447 
Dementia 4 30.00 4.06 
pH 
No dementia 3 6.35 0.28 
0.344 
Dementia 4 6.82 0.33 
Table 3.2 – Summary of covariates   
Dementia cases naturally have higher incidence of amyloid angiopathy, but not statistically significant in 
this pilot cohort. No significant difference in any covariates was observed between no dementia and 
dementia groups by Student’s t-test with Welch’ correction. 
 
3.2.2 Immunohistochemistry 
Fluorescence images were captured with Zeiss Axiocam fluorescence microscope at 20x 
objective magnification using Axiovision SE64 Rel 4.9.1 software. Brightfield images were 
captured with Leica microscope and software. 
Antibody stripping was performed according to the protocol established by Cattoretti Lab 
(Bolognesi et al., 2017) with slight modification. In brief, preincubation of slides in Laemmli 
buffer was for 30 min until the water bath temperature reached 56 °C followed by incubation 
for 2 hr 30 min with occasional shaking. Slides were rinsed in running water for 30 min before 
another round of standard staining procedures. All PBS-based solutions used in any staining 




Various methods of quantification have been tried for axon density as follows: % area of staining, 
the number of intersections between axons and equally spaced grid lines, and the number of 
intersections between axons and equally spaced grid points. The % area of staining was chosen 
because results from all methods were highly correlated (data not shown) and this approach 
provided the greatest face validity.  
For the density of ChAT-positive axons, colour deconvolution function was first used to separate 
DAB colour from the haematoxylin. Then for both VAChT and ChAT staining, unequal lighting 
background signal was eliminated by Subtract Background… function at 30px rolling ball radius. 
The percentage area of staining was then measured. For SPP, mean grey value was measured 
instead of percentage area of staining due to the high density of total puncta. Cells were 
measured as counts per mm of DG length. 
 
3.2.4 Statistical analyses 
Statistical differences in any variables between dementia and non-dementia groups were 
measured by Student’s t-test  and by one-way ANOVA between Braak stages (Appendix Table 
A.1). When covariates were taken into account, univariate general linear model (uniGLM) was 
used for both cholinergic and neurogenic markers, but negative binomial regression model 
(NegBin)  was used only for neurogenic markers which were count data. 
For a priori statistical power calculation, eta-squared or η2 value was computed from a uniGLM 
of each marker or dependent variable without any covariate or from a correlation between each 
pair of cholinergic and AHN markers. Effect size and a minimum sample size to achieve 80% 
statistical power were calculated from the η2 value by G*Power 3.1.9.2. Estimation of minimum 
80% power sample size for a uniGLM by dementia status or Braak stage was under an 
assumption of 5 covariates. Estimation of minimum 80% power sample size for both Pearson 
and Spearman correlation tests used the same correlation model in the G*power. 
Negative binomial regression (NegBin) models count data with covariates of interest including 
the main group factor. NegBin, as a generalised version of Poisson regression, allows 
overdispersion and heterogeneity of data. Count density was calculated by setting natural log 
values of length or area as offsets or exposure variables.     
All statistical tests including uniGLM and NegBin except power calculation were conducted in 





3.3.1 Changes in cholinergic and neurogenic markers between control and dementia 
Staining of cholinergic axons with ChAT in the present study was consistent with what has been 
described in previous studies (Figure 3.1A-C) (Kooi et al., 2011; Perry et al., 2012). VAChT-
positive axons in the ML share similar morphological characteristics with ChAT-positive axons 
but were thinner and more punctate as expected of a synaptic vesicle marker (Figure 3.1D-F). 
The non-specific staining in cell bodies, especially in the GCL, was intense such that 
determination of the extent of axon staining in the GCL was not feasible. For comparison, a more 
general marker of presynaptic terminals synaptophysin (SPP) was also examined. SPP staining 
was, as expected of presynaptic markers, very intense in the ML and hippocampal parenchyma 
but absent in the cell body and low in the cell-dense GCL (Figure 3.1G-I). In terms of the purpose 
of this pilot study, exploratory statistical analysis was undertaken. This analysis showed that 
staining of axons for ChAT in the ML (Figure 3.2A) and GCL (Figure 3.1B) was lower in the 
dementia cases than controls by 34.5% and 28.2% respectively but the difference was not 
statically significant. VAChT %area of staining in the ML (Figure 3.2C) was significantly reduced 
in the dementia group by 50.6% (p = 0.0095). SPP mean grey value in the ML (Figure 3.2D) was 








Figure 3.1 – IHC of cholinergic and synaptic markers in the DG of pilot cases 
Representative images of ChAT staining in the DG from cases with non-demented Braak stage II (A), non-
demented Braak IV (B), and demented Braak VI respectively (C). Representative images of VAChT (D-F) 
and SPP (G-I) staining from the same cases as above. Scale bar = 40 µm. Inset images of ChAT (Bʹ), VAChT 
(Eʹ), SPP (Hʹ), and SPP-VAChT colocalisation (J) illustrated the staining characteristics in details with 





Figure 3.2 – IHC of cholinergic and synaptic markers in the DG of pilot cases 
The percentage area of ChAT staining in the ML (A) and GCL (B), VAChT staining in the ML (C), and mean 
grey value of SPP staining (D) were compared between dementia and non-dementia groups with Braak 
stage label for each case. Only VAChT staining was higher in non-dementia than in dementia cases (C). 
Data are expressed as scattered dot plots and the horizontal line represents the mean and the error bars 
SEM (n=4). Unpaired Student’s t-test: **p < 0.01 compared with the control.  
 
DCX staining within the hippocampus was similar to what has been reported in previous articles 
by our group (Figure 3.3A-C) (Perry et al., 2012; Ekonomou et al., 2015). Large intense DCX-
positive cell bodies were mainly observed in dementia cases at high Braak stage. Relatively faint 
cell body staining was present in no-dementia cases as well. HuC/D staining was mainly in cell 
nuclei as previously shown (Figure 3.3D-F) (Ekonomou et al., 2015). Note that HuC/D was also 
highly expressed by large neurons in the hilus and the CA3 (Figure 3.3E). Density of DCX-positive 
cells in the dementia cases was significantly higher than in controls by 394.7 (p = 0.0245) (Figure 







Figure 3.3 – IHC of neurogenic markers in the hippocampus of pilot cases 
Representative images of DCX-positive cells (black arrow) in the DG from cases with non-demented Braak 
2 (A), non-demented Braak 4 (B), and demented Braak 6 respectively (C). Scale bar = 20 µm. 
Representative images of HuC/D-positive cells (white arrow) from the same cases as above (D-F). Scale 
bar = 200 µm. The number of DCX (G) and HuC/D (H) positive cells per the length of DG from each Braak 
group. Comparison by diagnosis shows that the density of DCX-positive cells in the controls is lower than 






3.3.2 Modelling data with covariates: screening with Pearson/Spearman correlation 
The total sample size of 8 or even less as 7 when pH is a covariate is too small for modelling with 
multiple covariates to be meaningful. Even for a sample size of up to 40 in the main study, a total 
number of 5 covariates could reduce model efficiency by overfitting (Hawkins, 2004) as a 
traditionally suggested ratio of samples to covariates is 10 to 1 (Lydersen, 2015). Pearson and 
Spearman correlation tests between each marker and covariate were conducted to check 
whether these correlation tests could be used to screen for significant predictors among the 5 
potential covariates. A comparison with uniGLM or NegBin models with one covariate and 
dementia as fixed factor showed that p-values of correlation coefficients generally follow similar 
trends with slightly higher sensitivity to the p-values of covariate coefficients in a model 
especially a uniGLM (Table 3.3). For example, Pearson correlation p-value at 0.138 between SPP 
in ML and cm_front was more indicative of covariate p-value of cm_front at 0.130 in a uniGLM 
for SPP than the Spearman correlation p-value at 0.227. On the other hand, Spearman 
correlation p-value at 0.023 between ChAT in ML and pH was closer to the covariate p-value of 
pH at 0.059 in a model for ChAT in ML than the Pearson correlation p-value at 0.388. Small 
sample size especially with covariates increased a chance of singular Hessian matrix in NegBin 
and indicated model instability. Nonetheless, pH was a significant predictor of the number of 
HuC/D-positive cells per mm length. While both correlations between HuC/D and pH were not 
less than 0.05, their p-values were relatively low at 0.15.       
Pearson correlation between pooled p-values from all covariate-marker pairs (n=30) of uniGLM 
and those from Pearson or Spearman correlation confirmed that correlation p-value was a 
significant predictor of uniGLM covariate p-value (uniGLM vs Pearson, r = 0.695, p<0.0001; 
uniGLM vs Spearman, r = 0.775, p<0.0001). For NegBin, there were only 2 AHN markers and 
NegBin was also more sensitive to small sample size and covariate. As a result, predictive 
capacity of correlation p-value for NegBin covariate p-value could not be corroborated (n=6; 
NegBin vs Pearson, r = 0.427, p = 0.399; NegBin vs Spearman, r = 0.414, p=0.414). Regardless, 
their correlation coefficients were still within a decent range of 0.400-0.450, so both Pearson 
and Spearman correlations were chosen as quick screening test for covariates in NegBin in the 
future main study. Overall, a significant p-value of either Pearson or Spearman correlation 
between a covariate and with any given marker should serve as a fast and effective criteria to 
include that covariate into a model of the given marker.  
















(n = 8) 
uniGLM 0.923 0.441 0.926 0.130 0.922 0.621 
NegBin     singular 0.600 
Pearson 0.808 0.373 0.872 0.138 0.888 0.657 
Spearman 0.798 0.313 0.910 0.227 0.910 0.776 
Sex 
(n = 8) 
uniGLM 0.633 0.757 0.885 0.919 0.869 0.355 
NegBin     0.677 singular 
Pearson 0.679 0.745 0.930 0.927 0.912 0.330 
Spearman 0.547 0.766 0.766 0.547 0.766 0.203 
Age 
(n = 8) 
uniGLM 0.264 0.143 0.307 0.679 0.897 0.765 
NegBin     0.860 singular 
Pearson 0.067 0.078 0.058 0.243 0.281 0.894 
Spearman 0.154 0.096 0.188 0.154 0.177 0.910 
PMI 
(n = 8) 
uniGLM 0.638 0.355 0.379 0.488 0.932 0.372 
NegBin     singular 0.234 
Pearson 0.943 0.510 0.891 0.289 0.946 0.507 
Spearman 0.867 0.493 0.493 0.320 0.779 0.260 
pH 
(n = 7) 
uniGLM 0.059 0.373 0.898 0.790 0.687 0.251 
NegBin     0.401 0.030 
Pearson 0.388 0.434 0.450 0.754 0.312 0.157 
Spearman 0.023 0.215 0.819 0.939 0.432 0.148 
Table 3.3 – Comparisons between p-values of covariate predictive ability in a model by 
dementia status and p-values of covariate correlations. 
The table compares p-value for predictive ability of each potential covariate in a uniGLM or NegBin of a 
dependent variable marker with dementia as fixed factor to a p-value of correlation test between a 
covariate and a marker. For any p-values less than 0.500, light green and light red shading indicates a 
positive and negative corresponding coefficient respectively. Any p-values less than 0.100 are highlighted 
in red. An unstable NegBin with a singular Hessian matrix is denoted singular. One case does not have pH 
value.    
 
3.3.3 Power calculation and sample size estimation 
A priori power analyses were performed to compute a required sample size to achieve 80% 
statistical power from an effect size of the pilot data. Specifically, effect sizes in this study would 
reflect potential mean difference in markers between dementia or Braak groups or correlation 
between any given pair of markers. An η2 value was computed from a uniGLM of each marker 
with dementia status or Braak stage as a fixed factor (Table 3.4). Subsequently, a corresponding 
effect size and a minimum sample size that achieve 80% statistical power for a uniGLM of the 
future main study were calculated from the η2 value using G*Power under an assumption of 5 
covariates and dementia status (2 groups; numerator degree of freedom = 6) or Braak stage (7 
groups Braak 0-VI; numerator degree of freedom = 11) as a fixed factor. Note that for power 
calculation, DCX and HuC/D were modelled in uniGLM since η2 value cannot be calculated from 
NegBin model. For models by dementia, ChAT in the ML, VAChT in the ML, SPP in the ML, and 
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DCX had minimum 80% power sample size less than 40. For models by Braak, all markers had 
minimum 80% power sample size less than 40 but it should be noted that η2 value could be 
exaggerated by a very small sample size per group (n = 1-2) and potentially small standard 
deviation. Under the current assumption of the model by Braak stages (5 covariates; 7 groups; 
numerator degree of freedom = 11), the least calculation-valid minimum 80% power sample size 
is 25 from the effect size of approximately 1.135 (η2 = 0.563). Despite a calculation error from 
the software and fluctuation from small sample size, large effect size still indicated a promising 
potential difference in a given marker between groups. Considering models by dementia and 
those by Braak together, a sample size of 40 or at least 34 would be sufficient to provide an 
approximate statistical power of 80% for any current markers of interest.          
 
Markers By Dementia By Braak 
 η2 Effect 
size 
Minimum sample size 
to achieve 80% power 
η2 Effect 
size 
Minimum sample size 
to achieve 80% power 
ChAT in ML 0.378 0.780 N =   30    0.444 0.894 N = 33 
ChAT in GCL 0.098 0.330 N = 132 0.642 1.339 N < 25  
VAChT in ML 0.701 1.531 N =   14 0.434 0.876 N = 34 
SPP in ML 0.338 0.715 N =   34 0.754 1.751 N < 25 
DCX 0.631 1.308 N =   16 0.865 2.531 N < 25 
HuC/D 0.080 0.295 N = 164 0.957 4.718 N < 25 
Table 3.4 – η2 and effect size from group statistics, and minimum sample size required for 80% 
power in the future study 
Effect size was calculated from η2 obtained from uniGLM of each variable of interest with dementia or 
Braak groups as fixed factor. An 80% power sample size was calculated from the effect size under an 
assumption of 2 dementia/non-dementia groups and 5 covariates or an assumption of 7 Braak groups and 
5 covariates. Red highlight text denotes a minimum 80% power sample size less than 40. Green shading 
indicates a promising but exaggerated effect size such that the minimum 80% power sample size is lower 
than a calculation limit.       
    
 
The main study would also include correlation tests to examine the relationship between 
cholinergic and AHN markers. Pearson and Spearman correlation coefficient between each pair 
of cholinergic/synaptic and AHN markers were used to compute a minimum 80% power sample 
size (Table 3.5). Overall, DCX was negatively correlated with VAChT but HuC/D was correlated 
with ChAT and SPP. A sample size of 40 was also enough to grant an 80% statistical power for 
either Pearson or Spearman correlation between DCX and VAChT, HuC/D and ChAT, or HuC/D 




Markers Pearson Spearman 
Cholinergic / 
synaptic 
AHN r Minimum sample size 
to achieve 80% power 
rs Minimum sample size 
to achieve 80% power 
ChAT in ML DCX -0.215 N = 167    -0.238 N = 136 
HuC/D 0.373 N =   54 0.548 N =   23 
ChAT in GCL DCX 0.002 N >> 1000 -0.119 N = 552 
HuC/D 0.481 N =   31 0.429 N =   40 
VAChT in ML DCX -0.509 N =   27 -0.714 N =   12 
HuC/D 0.016 N >> 1000 0.310 N =   79 
SPP in ML DCX -0.184 N = 229 -0.357 N =   59 
HuC/D 0.444 N =   37 0.381 N =   51 
Table 3.5 – Correlation coefficients and minimum sample size required for 80% power in the 
future study 
An 80% power sample size was calculated from Pearson or Spearman correlation coefficient between a 
cholinergic/synaptic marker and a neurogenic marker. Red highlight text denotes a minimum 80% power 
sample size less than 40.       
 
 
3.3.4 Development of staining protocols for the main study 
We planned to investigate proliferative status profiles of immature neurons by identifying PCNA 
immunopositivity in those immature neurons in the same way that a previous article by our 
group (Ekonomou et al., 2015) investigated colocalisation between HuC/D and PCNA. Although 
antibodies for HuC/D and PCNA used in our lab were both mouse monoclonal antibodies (see 
Table 2.1), the authors of this previous work used 4% paraformaldehyde to prevent the second 
round of anti-mouse secondary antibody (488) from binding to the first primary antibody, 
specifically anti-HuC/D, which had been occupied by the first round of secondary antibody (568). 
However, this sequential double labelling with two mouse monoclonal antibodies was not 
successfully replicated with either 4% paraformaldehyde or 70% ethanol. We therefore decided 
to find another HuC/D antibody produced from a rabbit such that we can perform a standard 
triple immunofluorescence staining of HuC/D, PCNA, and DCX. We have not found another 
antibody for rabbit anti-HuC/D so we opted for rabbit anti-HuB/D instead. Triple 
immunofluorescence staining with HuC/D, HuB/D and DCX was performed to confirm the 
colocalisation among the three markers (Figure 3.4). Most cells intensely positive for HuB/D 
were also highly positive for HuC/D. In general, HuB/D staining was slightly more specific in the 
GCL than in HuC/D. A few of HuB/D- and HuC/D-double positive cells were also positive for DCX. 
HuB/D and HuC/D were also expressed in some interneurons, hilar mossy cells, and CA3 
pyramidal neurons. This helped confirm our plan to use HuB/D and DCX as markers of immature 





Figure 3.4 – Overlap between HuC/D, HuB/D, and DCX 
DAPI (A) was used to locate the GCL. HuC/D (B) strongly overlaps with HuB/D (C) (rightward 
openarrowhead). Several cells that contained both HuC/D and HuB/D staining were larger than average 
DGCs and hence likely were GABAergic interneurons (leftward large openarrowhead) (B, C, E). Together 
with DCX staining (D), some cells express all 3 markers (arrowhead) but some also express DCX alone (long 





The unexpected presence of DCX staining in human cell nuclei prompted the validation of the 
goat anti-DCX antibody sc-8066 that would later be used in the main study. Since sc-8066 and 
its accompanying blocking peptide sc-8066P have been discontinued, a blocking DCX peptide 
ab19804 for another DCX antibody ab18723 was used instead in this experiment. An immuno-
genic C-terminal DCX fragment for ab18723 (YLPLSLDDSDSLGDSM) was only 2 amino acids 
shorter than an immunogenic C-terminal DCX fragment for sc-8066 (DLYLPLSLDDSDSLGDSM) 
(Bloch et al., 2011), and should therefore have sufficient binding affinity to block sc-8066. A 
1:400 dilution (0.5 µg/ml for sections) or 1:1,000 dilution (0.2 µg/ml for membrane) sc-8066 
solution was incubated with 1:100 dilution (10 µg/ml) or 1:250 dilution (4 µg/ml) blocking 
peptide for an hour at RT before it was applied to a section or membrane respectively. Sections 
were incubated with a mouse monoclonal DCX antibody sc-271390 and a rabbit HuB/D antibody 
prior to the incubation with a peptide-blocked sc-8066 solution or a control staining solution 
without blocking peptide. Control staining in mouse sections showed colocalisation between the 
two DCX antibodies in cytoplasm of cell bodies (arrow) and neurites (dotted arrow) in the DG 
(Figure 3.5A-C) and SVZ (Figure 3.5D-F). Preadsorption with the peptide completely blocked the 
sc-8066 from binding to DCX proteins on the sections that were prelabelled with sc-271390 
(Figure 3.5G-L). Mouse blood vessels (dotted open arrow) were labelled by DAPI and secondary 
anti-mouse antibody but completely devoid of sc-8066 staining or autofluorescence at 647 nm 
channel. Visualisation of the control staining in human hippocampal sections at a thin optical 
plane using confocal microscopy confirmed a colocalisation between the two DCX antibodies in 
both cytoplasm and nucleus (arrow) (Figure 3.5M-P). Blocking peptide completely prevented sc-
8066 staining in the sc-271390-labelled cells (Figure 3.5Q-T). It should be noted that human 
blood vessels (dotted open arrow) were also labelled by sc-8066 regardless of peptide blocking 
(Figure 3.5M-P; Figure 3.5U-X). Probing with the control sc-8066 solution showed predicted 
bands of DCX at approximately 41 kDa in human BA21 and BA24 homogenate samples (20 µg 
protein) and in hippocampus-including whole rat cortex homogenate (60 µg protein) (Figure 
3.5Y). Peptide incubation completely blocked labelling of the predicted 41 kDa DCX bands in all 
samples but had no effect on non-DCX bands at approximately 50 kDa in human samples. This 
unknown 50 kDa band may correspond to the human blood vessel-associated protein that was 
recognised by sc-8066 since their labelling was similarly not affected by the blocking peptide. 
Labelling with βIII-tubulin antibody confirmed that there was no abnormality in the samples 






Figure 3.5 – Validation of goat anti-DCX antibody sc-8066 
Colocalisation between two DCX antibodies sc-271390 and sc-8066 in cell bodies (arrow) and neurites 
(dotted arrow) but not in blood vessels (dotted open arrow) was demonstrated in the mouse DG (A-C) 
and SVZ (D-F). Preadsorbed sc-8066 yielded no signal in sc-271390-immunoreactive particles (G-L). 
Confocal microscopy revealed colocalisation between the two DCX antibodies in a human HuB/D-positive 
cell in its cytoplasm and nucleus (M-P). There was no colocalisation signal between sc-271390 and 
preadsorbed sc-8066 (Q-T). Blood vessels were positive for sc-8066 without (M-P) or with preadsorption 
(U-X). Immunoblot with sc-8066 showed predicted DCX band and unidentified higher MW band, the latter 
of which was not blocked by preadsorption (Y). Immunoblot for βIII-tubulin on the same membranes 




An attempt was made to develop antibody stripping method in order to have a more complete 
profile of markers expressed by specific neurogenic populations in the human DG. This protocol 
used standard Laemmli buffer and we incubated the sections for about 2 hours at 56°C. Here we 
showed that this protocol could successfully remove antibodies that recognise Aβ from amyloid 
plaques or cholinergic markers from neurites (Figure 3.6). However, it could not remove AT8 
antibodies from compact phospho-tau aggregates such as neurofibrillary tangles (Figure 3.7). 
This stripping protocol was also conducted on human pilot sections previously stained for SPP 
(Figure 3.8A) and VAChT. The initial round of VAChT staining at 1:1500 dilution yielded high 
cellular background in the DG that overwhelmed VAChT-positive axons in the GCL (Figure 3.8B; 
also see Figure 3.1D-F). After stripping and re-probing sections with VAChT antibody at higher 
dilution of 1:3000 (Figure 3.8C) and ChAT antibody (Figure 3.8D), the VAChT non-specific 
background in the GCL was considerably reduced and VAChT-positive axons in the GCL were 
visualisable. Double labelling with ChAT antibody also showed that some axons were more 
positive for VAChT or ChAT than the other (Figure 3.8E). SPP staining image prior to the stripping 
could also be superimposed with images of VAChT and ChAT for colocalisation analysis and 
identification of presynaptic terminals (Figure 3.8F). Unfortunately, relative low efficiency of the 
current Axiocam microscope in the 647nm channel that demanded approximately twice as much 
exposure time as other channels to acquire the same signal intensity together with 647nm 
autofluorescence in parenchymal axon fibres especially myelinated fibres (see Figure 3.4D and 
3.5L as examples) collectively discouraged staining of synaptic markers especially SPP in the 
647nm channel. While it is possible to have SPP in 488 and weaker but detectable ChAT signal 
in 647, the co-staining of VAChT and ChAT was the priority of the main study. As a result, double 
labelling of VAChT and ChAT in 488nm and 568nm without SPP staining would be performed in 
the main study so that the colocalisation between the two cholinergic markers could be 





Figure 3.6 – Antibody stripping was effective in removing cholinergic and Aβ staining 
Staining of Aβ42 (A) on amyloid plaques (arrowhead) and VAChT staining (B) on cholinergic axons 
(diamond-end arrow)  in TASTPM AD transgenic mouse section was successfully removed by the antibody 
stripping method (C and D). This also allowed reprobing with an primary antibody for Aβ40 that has the 
same host as the VAChT antibody (D). Endogenous mouse IgGs in blood vessels (dotted open arrow) were 
also removed in the process. Two sets of images before and after stripping could be superimposed to 
analyse colocalisation of multiple markers which could be labelled by primary antibodies generated from 






Figure 3.7 – Antibody stripping has not been optimised for intense pathology staining  
Intense pathological or cellular staining such as NFTs or ghost tangles (A), in the DG in this example (B), 
still could not be completely removed. NFT staining signals that were barely visible under the same 
exposure time as in the previous round of staining (C) were proven to remain on the section under higher 







    
Figure 3.8 – VAChT and ChAT as target candidates for the main study  
After SPP (A) and 1:1500 dilution VAChT (B) signals were eliminated by antibody stripping protocol, 
sections were reprobed with VAChT antibody at 1:3000 dilution which reduced background staining in cell 
bodies and improved visualisation of axons (C). While fibre and punctate staining was completely cleared, 
staining residuals in blood vessels still remained (leftward arrow). ChAT antibody (D) was also added 
together with VAChT antibody for potential colocalisation analysis (E). Images from two rounds of staining 




This antibody stripping method was tested for its efficiency in expanding the range of neurogenic 
marker profile on a single section. The antibodies for three key AHN markers for the main study, 
namely PCNA (Figure 3.9A), HuB/D (Figure 3.9B), and DCX (Figure 3.9C) were first probed to a 
section. After images of the DG were captured, the section was subjected to the antibody 
stripping buffer for two and a half hours and re-probed with the second set of antibodies NKCC1 
(Figure 3.9D), KCC2 (Figure 3.9E), and Calretinin (Figure 3.9F). Staining in a nucleus and cell body 
of PCNA and DCX was effectively removed by the stripping method. Intense nuclear staining by 
HuB/D antibody, however, remained to different extents depending on the types of cells and 
variably on different human cases. NKCC1 and KCC2 showed expected inverse pattern of 
expression, considering their opposing roles in Cl- balance and GABA signalling responses. A few 
HuB/D-positive neurons showed high expression of NKCC1 and there were multiple DGCs with 
no PCNA, HuB/D, or DCX that had extremely high NKCC1 and almost none KCC2. Furthermore, 
HuB/D antibody residuals obfuscated KCC2 immunopositivity in NKCC1-positive immature 
neurons and this dissuaded us from applying stripping method to in the main study. 
Interestingly, we found that all calretinin-positive cells also expressed HuB/D, there were few 
HuB/D positive cells with DCX but no calretinin, and few HuB/D-positive DGC-like cells had 
neither DCX nor HuB/D. This supported the notion that HuB/D expression spanned a wide range 
of neurogenic populations including those slightly more mature than DCX- or calretinin-positive 
groups. Therefore, in the main study, we would speculate that HuB/D-negative DCX-positive, 
HuB/D- and DCX-double positive, and DCX-negative HuB/D positive cells would represent 










Figure 3.9 – Additional profiles of immature neurons with staining of NKCC1, KCC2, and 
Calretinin after antibody stripping (i) 
Sections were first stained for PCNA (A), HuB/D (B), and DCX (C). After stripping, sections were stained for 
NKCC1 (D), KCC2 (E), and CR (F) with the matching fluorescence-labelled secondary antibodies respectively 
(488, 568, and 647 nm). HuB/D still remained in some neuronal nuclei (circle-tailed arrow). We can 
generally observe inverse relationship between NKCC1 (dotted rectangular box) and KCC2 signals (dotted 
ellipses). Several cells express both HuB/D and DCX (arrowhead), and few of them also contain faint but 
observable PCNA (green arrowhead). Most HuB/D and DCX-double positive cells also express CR. 
However, few cells have only CR and HuB/D but not DCX (open arrowhead). Bright PCNA-positive radial 






Figure 3.10 – Additional profiles of immature neurons with staining of NKCC1, KCC2, and 
Calretinin (ii)  
Shown above are superimposed image of triple markers for the main study prior to the stripping (A), 
superimposition of pre-strip HuB/D and post-strip CR (B), superimposition with DCX in addition to the 
previous image (C), post-strip NKCC1 and KCC2 (D), post-strip NKCC1 with the pre-strip HuB/D and DCX 
(E), and lastly DAPI (F). HuB/D still remained in some neuronal nuclei (circle-tailed arrow). Inverse 
relationship between NKCC1 (dotted rectangular box) and KCC2 signals (dotted ellipses) could be 
observed. Several cells express both HuB/D and DCX (arrowhead), and few of them also contain faint but 
observable PCNA (green arrowhead). Most HuB/D and DCX-double positive cells also express CR. 
However, few cells have only CR and HuB/D but not DCX (open arrowhead). Bright PCNA-positive radial 




The findings of this chapter were as follows; 
- Accurate staining patterns of cholinergic markers VAChT and ChAT and AHN markers 
DCX and HuC/D, as described in previous literatures. 
- Percentage area of staining with univariate GLM model and cell count per mm DG length 
with negative binomial regression models were chosen as methods of quantification and 
statistics 
- Results in this pilot study yielded a promising estimated effect size such that a moderate 
sample size of at least 40 should be sufficient to achieve a statistical power of 80%. 
- HuB/D is an adequate substitute for HuC/D for easier double labelling with PCNA.  
- DCX nuclear immunopositivity in human was validated.  
- ChAT and VAChT double labelling will also be performed in the main study. 
- Antibody stripping method has not been optimised but it was effective enough to 
confirm that HuB/D is expressed in some DCX-positive and in most calretinin-positive 
immature neurons.    
The pilot cases provided by the brain bank allowed us to establish the methods, find suitable 
choices of markers, examine potential confounding variables, and estimate statistical power in 
order to justify the feasibility of our main study to the brain bank. The pilot study was successful 
in that we were able to identify suitable markers of cholinergic and adult neurogenesis and 
determine that there were very few confounding variables that needed to be considered in the 
main study. Finally, statistical power analysis determined that the study investigating the 
relationship between cholinergic marker and neurogenesis was feasible with moderate number 
of samples. 
The most widely used marker of cholinergic neurons in the literature was acetylcholine-
synthesizing enzyme ChAT. Immunohistochemistry of ChAT has been proved to be a reliable 
marker of cholinergic axons allowed us to properly visualise the beads and chain-like 
morphology of varicosity-abundant cholinergic axons in target brain area. In the basal forebrain, 
ChAT also provides a good visualisation of the cholinergic cell bodies and processes. The 
cholinergic synaptic marker, VAChT, has been less widely used but in general provides a reliable 
marker for cholinergic terminals. The present study is consistent with these previous results in 
that it shows the expected distribution of cholinergic terminals within the hippocampus (Kooi et 
al., 2011; Schafer et al., 1995). 
There were 5 potential covariates: cm_front, sex, age, PMI, and pH. The reason we included 
estimated distance of coronal section in cm from the front was that different part of the DG 
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reportedly had different adult neurogenesis patterns in human (Boldrini et al., 2018) and they 
also have different functions based on experiments in rodents. Sex may have effect on disease 
pathology. Aging was shown to reduce rates of adult hippocampal neurogenesis in human 
(Knoth et al., 2010; Spalding et al., 2013; Boldrini et al., 2018). Longer PMI was shown to reduce 
DCX expression in postmortem rat brains (Boekhoorn et al., 2006) and here it was correlated 
with VAChT %area of staining in our study. Lastly, pH was correlated with ChAT %area of staining. 
For choices of cholinergic markers, VAChT and ChAT were chosen as our IHC methods. Another 
possible marker for cholinergic was CHT1 but its immunohistochemical protocol has not been 
optimised. Percentage area of staining was selected as the main quantification method for 
cholinergic axons since it took into account the total area of selection and also reflected the 
morphology and distribution of axons. For neurogenic markers, a previous study of our group 
(Ekonomou et al., 2015) has established the method of HuC/D and PCNA containing to 
determine pre- and postmitotic faction of specific neurogenic subpopulation in human. This pilot 
study confirmed the staining pattern of HuC/D and further showed that the immunopositivity 
pattern of our new candidate marker HuB/D closely resembled that of HuC/D. We showed the 
difference in the number of DCX-positive cells across Braak stages and that the expression of 
DCX and HuB/D share a common phase during new-born DGC development but not completely 
overlapped by one another. Not only that PCNA was found in some DCX- or HuB/D-positive cells, 
it was also intensely expressed by cells with radial glia-like morphology which helped ensure the 
validity of the staining. The cell quantification method of choice was the number of cells per mm 
DG length since sections from different cases had different shapes and hence length of the DG.  
One weakness of this pilot study was that the sample size of n=8 was too small for analyses with 
several covariates. Nonetheless, it was still possible to calculate effect size from η2 value 
computed from uniGLM of each marker without any covariate. While AHN markers would be 
modelled with NegBin in the main study, the process of calculating effect size for NegBin was 
too complex and not suitable considering the instable this model under small sample size.    
Human DCX nuclear staining has been shown in several studies that used paraffin-embedded 
sections (Boekhoorn et al., 2006; Knoth et al., 2010; Gatt et al., 2018). One study demonstrated 
in adult rat DG sections that longer PMI continuously degraded cytoplasmic DCX staining 
especially in the neurites and eventually resulted in DCX-positive granules after 12 hrs of PMI 
(Boekhoorn et al., 2006). Interestingly, they observed DCX nuclear staining even in a cohort of 
AD patients that had a PMI average of 5.1 hrs. Considering that DCX nuclear staining was not 
explicitly shown or discussed in the above varying PMI experiment in rat brains, it is possible 
that this phenomenon is specific to human tissues. Standard human tissue processing from 
prolonged formalin incubation at RT up to paraffin embedding may contribute to DCX nuclear 
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staining since there was no or minimal DCX nuclear staining in the latest study that incubated 
the tissues in 4% PFA o/n at 4°C without freezing or paraffin embedding (Moreno-Jiménez et al., 
2019) or in studies that used frozen samples (Boldrini et al., 2018; Sorrells et al., 2018). The non-
specific staining in human blood vessels by sc-8066 was observed in the recent study (Moreno-
Jiménez et al., 2019) but it was also demonstrated to be successfully minimised by proper 
antigen retrieval procedures. Colocalisation between sc-8066 and the monoclonal mouse anti-
DCX sc-271390 was also confirmed by the above recent study. Regarding the WB of sc-8066, one 
study on a cohort of AD patients and age-matched controls found a faint band of undetermined 
size above the predicted band in several human cases (Jin et al., 2004a). Another study also 
observed a small band above the predicted band but at an approximate size of 60 kDa instead 
of 50 kDa in the current experiment (Knoth et al., 2010).  Both studies, however, did not conduct 
a peptide blocking experiment in parallel.             
It would be a considerable advantage that multiple rounds of staining with different antibodies 
even from the same animal hosts could be performed on a single section. This would allow a 
more complete marker profile which could partially elucidate the interactions between different 
markers in a system. This antibody stripping method, despite its claimed success for multiple 
rounds of fluorescence IHC, has not been optimised for our staining of interest.           
This pilot study also demonstrated that our current antibody stripping protocol has not been 
effective enough especially for the staining of neurogenic markers in the main study. 
Nonetheless, it helped us improve VAChT staining protocol by removing non-specific 
background from the staining at 1:1500 and revealed that staining at 1:3000 visualised more 
VAChT-positive axons especially in the GCL without having to spend 2-3 more slides to optimise 
the staining method.      
In summary, the pilot study was successful in identifying the markers of cholinergic and adult 
neurogenesis. Potential confounding variables were identified and the moderate sample size to 
achieve 80% statistical power was calculated on the basis of these results,     





4 Contribution of cholinergic innervation to adult hippocampal 
neurogenesis in Alzheimer’s disease patients: Main cohort 
4.1 Introduction 
Adult neurogenesis in the DG is abnormally regulated in AD cases (Jin et al., 2004a; Perry et al., 
2012) with one of the main characteristics commonly reportedly being maturation defect (Li et 
al., 2008; Ekonomou et al., 2015). The relationships with cognitive performance were supported 
by several studies which reported the associations between AHN impairment and disease 
severity indicators such as astrocyte density (Ekonomou et al., 2015) and between AHN and 
preserved MMSE score despite extensive pathology (Briley et al., 2016). The plasticity of the 
AHN system was reflected by a relative tolerance of the DG to the NFT pathology (Braak and 
Braak, 1991) and its important roles in cognition have garnered increasing interest in its 
potentials as a therapeutic target. Plasticity of the septohippocampal cholinergic innervation in 
AD has also been demonstrated by higher hippocampal ChAT activity in MCI patients (DeKosky 
et al., 2002 and relative sparring of BFCNs in the Ch2 MS/VDB (Mesulam et al., 1983a). With 
multiple findings that direct cholinergic presynaptic signalling on adult-born DGCs regulates 
their maturation (Campbell et al., 2010) and survival (Zhen et al., 2017; Zhu et al., 2017), the 
notion of upregulated cholinergic innervation contributing to preservation of AHN and cognitive 
performance is appealing as a topic of research interest.  
The pilot study on 9 cases revealed a promising result of differences in % staining areas of ChAT 
and VAChT and in density of DCX- and HuC/D-positive cells across Braak stages such that it is 
possible to achieve at least an 80% statistical power in a main cohort of 36 cases given estimated 
sample sizes of each marker from the pilot study. The pilot study also confirmed the choices or 
these cholinergic or neurogenic markers and their respective antibodies for IHC analyses 
including the use of HuB/D antibody instead of the HuC/D antibody for double-labelling IHC with 
PCNA antibody. Paraffin-embedded sections from a total number of 41 cases were subsequently 
requested from the London Neurodegenerative Disease Brain Bank (LNDBB)/ Brain for Dementia 
Research (BDR) for this main study. 
The hypotheses of this chapter are as follows: % staining area of VAChT and ChAT would be 
lower in higher Braak V-VI, and ChAT may reach its peak in Braak III or IV in the same manner as 
ChAT activity in previous studies. In upper Braak stages, HuB/D is a marker of maturation so 
HuB/D positive cells with no PCNA would decrease, but the immature marker DCX would 
increase. As suggested by the pilot data, ChAT would be correlated with HuB/D, but VAChT 
would be negatively correlated with DCX and to less extents with HuB/D.  
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4.2 Materials and Methods 
4.2.1 Human cohort and data management 
All brain sections were requested from London Neurodegenerative Diseases Brain Bank, part of 
the Brains for Dementia Research & the Medical Research Council networks (LNDBB, BDR & 
MRC). A total of 41 cases were originally requested according to the power analysis in chapter 
3, but 36 cases were included for this study (Table 4.1). Sections from 2 cases did not contain 
the DG. Percentage area of ChAT staining on sections from 1 case with Braak V was the highest 
among the entire cohort and was also an extreme outlier of the Braak V group. There was no pH 
data available for another 2 cases. Those were the reasons of excluding 5 cases. Braak 0 and 
Braak I were grouped together. All 20 cases with Braak 0-III (Braak 0 = 4; Braak I = 2; Braak II = 
8; Braak III = 6) were diagnosed to not have dementia and all 16 cases with Braak IV-VI (Braak IV 
= 4; Braak V = 5; Braak VI = 8) were diagnosed as AD dementia. Nevertheless, one supposedly 
non-demented Braak III case had an MMSE record of 15. This small evidence of cognitive 
diagnosis inconsistency and lack of MMSE scoring for most cases warranted the focus of this 
study on Braak staging instead of cognitive status. The 5 potential covariates including 
demographic variables to be included in our models were the same as those in the pilot study: 
namely cm_front or estimated cm of sections from the front with reference to the online virtual 
microscopy (TheHumanBrain.info, 2018a), sex, age, PMI, and pH (Table 4.2). Additional 
information such as BBN-ID, BDR no, or APOE genotypes (Appendix Table A.1) and the raw data 






























1  A053/11 0 0 0 - 0 30.9 M 77 11 6.09 
2  A473/15 0 0 0 - 0 14.7 M 74 72 6.48 
3  A127/11 0 0 0 Mod 0 12.7 M 73 23 5.96 
4  A250/14 0 1 1 - 0 27.3 F 69 48 6.09 
5  A367/12 I 0 0 - 0 20.0 M 83 48 6.85 
6  A319/11 I 1 1 mild 0 18.9 M 74 24 6.22 
7  A404/12 II 0 0 - 0 28.0 F 89 87 6.67 
8  A130/12 II 0 0 - 0 27.3 F 89 44 6.10 
9  A242/15 II 0 0 - 0 21.6 M 82 26 6.62 
10  A176/15 II 0 1 - 0 21.6 F 98 24 6.77 
11  A368/13 II 1 1 mildCp 0 25.2 F 87 45 6.16 
12  A246/14 II 1 1 mild 0 18.9 F 97 39 5.98 
13  A174/14 II 1 1 Mod 0 18.9 M 83 31 5.95 
14  A448/15 II 1 2 mild 0 17.0 M 79 53 6.45 
15  A085/11 III 0 0 - 0 33.7 F 86 43 6.56 
16  A282/14 III 0 0 - 0 20.4 F 68 53 6.81 
  17  A112/12 III 1 2 Mod 0 30.0 M 94 26 5.99 
18  A402/14 III 2 1 mild 0 17.3 M 83 10 6.72 
19  A347/10 III 2 2 - 0 18.6 F 84 89 6.91 
-1  A132/13 III 2 2 Mild 0  M 85 23 - 
-2  A160/12 III 2 2 Mod 0  M 97 41 - 
20  A160/11 III 2 2 Mod 0 18.9 F 89 57 6.07 
21  A233/13 IV 2 1 mild 1 20.4 M 92 72 6.55 
22  A160/13 IV 2 3 Mod 1 35.5 F 84 42 6.39 
23  A383/11 IV 2 3 ExtCp 1 23.1 M 80 51 6.09 
24  A451/15 IV 2 4 mild 1 18.3 M 87 70 6.85 
25  A216/09 V 2 2 mild 1 13.4 F 88 22 5.95 
26  A170/13 V 3 2 mild 1 29.0 F 85 23 6.55 
-3  A221/13 V 3 2 Mod 1  M 89 49 6.20 
27  A026/14 V 3 2 Mod 1 42.7 F 85 35 6.40 
28  A267/09 V 3 3 mild 1 32.5 F 90 70 5.95 
29  A193/12 V 3 3 mild 1 21.1 M 92 29 6.86 
30  A292/10 VI 3 2 mild 1 18.3 M 90 44 6.50 
31  A277/12 VI 3 2 Mod 1 18.3 M 79 20 6.88 
32  A255/14 VI 3 2 Sev 1 42.7 F 79 63 5.86 
33  A111/12 VI 3 2 Ext 1 28.0 M 70 20 6.31 
34  A356/12 VI 3 3 Mild 1 18.9 M 81 59 6.77 
35  A162/15 VI 3 4 Mod 1 42.7 F 73 34 6.39 
36  A121/14 VI 3 5 ExtCp 1 35.5 F 78 60 6.15 
Table 4.1 – List of cases in this main cohort   
Cases labelled in grey were excluded because of the lack of pH values which were correlated with ChAT % 
area. Cases labelled in light green were excluded since its ChAT % area was an extreme outlier of Braak V. 
Cases with ID labelled in light blue were cases with dementia diagnosis and medication records. Among 
the above, cases labelled in darker light blue had been prescribed donepezil. Mod – Moderate; Sev – 







Covariates Braak N Mean SEM Kruskal-
Wallis 
cm_front 
0 4 21.40 ± 4.52 
KW = 2.878  
p = 0.824 
I 2 19.45 ± 0.55 
II 8 22.31 ± 1.45 
III 6 23.15 ± 2.82 
IV 4 24.33 ± 3.86 
V 5 27.74 ± 5.00 
VI 7 29.20 ± 4.22 
Sex 
0 4 0.75 ± 0.25 
KW = 6.912  
p = 0.329 
I 2 1.00 ± 0.00 
II 8 0.38 ± 0.18 
III 6 0.33 ± 0.21 
IV 4 0.75 ± 0.25 
V 5 0.20 ± 0.20 
VI 7 0.57 ± 0.20 
Age 
0 4 73.25 ± 1.65 
KW = 15.955  
p = 0.014 
I 2 78.50 ± 4.50 
II 8 88.00 ± 2.41 
III 6 84.00 ± 3.59 
IV 4 85.75 ± 2.53 
V 5 88.00 ± 1.38 
VI 7 78.57 ± 2.40 
PMI 
0 4 38.50 ± 13.57 
KW = 3.668  
p = 0.722 
I 2 36.00 ± 12.00  
II 8 43.63 ± 7.13 
III 6 46.33 ± 11.14 
IV 4 58.75 ± 7.32 
V 5 35.80 ± 8.86 
VI 7 42.86 ± 7.05 
pH 
0 4 6.16 ± 0.11 
KW = 3.667  
p = 0.722 
I 2 6.54 ± 0.32 
II 8 6.34 ± 0.12 
III 6 6.51 ± 0.16 
IV 4 6.47 ± 0.16 
V 5 6.34 ± 0.13 
VI 7 6.41 ± 0.06 
Table 4.2 – Potential covariates for analyses of the main study cohort 
Estimated cm from the front (cm_front), sex, age, postmortem interval (PMI), and pH were 5 potential 





IHC was performed according to the standard protocol in Chapter 2. For each case, three 
sections were subjected to IHC: one for VAChT (488) and ChAT (568); one for PCNA (488), HuB/D 
(568), and DCX (647); and the last one for AT8 (488) and p-S396 (568). Fluorescence images were 
captured with Zeiss Axiocam fluorescence microscope at 20x objective magnification using 
Axiovision SE64 Rel 4.9.1 software. All images taken with Axiocam microscope have a conversion 
ratio of 1px equal to 0.324 µm in length and 0.105 µm2 in area. 
4.2.3 Quantification 
For each case, at least 4 montage images, each of which contain several fields to cover the ML, 
GCL, SGZ, and hilus. Images were analysed on ImageJ software as demonstrated in Figure 4.1. 
Background was subtracted from each image by Subtract Background… function with a rolling 
ball radius of 6px. Threshold for the grey values of at least 15 was applied to both VAChT and 
ChAT images. Images after thresholding were converted into binary masks and image with 
colocalisation between two images were produced by Image Calculator… command with AND 
function. Only particles with size of at least 5px on VAChT, ChAT, and colocalised images were 
analysed to exclude background noises. Percentage area of staining per selection area spanning 
the ML to the hilus of each marker was calculated.  
For dystrophic neurite quantification, images were subjected to Subtract Background… function 
with a rolling ball radius of 25px. The grey value threshold of at least 45 was applied and only 
particles with size of at least 150px were quantified. Percentage areas of dystrophic neurite 







              
Figure 4.1 – Quantification of cholinergic axons in the DG 
Images of ChAT and VAChT staining were subjected to background subtraction and threshold setting to 
remove other objects other than cholinergic axons from the images. Colocalisation between the binary-





Images of the GCL along the entire DG in each section were used for the study. There were 6 
basis marker combinations that represent our cell types of interest as follows: exclusively DCX-
positive (xD), exclusively HuB/D-positive (xH), HuB/D- and DCX-positive with no PCNA (xHD), 
DCX-negative HuB/D-positive with PCNA (xPH), HuB/D-negative DCX-positive with no PCNA 
(xPD), and HuB/D- DCX- PCNA- triple positive (xPHD). The number of cells with less specific 
marker combinations can also be calculated from the numbers of these 6 basis groups. For 
example, total HuB/D-positive cells with no PCNA equal to the sum of xH and xHD (Table 4.3). 
The investigator was blind to the identity of the cases during data acquisition and quantification. 
 
 6 basis groups of cells 
Neurogenic markers xD xH xHD xPH xPD xPHD 
DCX ✓  ✓  ✓ ✓ 
HuB/D  ✓ ✓ ✓  ✓ 
PCNA    ✓ ✓ ✓ 
       
More inclusive groups Combination of basis groups 
HuB/D no PCNA  (HnP) =  + +    
HuB/D with PCNA  (HP) =     +  + 
DCX no PCNA  (DnP) = +  +    
DCX with PCNA  (DP) =     + + 
Table 4.3 – Cell types of interest represented by different combinations of markers and 6 basis 
groups  
There were 6 distinct basis groups of cells from combination of 3 neurogenic markers when a group of 
cells exclusively PCNA-positive was not included. HuB/D no PCNA = xH + xHD. HuB/D with PCNA = xPH + 
xPHD. DCX no PCNA = xD + xPHD. DCX with PCNA = xPD + xPHD.     
 
4.2.4 Statistical Analyses 
The same covariates were used for analyses of both cholinergic and neurogenic markers. Any 
covariates significantly correlated with markers of interest by parametric Pearson or non-
parametric Spearman correlation tests were selected for the subsequent analyses. Only sex was 
not significantly correlated with any markers of interest (Table 4.4). Furthermore, age was highly 
correlated with cm_front (Pearson coefficient r = 0.589, p = 0.002) and therefore was excluded 
from the study to avoid multicollinearity effect. The 4 covariates selected were cm_front, age, 






Covariates Correlation Sex Braak xD xPH xPD xPHD ChAT 
cm from 
front 
Pearson -0.498 0.386  -0.397  0.403  
p-value 0.002 0.026 ns 0.017 ns 0.015 ns 
Sex 
Pearson        
p-value ns ns ns ns ns ns ns 
Age 
Pearson     -0.419   
p-value ns ns ns ns 0.011 ns ns 
PMI 
Spearman   0.346     
p-value ns ns 0.039 ns ns ns ns 
pH 
Pearson       0.356 
p-value ns ns ns ns ns ns 0.033 
Table 4.4 – Examples of significant correlations between selected covariates and variables of 
interest  
Four of the potential covariates – cm_front, age, pH, and PMI – had significant correlations with at least 
one of the variables of interest. There was no significant parametric or non-parametric correlation 
between any variable of interest and sex. The cm_front and sex were also highly correlated, further 
supporting the exclusion of the sex variable.   
 
As previously undertaken in the pilot study, cholinergic % area of staining was subjected to 
analysis of covariance (ANCOVA) as a univariate general linear model (uniGLM). All 3 cholinergic 
variables were highly positively skewed and not normally distributed by Shapiro-Wilk test. 
Fourth root transformation was applied to all 3 variables to reduce positive skewness enough 
such that residuals of their uniGLM were normally distributed. The Modified Breusch-Pagan test 
and F test were also checked to ensure the lack of heteroskedasticity in our models. Two 
uniGLMs were performed for each cholinergic marker variable. The main model had no 
interaction terms and was for measuring difference in cholinergic markers across main factor 
groups. The other had interaction terms between main factor, specifically Braak stages or 
dementia status, and each covariate e.g. Braak * cm_front, Braak * age, Braak * pH, and Braak 
* PMI. Lack of statistical significance of interaction between main factor group and each 
covariate was checked to ensure the assumption of homogeneity of regression line slopes. Only 
Dementia * cm_front interaction in VAChT-ChAT colocalisation was statistically significant (F = 
5.269, p = 0.030) and we nonetheless proceeded to model VAChT-ChAT colocalisation with the 
uniGLM. Dystrophic neurite data were transformed by square root function since fourth root 
transformation of these data violated uniGLM ANCOVA assumptions of homoscedasticity and 
normally distributed residuals. 
The density of cells was modelled with negative binomial model (NegBin) with maximum-
likelihood estimation as in the pilot study since our cell density data were over dispersed and 
could not be simultaneously transformed into normally distributed data with a single 
transformation. The number of maximum step-halving was set to 50 but the log-likelihood of 
each cell density variable here was found to improve within the maximum step-halving of 5. 
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Large number of covariates leads to higher possibility of multicollinearity and consequently 
increases the chance of singular Hessian matrix. An inverse of a Hessian matrix is used to 
calculate maximum-likelihood estimation and singularity of Hessian matrix hence indicates 
model instability. Here we fortunately found no singular Hessian matrix incidence for any 
variables despite the presence of 4 covariates in their models. We had attempted to model cell 
proportion variables such as percentage of HuB/D-positive cells with no PCNA in total HuB/D-
positive cells with NegBin by using natural log of the total number of HuB/D-positive cells as 
offset. However, the numbers of HuB/D-positive cells with no PCNA and of total HuB/D-positive 
cells were too highly correlated and this always led to singularity of Hessian matrix. We therefore 
deemed that density of each cell group should provide enough information for the change in 
neurogenesis and that proportion of one cell type within another was not necessary.  
Nonparametric partial correlation controlled for the 4 covariates was performed with SPSS 
syntax by conceptually performing regular parametric partial correlation but instead with rank 
values of all pair variables and covariates instead.   
Variable modelling with uniGLM and NegBin were conducted in IBM SPSS Statistics version 25. 
For pairwise comparison of each variable across Braak stages, 21 p-values were adjusted with 
two-stage step-up Benjamini, Krieger, and Yekutieli false discovery rate controlling procedure 
(BKY-FDR or TSBH) (Benjamini et al., 2006) using mt.rawp2adjp function with “TSBH” option 
from ‘multtest’ R package (Bioconductor). All p-values from partial correlation between 
variables of interest were also adjusted with BKY-FDR. 
 
4.3 Results 
The pattern of cholinergic markers in this main study was similar for VAChT and ChAT staining 
(after antibody stripping) to that observed in the pilot study (see Figure 3.7). Most axons were 
positive with both ChAT and VAChT, but some of them were prominent with one over the other 
antibody and occasional large cholinergic dystrophic neurite particles were observed in the DG 
(Figure 4.2). By uniGLMs of ChAT staining with cm_front, age, PMI, and pH as covariates, pH was 
a significant predictor (F = 5.319, p = 0.029) of the staining. There was no significant change in 
VAChT staining across Braak stages (Figure 4.3A). The adjusted mean 4th root of ChAT percentage 
area of staining estimated by the uniGLMs was significantly reduced in Braak IV-VI compared 
with Braak III by 46%, 37%, and 40% (p = 0.032; BKY-FDR adjustment) respectively (Figure 4.3B). 
ChAT staining in Braak III was also non-significantly higher than that of Braak 0-I and II by 25% 
and 19% respectively. Colocalisation between the two markers followed a very similar trend to 
that of ChAT staining with a peak at Braak III but there was no statistically significant change. 
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There were significant changes in dystrophic neurite % area across Braak stages only in ChAT 
staining in the ML (Figure 4.3C). Here we found that square root of % area of large ChAT-positive 
dystrophic neurite particles in Braak III was significantly higher than Braak 0-I, II, IV, V, and VI by 




Figure 4.2 – Representative images of cholinergic markers in the DG 
A representative of images used in this study which were produced from stitching of several image fields 
to cover the ML, GCL, SGZ, and hilus of a case with Braak III. DAPI staining was used to locate the densely 
packed DGCs of the GCL (A). VAChT staining (B), ChAT staining (C), and colocalisation (D) showed axons 
which were prominently VAChT-positive (north-west, dotted arrow), prominently ChAT-positive (north-
east, dotted open arrow), or equally positive for both markers (rightwards short arrow) (D). A large 
cholinergic dystrophic neurite positive for both VAChT and ChAT was also present in the ML below the 





Figure 4.3 – Cholinergic changes across Braak stages 
Cholinergic marker variables were modelled in uniGLM with cm_front, age, PMI, and pH as covariates. 
Pairwise comparison showed no significant pairwise change in VAChT staining between any Braak stages 
(A). However, there were significant decreases in ChAT % area of staining in Braak IV-VI compared with 
Braak III (B). Furthermore, trend in colocalisation between VAChT and ChAT along Braak stages was similar 
to that of ChAT staining (A-B). The % staining area of dystrophic ChAT-positive axons in the entire DG and 
in the ML were shown with significant pairwise differences only in the ML between the peak at Braak III 
and other stages (C). Data are expressed as non-stacked area chart with vertices and error bars 
representing adjusted mean or EMM and SEM respectively; # p<0.05 compared with the Braak stage III 
after BKY-FDR adjustment of 15 pairwise p-values for each cholinergic variable separately.         
 
We then proceeded to investigate the density of proliferative profiles of HuB/D-positive cells 
and DCX-positive cells. As previously mentioned in the method section, there were 6 basis 
groups (Figure 4.4A-F) based on 6 distinct combination of 3 markers excluding the group with 
only PCNA (Figure 4.4G).  
The 6 basis groups can be divided into 3 main groups: HuB/D-negative DCX-positive (xD and xPD) 
(Figure 4.5A), DCX-negative and HuB/D-positive (xH and xPH) (Figure 4.4B), and HuB/D- and DCX-
double positive (xHD and xPHD) (Figure 4.5C). Both xHD and xH consistent had the same trend 
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as the total PCNA-negative HUB/D-positive cells with overall significant changes across Braak 
stages (xHD: Wald χ2 = 11.298, p = 0.046) (xH: Wald χ2 = 22.691, p = 0.000) but only xH had 
significant pairwise differences. Among the 3 PCNA-positive basis groups, only xPH had overall 
significant changes (Wald χ2 = 14.387, p = 0.013) with Braak I and Braak IV-V higher than other 
Braak stages but there was no significant pairwise difference after BKY-FDR adjustment. By 
observation from the overall stacked area chart (Figure 4.5D), we found decrease in xH and xHD 
in Braak IV-V compared with other groups surprisingly including Braak VI. Only xPH had 
noticeable increase in Braak IV-V, while other PCNA-positive basis groups namely xPD and xPHD 
had low density and negligible changes. When we pool xH and xHD together and xPH and xPHD, 
then we have the total number of HuB/D-positive cells with no PCNA and with PCNA respectively 
(HnP = xH + xHD; HP = xPH + xPHD). The same goes for DCX-positive cells (DnP = xD + xHD; DP = 
xPD + xPHD). The adjusted mean numbers of PCNA-positive or PCNA-negative DCX-positive were 
not statistically significant (Figure 4.5E). Significant decreases in the adjusted mean number of 
cells per mm DG length of PCNA-negative HuB/D-positive cells were observed between Braak 
IV-V and other Braak stages including Braak VI (Wald χ2 = 28.067, p = 0.000) (Figure 4.5F). The 
overall change in PCNA-positive HuB/D-positive cells across Braak stages was no significant.  
 
Figure 4.4 – Representative images of the 6 basis cell groups    
All cell types of interest in this study can be divided into 6 basis groups: exclusively DCX-positive or xD (A), 
exclusively HuB/D-positive or xH (B), HuB/D- and DCX-positive with no PCNA (C), DCX-negative HuB/D-
positive with PCNA (D), HuB/D-negative DCX-positive with PCNA (E), and HuB/D- and DCX-positive with 
PCNA (F). Cells that express PCNA with neither DCX nor HuB/D were not included in the study (G). Scale 






Figure 4.5 – Changes in HuB/D- or DCX-positive neurogenic populations across Braak stages  
The number of each of the 6 basis cell groups per mm DG length across Braak stages was modelled in 
NegBin with cm_front, age, PMI, and pH as covariates. There was no change in xD or xPD (A). The xH but 
not xPH was the only one of the 6 basis groups with significant pairwise changes (B). Pairwise changes in 
xHD and xPHD were not statistically significant (C). All 6 basis cell groups were presented together with 
different colours (D). There was also no change in DCX-positive cells (E). Pairwise comparison showed 
significant differences in HuB/D-positive cells with no PCNA between Braak IV-VI and all other Braak stages 
(F). For the 6 basis groups, Data are expressed as stacked area chart with vertices and error bars 
representing adjusted mean or EMM and SEM respectively; *p<0.05 in a PCNA-negative subpopulation 
between the dotted line-indicated Braak stages after BKY-FDR adjustment of 15 pairwise p-values for each 




CERAD NP scores were incorporated into a separate model for each variable of interest with an 
interaction term CERAD*Braak01 (where Braak 0 and Braak I were combined in order to reduce 
heteroskedasticity) as a major group factor. The % staining area of ChAT-positive axons was 
significantly decreased as the CERAD score increased (F = 5.556, p = 0.006) (Appendix Table A.5). 
Furthermore, within Braak III (F = 3.929, p = 0.036), cases with CERAD 0 had significantly higher 
ChAT % area of staining than those with CERAD II (p = 0.042; Bonferroni-FWER for 3 values). 
While VAChT and colocalisation % staining area were not significantly different across CERAD, 
the % staining area of colocalisation in Braak III (F = 4.037, p = 0.033) followed the same 
alteration patterns of higher % staining area in CERAD 0 than CERAD 2 (p = 0.036; Bonferroni-
FWER for 3 values).      
Pearson and Spearman correlation tests between 4th root of % staining area of cholinergic 
markers (VAChT, ChAT, colocalised VAChT-ChAT), and the number of cells per mm DG length of 
6 basis groups (xD, xH, xHD, xPH, xPD, and xPHD) were performed. While VAChT was not 
significantly correlated with any AHN basis group (Appendix Table A.6), ChAT was positively 
correlated with the PCNA-negative HuB/D-positive xH (r = 0.466, p = 0.0042; rs = 0.467, p = 
0.0041) (Figure 4.6A) and xHD (r = 0.427, p = 0.0094; rs = 0.538, p = 0.0007) (Figure 4.6B) basis 
groups and negatively correlated with the PCNA-positive xPH group (r = -0.445, p = 0.0065; rs = 
-0.527, p = 0.0010) (Figure 4.6C). The colocalised % area was almost significantly correlated with 
xH (r = 0.284, p = 0.0938; rs = 0.309, p = 0.670) (Figure 4.6D), but at least significantly positively 
and negatively correlated with xHD (r = 0.347, p = 0.0382; rs = 0.511, p = 0.0014) (Figure 4.6E) 
and xPH (r = -0.420, p = 0.0110; rs = -0.582, p = 0.0002) (Figure 4.6F) respectively.       
Preliminary correlation tests between covariates and markers of interest revealed that age was 
inversely correlated with the xPD group (r = -0.419, p = 0.011) (see Table 4.2). To investigate this 
interaction, the cohort was divided into two groups based on the cm_front as the anterior (12.7 
≤ x < 22.7; n=20) and mid-posterior (22.7 ≤ x ≤ 42.7; n=16) and subjected to correlation analyses 
separately. Parametric partial correlation controlled for PMI, pH, and Braak stage in the anterior 
DG sample group between age and neurogenic cell groups showed no significant difference. On 
the other hand, by partial correlation controlled for PMI, pH, and Braak in the mid-posterior DG 
sample group, age was significantly negatively correlated with xHD (r = -0.771, p = 0.021), DCX 
with no PCNA (r = -0.759, p = 0.021), and consequently total DCX (r = -0.799, p = 0.021) after 
BKY-FDR adjustment of pooled p-values from both correlation analyses on anterior and mid-




Figure 4.6 – Significant correlation between cholinergic and neurogenic markers   
Pearson and Spearman correlation between 4th root % staining area of cholinergic markers ChAT (A-C) 
and VAChT-ChAT colocalisation (D-F) and AHN basis groups xH (A, D), xHD (B, E), and xPH (C, F). Pearson 
(r) and Spearman (rs) coefficients are shown with their corresponding raw unadjusted p-value. 
 
IHC for two different phospho-tau epitopes – AT8 and pSer396 – were performed on the main 
cohort (Figure 4.7). Unfortunately, full statistical analyses of their staining and colocalisation 
have not been successfully conducted as the staining patterns were quite varied in terms of 
immunoreactive intensity and spatial density both in neuropil regions such as the ML or hilus 
and in cell bodies of the DGCs. Preliminary observation revealed a potentially progressive 




Figure 4.7 –Phosphorylated tau in the DG 
Staining of phosphorylated tau was in cell nucleus and neurite network in Braak 0 case but not in the 
pathological forms of NFT or dystrophic neurites (A) with normal cholinergic axons (B). Braak III case had 
few DGC NFTs (dotted ellipse) (C) with preserved ChAT staining (D). This specific Braak II case, diagnosed 
with argyrophilic grain disease (AGD) had higher density of tau-positive dystrophic neurites and more 
intense NFT-containing DGCs (ellipse) (E) and especially lower ChAT staining than Braak III (F). Some cells 
contained faint pS396-positive signal but still higher than AT8 signal (dotted box). Braak VI cases had 
extensive NFT-containing dystrophic neurites and NFT-containing DGCs (G). In this representative case, 
most of the NFT-positive cells contain higher pS396 than AT8 (box). Few NFT-positive dystrophic ChAT-





The major findings of this chapter were as follows; 
- Percentage staining area of ChAT-positive axons was significantly upregulated in Braak 
III compared with Braak IV-VI. There was no change in staining of VAChT-positive axons 
across Braak stages. Axonal swelling or dystrophy also reached its peak in Braak III.   
- Immature DGCs were divided into 6 basis groups based on exclusive staining of PCNA, 
HuB/D, and DCX:  xD, xH, xHD, xPH, xPD, and xPHD.  
- Only xH had significant pairwise difference with the lowest number in Braak IV-V. The 
xPH had a general opposite trend with significant overall difference but not pairwise. 
- CERAD NP score had significant deleterious effect on ChAT staining with a focus on cases 
with Braak III. However, the sample size was too small for conclusion. 
- Staining of ChAT-positive axons was positively correlated with xH and xHD, but inversely 
correlated with xPH. 
The main findings of this study were that unlike the pilot study, VAChT %area of staining was not 
significantly negatively correlated with Braak stages despite its generally decreasing trend. On 
the other hand, ChAT-positive axon %area of staining was upregulated in Braak III and 
significantly decreased in Braak IV-VI compared with the Braak III but not statistically significant 
compared with Braak 0-I and II. For analyses on population of neuroblasts or immature neurons 
marked by expression of DCX or HuB/D, we found that PCNA-negative HuB/D-positive cells (xH 
+ xHD) and especially the exclusively HuB/D-positive group xH were significantly decreased in 
Braak IV-VI compared with other Braak stages. ChAT %area also had significant positive 
correlations with PCNA-negative HuB/D-positive cell groups but negative correlation with PCNA-
positive HuB/D-positive cells.     
This finding of higher % area of ChAT-positive axons in Braak III was consistent with the previous 
finding on hippocampal ChAT activity upregulation in MCI patients (DeKosky et al., 2002) and 
that this upregulation of hippocampal ChAT activity was limited to those MCI cases with Braak 
III-IV (Ikonomovic et al., 2003). Higher incidence of cholinergic fibre swelling in the nbM was also 
reported in cases with Braak I-III compared with Braak 0 and Braak IV-VI cases (Stokin et al., 
2005). While most of the small swellings were included in the analysis of axon % area, we 
separately quantified % area of large ChAT-positive dystrophic neurites and found the highest % 
area of these swellings mainly in the ML of Braak III cases. Conspicuously high ChAT 
immunopositivity of these particles possibly suggested the accumulation of ChAT enzymes that 
may contribute to higher ChAT activity reported in previous articles. However, our findings were 
different from a previous study by our group (Perry et al., 2012) that ChAT-immunopositivity in 
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the DG steadily decreased along the increasing Braak stages and another study by our group 
(Kooi et al., 2011) with corroboration that ChAT %area of staining in the hilus (CA4) in cases with 
Braak 0-I (control) was significantly higher than that in cases with Braak V-VI (AD).  
The differential cholinergic staining results especially in Braak III-IV groups in different studies 
were likely influenced by high neuropathological variability and dynamic transitioning of disease 
progression. For example, the two excluded Braak III cases due to their lack of pH data had lower 
ChAT % staining area than the rest (Appendix Table A.3). While this reduction might involve pH, 
it could also be caused by collective effects of CERAD 2, presence of CAA and α-synuclein 
pathology, and unknown APOE genotypes. Both CERAD and Thal stages were quite varied within 
this Braak group, so it was possible that Braak III cases with less ChAT staining might have more 
severe Aβ or other neuropathological features within the DG or other brain regions associated 
with MS/VDB. Furthermore, while all Braak IV subjects in this study and a previous study (Perry 
et al., 2012) had dementia status, the pilot study of this thesis included one Braak IV with high 
ChAT staining with no dementia and several studies (Ikonomovic et al., 2003; Ekonomou et al., 
2015) also grouped Braak III and IV together without mentioning any caveats on potential 
differences between the two Braak stages.              
The original study that established investigation of PCNA and HuC/D, or HuB/D in this study, 
found significant decrease in PCNA-negative HuB/D-positive cells in Braak V-VI group 
(Ekonomou et al., 2015). This study however found significant increase in PCNA-negative HuB/D-
positive cells (xH + xHD) in Braak VI compared with Braak IV-V. This increase was contributed 
more by a statistically significant increase in xH group than by that of xHD group. This result was 
different from the pilot finding where the number of HuC/D-positive cells was the lowest at 
Braak V-VI. Staining with calretinin after the first round of IHC with PCNA, HuB/D, and DCX in the 
pilot study lent support to the notion that xH was more mature than xHD and xD in the course 
of adult-born DGC development. A previous study reported the highest βIII-tubulin 
immunoreactivity in Braak stage VI and noticeably but not statistically significantly lower 
immunoreactivity in Braak stage IV (Perry et al., 2012). Since βIII-tubulin was one of the first 
markers to be expressed when immature neurons or neuroblasts reached their postmitotic 
stages, total immunoreactivity in the GCL may be associated with the number of immature 
neurons such as the xH and xHD groups. The same study (Perry et al., 2012) also found significant 
correlation between ChAT immunoreactivity and only Msi-1 staining.  
Reasons behind the differences in DCX staining results reported by various articles may include 
different processing and immunohistochemical technique and different criteria of 
quantification. The recent study demonstrated that DCX staining was sensitive to tissue 
processing and antigen retrieval procedures (Moreno-Jiménez et al., 2019). In addition, several 
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studies quantified DCX based on immunoreactivity (Boekhoorn et al., 2006; Perry et al., 2012) 
but the previous article of our group (Ekonomou et al., 2015) and this thesis quantified by cell 
counting. Different quantification criteria may affect the result especially under different 
staining sensitivity and specificity. The number of DCX-positive cells in this study especially in 
control groups was larger than the previous study (Ekonomou et al., 2015) which barely find any 
DCX-positive cells in Braak 0-II group. It was possible that the criteria in this study were more 
compromising as some cells with relatively weak DCX immunoreactivity such as those in Figure 
4.4E or 4.4F might not meet the criteria in the previous study. 
Hippocampal atrophy is an early feature of AD and could have affected the result of 
quantification. One advantage of quantification by % area of staining was that it automatically 
considered the possible changes in the total area of quantification fields. Nonetheless, 
hippocampal atrophy could have a potential influence if it differentially affected the thickness 
of different DG sublayers considering that cholinergic axon density in each subregion is possibly 
different from that of one another. However, despite multiple articles that reported atrophy in 
the DG (reviewed in de Flores et al., 2015), there has been no in vivo study that described 
differential effects on the DG subregions. Furthermore, several articles showed that the DG was 
relatively preserved in AD compared with the CA1 (Adler et al., 2018; Zhao et al., 2019). In terms 
of AHN, if hippocampal atrophy is associated with loss of adult-born DGCs or pools of stem cells 
or progenitors, quantification by cells/mm DG length would reflect such hippocampal atrophy-
associated changes. However, cells/mm length would not be as affected if hippocampal atrophy 
reduces the cross-sectional DG length. This is possible considering that a change in DG volume 
but not DG thickness was significant in one study (Adler et al., 2018). 
Immunohistochemistry of AT8 and pSer396 in the DG showed a general trend of increasing 
density of NFT-positive fibres in the neuropil regions namely the ML and the hilus and increasing 
number of immunoreactive neurons or ghost tangles in the GCLs as Braak stage increased. This 
finding was similar to what were reported by Braak and colleagues that NFT pathology 
continuous progressed in the hippocampus with higher Braak stages (Braak and Braak, 1991). 
Nonetheless, there were also variations in distribution of NFT-positive neuropil and cell body 
particles in the DG of different cases with the same Braak stages. Braak stages were identified 
by progression of NFT to the higher orders of neocortical areas but they did not monitor the 
changes in hippocampal NFT distribution. This observation of higher NFT pathology in the DG in 
higher Braak stages indicated the continuous aggravation of NFT-induced damage to the local 
system. Future study would include a formal image analysis of the local NFT pathology and 




5 Cholinergic degeneration and adult hippocampal neurogenesis 
in a mouse model for Lewy body dementia 
5.1 Background 
This project was collaboration with Dr Emily Clarke to characterise a mouse model with 
heterozygous D427V (D427V/WT) GBA1 mutation. This D427V/WT GBA1 mouse model was first 
demonstrated by Sardi et al. (2011) to have lower brain GCase activity and develop α-synuclein 
aggregates in the hippocampus, albeit without evidence of abnormal cognition or 
glucosylsphingosine (GlcSph) accumulation at 6 months old. Dr Clarke first found this mouse 
exhibited cognitive deficits starting at 12 months in Morris water maze (MWM) performance 
and spontaneous alternation in Y-maze (SAYM) (Dr Emily Clarke, personal communication, 
Clarke, 2018; Appendix Figure A.1). Both hippocampal function and ACh signalling contribute to 
performance in MWM (reviewed in McNamara and Skelton, 1993) and SAYM (reviewed in 
Lalonde, 2002) . Lesion of the MS/VDB with 192 IgG-saporin injection impaired spatial working 
memory performance as measured by SAYM in rats (Chang and Gold, 2004). Furthermore, 
extensive lesion of the MS/VDB and nbM/SI also induced deficits in MWM performance (Leanza 
et al., 1995). Nonetheless, 192-IgG has a low affinity to mouse p75NTR and there are differences 
in the hippocampal cholinergic innervation patterns between the two rodents where rat CA1 
cholinergic axon density is lower than that of mice (Aznavour et al., 2002). Lesion of the MS/VDB 
in mice with anti-murine-p75NTR-saporin decreased hippocampal ChAT activity and impaired 
cognitive performance aspects of the MWM (Berger-Sweeney et al., 2001). These lines of 
evidence incentivised this project to include characterisation of hippocampal cholinergic 
innervation in the D427V/WTGBA1 heterozygous mouse. There is strong evidence from selective 
ablation of p75-positive BFCNs with 192IgG-saporin experiments indicating that cholinergic 
outputs from BFCNs play an important role in adult hippocampal neurogenesis (Cooper-Kuhn et 
al., 2004) and spatial memory performance (Mohapel et al., 2005). It should be noted 
nonetheless that alterations in adult neurogenesis alone may have complex effects on spatial 
memory such as strategy patterns (reviewed in Garthe and Kempermann, 2013) that cannot be 
demonstrated in terms of traditional parameters alone such as latency, retention, and speed 
(Saxe et al., 2006; Zhu et al., 2017). However, it is still within our interest to investigate adult 
neurogenesis in the DG as a potential link between cholinergic signalling and spatial memory. 
Furthermore, GCase is also highly expressed in both BFCNS and DGCs in macaques (Dopeso-




5.1.1 D427V GBA1 mutation and the heterozygous mouse model 
This D427V/WTGBA1 heterozygous mouse model was first characterised together with its 
homozygous counterpart, a model for Gaucher’s disease (GD) (Sardi et al., 2011) . While D427V 
heterozygous and homozygous mice have lower GCase activity and higher α-synuclein 
aggregates than the WT/WT at 6 mo, the D427V/D427V GBA1 was more severely affected with 
approximately 68% reduction in GCase activity and 53.3% increase in α-synuclein aggregates 
compared with the D427V/WT mice.  Furthermore, only the homozygous D427V/D427V mice 
have GlcSph accumulation and defects in hippocampal memory. Unlike GD patients, neither of 
them has GlcCer accumulation (Nilsson and Svennerholm, 1982). Brain GlcSph level was 
significantly higher in GD patients with neuronopathic symptoms than type 1 GD patients, 
implicating neurotoxic effects of GlcSph (Orvisky et al., 2002). GlcSph has also been 
demonstrated to induce and even shift α-synuclein aggregation equilibrium toward a β-sheet 
containing oligomeric species (Taguchi et al., 2017). Nonetheless, a recent article reported that 
GlcSph, unlike GlcCer, could not convert physiological HMW α-synuclein oligomer species into a 
more compact and toxic proteinase K-resistant species (Zunke et al., 2017). The D427 SNPs in 
the GBA1 gene in this mouse model correspond to the D409 SNPs in human, which include GD-
causing and DLB/PDD-associated mutations D409H. Homozygous D409V have been found in GD 
patients but only in recombination with L444P (Theophilus et al., 1989; Latham et al., 1991). 
D409V, nevertheless, has not been found in PD patients. D409V/D409V mice have lower GCase 
activity than D409H/D409H and also have GD-like characteristics of GlcCer accumulation in the 
liver, lung, and spleen at 6.5 mo albeit to lesser extents compared with D409V/null mice (Xu et 
al., 2003). This number notation in mouse starts from the first residue of the 19-amino acid ER 
signal sequence whereas the common notation in human starts from the functional form of 
GCase after signal peptide cleavage. Because of the different start position together with an 
additional H273 residue in human that is missing in mouse, the number describing the position 
of D427 is hence larger than the position number of its equivalent human mutation D409 by 18. 
Given the novelty of this mouse line and the potential as a model of Lewy body dementia and 
our own studies demonstrating cognitive deficits, we hypothesized that this mice model may 
have significant reduction in VAChT and ChAT in the DG and cortex, both IHC and WB wise 
compared with the WT/WT. One marker could be more severely affected than the other. Deficits 
in cholinergic axons could be accompanied by loss of BFCNs in the VDB/HDB. Lastly, as a 
potential DLB model, it would have higher number of DCX-positive cells but lower number of 




5.2 Materials and Methods 
5.2.1 Mouse cohorts 
All mice were managed by Dr Emily Clarke as follows. In brief, D427V/WT GBA1 mice were 
generated by crossing between homozygous D427V/D427V GBA1 mice from the Jackson Lab 
(Maine, USA) and C57BL/6 WT mice. Mice of mixed sexes were maintained in a 12-hour light 
dark cycle at ambient temperature and humidity with ad libitum food and water access. 
Maintenance, procedures, and cervical dislocation were conducted according to UK Home Office 
Regulations. All mice including those not included in this study are listed in Table 5.1.   
6 month-old 12 month-old 
ID genotype sex ID genotype sex 
101                         hWB,cWB  WT/WT F 157    DG,          DB,        cWB WT/WT M 
104                         hWB,cWB WT/WT F 158    DG,MCtx,     hWB,cWB WT/WT M 
107                         hWB,cWB WT/WT F 159    DG,MCtx,DB,hWB WT/WT M 
108                         hWB,cWB WT/WT F 160    DG,          DB WT/WT M 
109 WT/WT M 161    DG,MCtx,     hWB,cWB WT/WT F 
110                         hWB,cWB WT/WT M 162    DG,MCtx,DB,hWB,cWB WT/WT F 
111 WT/WT M 163    DG,MCtx,DB,hWB,cWB WT/WT F 
112 WT/WT M 164    DG,          DB WT/WT M 
113 WT/WT M 165    DG,          DB WT/WT M 
114 WT/WT M    
   1        DG,MCtx,DB,hWB,cWB D427V/WT M 
99                            hWB,cWB D427V/WT M 2        DG,MCtx,      hWB,cWB D427V/WT M 
100                         hWB,cWB D427V/WT M 3        DG,MCtx,DB,hWB,cWB D427V/WT M 
102                         hWB,cWB D427V/WT F 4        DG,MCtx,DB,hWB,cWB D427V/WT M 
103                          D427V/WT F 5        DG D427V/WT F 
106                                 cWB D427V/WT F 6        DG,          DB D427V/WT F 
117                         hWB D427V/WT M 7        DG,          DB D427V/WT M 
119                         hWB,cWB D427V/WT M 8        DG,          DB D427V/WT M 
120 D427V/WT F 9        DG,MCtx,DB,hWB,cWB D427V/WT M 
Table 5.1 – List of D427V/WT GBA1 mice and their WT/WT littermates according to age at death 
Tissue of each mouse in the table could be used in up to one or more of the following 5 experiments: DG 
IHC for cholinergic innervation and AHN in the DG; MCtx IHC for cholinergic innervation in the motor cortex; 
DB IHC for cholinergic markers and neurons in the VDB/HDB; hWB WB of hippocampal homogenates; and 




For each mouse brain, two 7 µm-thick sagittal sections were stained for a set of cholinergic 
synaptic markers (SPP, VAChT, ChAT) and the other set of neurogenic markers (PCNA, HuB/D, 
DCX). See the details of standard IHC protocol (Section 2.1) and antibodies (Table 2.1) in Chapter 
2. 
5.2.2.1    Imaging methods 
Images of the entire dentate gyrus (about 10-15 fields) and/or a strip of the motor cortex (about 
3-5 fields) on a section were captured with Zeiss LSM 710 upright confocal microscope at 40x 
objective magnification using Zen software. Staining was visualised in 4 channels: 405 nm (DAPI), 
488 nm (SPP or PCNA), 568 nm (VAChT or HuB/D), and 647 nm (ChAT or DCX). For each field, a 
single slice from Z-stack with approximately highest density of ChAT-positive axons was selected 
for analysis. 
Images of the VDB/HDB were captured with Zeiss Axiocam fluorescence microscope at 20x 
objective magnification using Axiovision SE64 Rel 4.9.1 software. The VDB/HDB is located 
posterior to the fine cholinergic axon-dense olfactory tubercle, which sits below another 
cholinergic axon-dense body the nucleus accumbens shell, in the anterior ventral part of the 
sagittal brain section.  
5.2.2.2    Quantification methods 
Image analysis and quantification of 3 channels (SPP, VAChT, and ChAT) of each cholinergic axon 
innervation image or 2 channels (VAChT and ChAT) of each basal forebrain image were run 
automatically with macros (Appendix Table A.7) in the ImageJ software (NIH) with Fiji platform 
(Schindelin et al., 2012) to facilitate coding. 
For cholinergic innervation analysis, staining of blood vessels in the SPP channel (488) was first 
removed. The staining of blood vessels resulted from a phenomenon that secondary antibodies 
against mouse IgG also recognises endogenous mouse IgG in blood vessels. Grey value threshold 
was set to primarily select blood vessels, which usually have higher mean signals than 
presynaptic SPP staining (Figure 5.1A). In this example, the threshold value is 14 to highlight all 
pixels with grey values ranging from 14 to 255 (absolute white). Size limit of 20 pixels to exclude 
smaller presynaptic particle was conducted by Analyze Particles… function (Figure 5.1B). 
Selections of all blood vessel particles were combined in ROI manager (ImageJ, NIH). The area 
of interest, specifically the ML in an image of the DG, was selected by Polygon Selections tool 
(Figure 5.1C). Since A-B = A∩B', intersection between the ML polygonal selection and inverse of 
combined blood vessel selections was performed to exclude blood vessels from the area 
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selection of interest (Figure 5.1D). This blood vessel-excluded ML selection was applied to the 
VAChT (Figure 5.1E) and ChAT (Figure 5.1F) channels. Both images were then subjected to 
Subtract Background… function with a rolling ball radius of 8 pixels to homogenize uneven 
lighting before subsequent analyses starting with threshold setting to obtain percentage area of 
staining. An algorithm of this automatic threshold setting for both VAChT and ChAT was 
developed to use the threshold value X that yielded local maximum average particle size when 
all pixels of grey values X to 255 were analysed (Figure 5.1G-H). In principle, it was to balance 
highlighting axons and minimizing the number of pixel noise signals. After the threshold values 
were chosen, Analyze Particles…with a minimal particle size of 2 pixels was used to quantify the 
total area of axon or punctate particles. Binary masks of highlighted particles were also 
skeletonised to measure the total length of axon and punctate particles in both VAChT (Figure 
5.1I) and ChAT (Figure 5.1J). SPP staining was quantified as mean grey value of the fluorescence 
signals in the selected area. To account for the background signals, threshold was set to highlight 
areas with grey values 0 to X which were not considered to have presynaptic staining such as 
holes in sections and cell nuclei (Figure 5.1K). The final mean grey values of SPP staining here is 





Figure 5.1 – Image analysis steps for cholinergic axon quantification 
Threshold was set to highlight blood vessels (A-B). Area of interest was selected and subtracted with 
selections of blood vessels (C-D). Final area selections were applied to images of VAChT and ChAT 
respectively (E-F). The macro chose the threshold value that maximized average particle size in each image 
(G-H). Binary masks of highlighted axons were skeletonised for length measurement if applicable (I-J). 
Reverse threshold setting to measure grey values of holes and cell nuclei that were later subtracted from 




Images of VDB/HDB were first subjected to Subtract Background… with a rolling ball radius of 
30 µm to eliminate uneven background lighting. In ChAT staining images, the threshold was set 
to highlight ChAT-positive cell bodies and neurites. Cell bodies were selected by Analyze 
Particle… with a minimal size of 500 pixels or 52.6 µm2. Staining signal intensity as mean grey 
values of both VAChT and ChAT were measured within these selections of ChAT-positive cell 
body particles (Figure 5.10C-D). ChAT-positive neurite density was measured as area of staining 
at the same threshold was measured minus the total area of cell body particle selections. For 
VAChT-positive neurite density, the threshold value, not necessarily the same as that for ChAT, 
was set to measure percentage area of staining. However, the total area of particle with 
minimum size of 200 pixels instead of 500 pixels was subtracted from the area of VAChT staining 
to exclude non-specific staining in nuclei of other cells. The percentage area of staining was 
divided by cell particle density (specifically the number of cell particles per 0.1 mm2 area).  From 
this point onward, neurite or puncta density, unless specified as punctate particle density, was 
defined as percentage area of staining but cell or particle density is defined as the number of 
cells or particles per area unit. 
 
5.2.3 Western blotting 
Full details of Western blotting protocol (Section 2.2) and antibodies (Table 2.2) are provided 
elsewhere (chapter 2). All antibodies showed bands of the corresponding size previously 
reported or described in manufacturer’s datasheets. WB bands of SPP had the size of 38 kDa 
and do not overlap with the bands of mouse endogenous 52 kDa-IgG heavy chain (HC) and 25 
kDa-IgG light chain (LC), which were expectedly visualised in a negative control condition with 
only secondary antibody anti-mouse and no primary antibody. 
5.2.4 Statistical analysis 
Differences in variables between D427V/WT GBA1 and WT/WT mice were analysed by Student’s 
t-test with Welch’s correction if the variable data is normally distributed or by Mann-Whitney 
U-test if the data is not normally distributed. Normality of distribution of the data was examined 
by Shapiro-Wilk test. Statistical analyses above were conducted in GraphPad Prism 8.0.0 except 
as described below. 
For Western blotting data, two-way ANOVA was used to assess the effects of age, group, or the 
interaction of both on levels of proteins of interest. For each protein, four pairs of comparison 
with Student’s t-test with Welch’s correction were conducted: WT/WT vs D427V/WT in both age 
groups and 6 mo vs 12 mo in both genotypic groups. Four p-values were adjusted with two-stage 
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step-up Benjamini, Krieger, and Yekutieli false discovery rate controlling procedure (BKY-FDR or 
TSBH) (Benjamini et al., 2006) using mt.rawp2adjp function with “TSBH” option from ‘multtest’ 
R package (Bioconductor) 
 
5.3 Results 
Representative images of the DG from WT/WT (Figure 5.2) and D427V/WT (Figure 5.3) showed 
the fundamental staining patterns of each marker exactly as expected. Overall, this VAChT 
antibody (139 103, Synaptic Systems) (Al-Onaizi et al., 2017) stained numerous puncta along 
cholinergic axons visualised by ChAT antibody (AB144P, Millipore) (Blusztajn and Rinnofner, 
2016) in the cortex and hippocampus. The SPP antibody (ab8049, Abcam) visualised whole brain 
parenchyma as tightly packed punctate staining without labelling DAPI-visualised cell nuclei or 
white matter.  
IHC in 12-mo mice revealed a significant reduction of synaptophysin staining mean grey value 
by 42.1% (p = 0.0400; Mann-Whitney U-test) (Figure 5.4A) and considerable loss of VAChT 
percentage area of staining by 69.4% (p= 0.0003; Mann-Whitney U-test) (Figure 5.4B) in the ML 
of the DG of D427V/WT mice compared with the WT/WT mice. On the other hand, ChAT staining 
percentage area was higher in the D427V/WT by 31.8% compared to WT/WT (p = 0.0142; Mann-
Whitney U-test) (Figure 5.4C). There were no significant changes in either total length or average 
width (area divided by length) of ChAT-positive axons. Average ChAT-positive axon particles in 
the D427V/WT were also significantly longer with 13.7% increase than those in the WT/WT (p = 
0.04; Mann-Whitney U test). This result potentially reflected the loss of VAChT-positive puncta 
without the degeneration of axons per se because homogeneous swelling of an axon with fewer 
punctate characteristics would render axon particles to be more intact in the image analysis 
protocol after threshold setting. The most prominent difference was in the ratio of VAChT to 
ChAT staining area that served to approximately measure the density of functional VAChT-
positive boutons on ChAT-positive axons. The decrease in VAChT/ChAT staining area in 
D427V/WT GBA1 compared with WT/WT by 78.3% was statistically significant in the ML (p< 





Figure 5.2 – Representative images of SPP, VAChT, ChAT in the DG of GBA1 WT/WT mice  
Representative images of DAPI (A), SPP (B), VAChT (C), ChAT (D), and VAChT-ChAT colocalisation (E) in the 
DG ML of WT/WT mice. Scale bar = 40 µm. VAChT-positive puncta, as presynaptic terminals, were also 





          
Figure 5.3 – Representative images of SPP, VAChT, ChAT in the DG of GBA1 D427V/WT mice  
Representative images of DAPI (A), SPP (B), VAChT (C), ChAT (D), and VAChT-ChAT colocalisation (E) in the 
DG ML of D427V/WT mice. Scale bar = 40 µm. VAChT-positive puncta, as presynaptic terminals, were also 









Figure 5.4 – Reduced VAChT and elevated ChAT in the DG of 12-month-old D427V/WT GBA1 
mice 
The mean grey values of SPP in the ML was significantly lower in the D427V/WT mice compared to WT/WT 
(A). The percentage area of VAChT staining (B) was significantly decreased but that of ChAT (C) was 
significantly increased in the D427V/WT compared with the WT/WT mice. The ratio of VAChT staining 
area to that of ChAT (D) was drastically reduced in the D427V/WT mice. Data are presented as scattered 
dot plots and the horizontal line represents the mean and the error bars SEM (n=9). Mann-Whitney U-
test *p<0.05; ***p<0.001; **** p<0.0001 compared with the WT/WT. 
 
This pattern of changes was also observed in the motor cortex (MCtx) as shown with 
representative images from the upper cortical layers approximately layers II-III (Figure 5.5 and 
5.6). A decrease in synaptophysin mean grey value in the D427V/WT mice by 30.7% was close 
to statistical significance (p = 0.0520; Student’s t-test with Welch’s correction) (Figure 5.7A). 
Similar to VAChT staining in the DG, VAChT percentage area of staining in the motor cortex was 
significantly decreased in the D427V/WT mice by 61.9% (p = 0.0100; Student’s t-test with 
Welch’s correction) (Figure 5.7B). However, a small increase in ChAT percentage area (Figure 
5.7C) in D427V/WT by 17% compared with WT/WT mice was not statistically significant. Despite 
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the smaller change in ChAT-positive axons, VAChT/ChAT staining area ratio in the motor cortex 
was significantly lower in the D427V/WT than in the WT/WT mice by 71.2% (p = 0.0210; 
Student’s t-test with Welch’s correction) (Figure 5.7D). 
  
Figure 5.5 – Representative images of SPP, VAChT, ChAT in the MCtx of GBA1 WT/WT mice  
Representative images of DAPI (A), SPP (B), VAChT (C), ChAT (D), and VAChT-ChAT colocalisation (E) in the 
MCtx of WT/WT mice. Scale bar = 40 µm. VAChT-positive puncta, as presynaptic terminals, were also SPP-






Figure 5.6 – Representative images of SPP, VAChT, ChAT in the MCtx of GBA1 D427V/WT mice  
Representative images of DAPI (A), SPP (B), VAChT (C), ChAT (D), and VAChT-ChAT colocalisation (E) in the 
MCtx of D427V/WT mice. Scale bar = 40 µm. VAChT-positive puncta, as presynaptic terminals, were also 





Figure 5.7 – Reduction of VAChT in the MCtx of 12-month-old D427V/WT GBA1 mice 
The mean grey values of SPP in the cortex was lower, but not statistically significant, in the D427V/WT 
mice than in WT (A). The percentage areas of staining of VAChT were significantly decreased in the 
D427V/WT compared with the WT/WT mice (B). There was no change in ChAT (C) but VAChT/ChAT was 
still significantly lower in the D427V/WT (D). Data are expressed as scattered dot plots and the horizontal 
line represents the mean and the error bars SEM (n=5). Mann-Whitney U-test *p<0.05 compared with the 
WT/WT.  
 
In an attempt to support the immunohistochemical findings, WB was also performed on 6mo 
and 12mo D427V/WT GBA1and WT/WT mice brain homogenate (n=5 each) to measure in a 
semiquantitative manner the protein levels in the whole regions of interest. In the hippocampus 
(Figure 5.8), there was no significant difference or effect of age or genotype on the level of a 
single marker relative to the housekeeping βIII-tubulin protein between groups according to 
two-way ANOVA analysis. The interaction between genotype and age was close to statistical 
significance (F = 4.41; p = 0.0519; two-way ANOVA) for relative VAChT levels (Figure 5.8B). There 
was a 44% reduction in the hippocampal VAChT/ChAT protein level ratio in the D427V/WT mice 
compared with the WT/WT (p = 0.015; BKY-FDR after Student’s t-test with Welch’s correction) 
(Figure 5.8D). This change in VAChT/ChAT ratio was similar to that of the DG by IHC, but smaller. 
Here, there was also a significant difference between 6mo and 12mo WT/WT mice by 127% (p 
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= 0.002; BKY-FDR after Student’s t-test with Welch’s correction) (Figure 5.8D). Two-way ANOVA 
also confirmed the significant effects of each variable: interaction (p = 0.0107), genotype (p = 
0.0355), and age (p = 0.0022). There was no significant change or effect in any proteins of 
interest in the cortex (Figure 5.9). However, there was a significant effect of age on βIII-tubulin 
(p = 0.0002) with significant pairwise difference between 6mo and 12mo WT/WT (p = 0.015; 









Figure 5.8 –Western blots of cholinergic synapse-related proteins in the hippocampus. 
Immunoblot bands of VAChT, ChAT, and SPP as main proteins of interest and βIII-tubulin as housekeeping 
protein in the cortex were shown (A). Incubation with secondary goat anti-mouse without primary 
antibody showed protein bands corresponding to the heavy chains and light chains of IgG, which did not 
overlap with the bands of mouse monoclonal-targeted SPP. There were no significant differences in 
relative levels of VAChT (B), ChAT (C), SPP (E), and βIII-tubulin (F) between WT/WT (circle) and D427V/WT 
(triangle) mice. The ratio of VAChT to ChAT(D) in the hippocampus of 12mo GBA WT/WT(D) was 
significantly higher than that of both 6mo WT/WT and 12mo D427V/WT. Data are expressed as scattered 
dot plots and the horizontal line represents the mean and the error bars SEM (n=5). Student’s t-test with 








Figure 5.9 – Western blots of cholinergic synapse-related proteins in the cortex.  
Immunoblot bands of VAChT, ChAT, and SPP as main proteins of interest; βIII-tubulin as housekeeping 
protein in the cortex; and IgG as negative control for secondary anti-mouse were shown (A). There were 
no significant differences in relative levels of VAChT (B), ChAT (C), VAChT/ChAT (D), and SPP (E) between 
WT/WT (circle) and D427V/WT (triangle) mice. The level of βIII-tubulin in 12mo cortex was lower than 
that in 6mo cortex with significant pairwise difference between 6mo and 12mo WT/WT (F). Data are 
expressed as scattered dot plots and the horizontal line represents the mean and the error bars SEM 




Staining patterns for cholinergic markers were also investigated in the cholinergic basal 
forebrain specifically the VDB/HDB, which projects to the hippocampus (Figure 5.10). This 
enabled an assessment as to whether the changes seen in the DG were confined to terminals or 
were also reflected in the projecting cell bodies. Cell bodies of ChAT-positive BFCNs in the 
D427V/WT VDB/HDB showed negligible change in VAChT (Figure 5.11A), a non-significant 
increase in ChAT immunoreactivity by 31.5% (p = 0.2573; Mann-Whitney U-test)(Figure 5.11B) 
and lower VAChT/ChAT immunoreactivity ratio by 37.1% (p=0.0842; Mann-Whitney U-
test)(Figure 5.11C). On the other hand, the density of ChAT-positive neurites as percentage area 
of staining per ChAT-positive cell body particle (cell/0.1 mm2) was significantly higher by 95.5% 
(p = 0.0474; Mann-Whitney U-test) (Figure 5.11E) and the ratio of VAChT-positive to ChAT-
positive neurite density was significantly lower by 65.1% (p = 0.0023; Mann-Whitney U-test) in 




                                                                                              
Figure 5.10 – Representative images of VAChT and CHAT in the VDB/HDB  
ChAT-positive particles representing BFCNs were selected (yellow line) in the VDB/HDB such that the 
intensity of both ChAT and VAChT staining in each particle and the density of ChAT and VAChT-positive 
neurites were quantified separately. Representative images of VAChT (A-B), ChAT (C-D), and colocalisation 





Figure 5.11 – Immunoreactivity of cholinergic markers and neurite density in the VDB/HDB 
VAChT (A) and ChAT (B) staining intensity in ChAT-positive cell body particles and the ratio of VAChT to 
ChAT in cell bodies (C) were not significantly different between WT/WT and D427V/WT. The density of 
VAChT-positive neurites was not different between the two groups (D), but D427V/WT had higher density 
of ChAT-positive neurites (E) and lower ratio of VAChT to ChAT-positive neurite density (F). Data are 
expressed as scattered dot plots and the horizontal line represents the mean and the error bars SEM 
(n=7). Mann-Whitney U-test * p<0.05; ** p<0.01 compared with the WT/WT. 
 
In parallel to the investigation in AD cohorts in the previous chapter, IHC was also used to 
investigate AHN in WT/WT (Figure 5.12A-C) and D427/WT GBA1 mice (Figure 5.12D-G). 
Representative images showed the theoretically expected staining patterns of these markers. 
The DCX antibody (sc-8066, Santa Cruz) (Poser et al., 2015) (blue) stained few neurons in the 
GCL and some immature cells in the SGZ. It also recognised immature neurons in the SVZ and in 
the olfactory bulb. The HuB/D antibody (PA5-38596, Thermo Fisher) (red) visualised few cells in 
the SGZ, most large neurons in the hilus and few in the GCL, and the entire CA3. The PCNA 
antibody (M0879, Dako) (green) brightly stained a few cell nuclei notably of several DCX-positive 
cells in the SGZ and SVZ.  
D427V/WT mice had significantly higher density of DCX-positive neuroblasts or immature 
neurons than WT/WT mice by 135% (p = 0.0031; Mann-Whitney U-test) (Figure 5.12H). 
Specifically, this difference in the total density was attributed to the significantly higher density 
of pre-mitotic neuroblast/immature neurons or PCNA/DCX-double positive cells by 353% 
compared with the WT/WT (p = 0.0126; Mann-Whitney U-test) and higher but not statistically 
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significant density of post-mitotic population or PCNA-negative DCX-positive cells by 84.2% (p = 
0.1325; Mann-Whitney U-test). The number of total HuB/D positive cells was higher than the 
total number of DCX-positive cells in both groups but there was no significant difference in 
PCNA-negative or PCNA/ HuB/D-double positive cells between groups (Figure 5.12I). In relation 
to cholinergic innervation, only the density of PCNA-positive DCX-positive cells (rs = -0.662, p = 
0.003; Spearman correlation) and total DCX-positive cells (rs = -0.629, p = 0.005; Spearman 





Figure 5.12 – Abnormal adult hippocampal neurogenesis in the D427V/WT GBA1 mice 
Representative Z-projection images of DAPI (grey), PCNA (green), HuB/D (red), and DCX (blue) in the DG 
of the WT/WT (A-C) and D427V/WT (D-G) mice. Large HuB/D-positive neurons in the GCL (circle) and in 
the hilus (square) are likely GABAergic interneurons and hilar mossy cells or hilar GABAergic neurons or 
CA3 pyramidal neurons respectively. Some small HuB/D-positive neurons in the SGZ have PCNA (thick 
short green up arrow) but some others do not (short upward arrow). Mitotic DCX-positive cells (thick 
green up-left arrow) express PCNA and contain mainly horizontal processes. Postmitotic DCX-positive 
neurons (up-left arrow) lack PCNA and have distinguishable apical dendrites (leftward arrow). Scale bar = 
40 µm. The D427V/WT GBA1 mice have higher density of total DCX-positive and PCNA/DCX-double-
positive cells than the WT/WT (H). There was no significant difference in HuB/D-positive cell density 
between WT/WT and D427V/WT mice (I). Data are expressed as scattered dot plot and the horizontal line 
represents the mean and the error bars SEM (n=9). Mann-Whitney U-test; *p<0.05; **p<0.01 compared 





5.4.1 Result discussion 
The findings of this chapter were as follows;  
- Drastic reduction in VAChT % staining area but with a moderate increase in ChAT % 
staining area in the DG of D427V/WT GBA1 mice compared with WT/WT. The staining 
intensity of SPP was also significantly decreased. 
- Significant decrease in VAChT staining area, but to a milder extent than the decrease in 
the DG, was also found in the motor cortex with no significant increase in ChAT. SPP 
staining intensity was decreased but not statistically significant. 
- WB showed a similar trend of VAChT reduction in the hippocampus with a significant 
decrease in VAChT/ChAT ratio in D427V/WT compared with WT/WT. There was no trend 
of disparity in any markers in the cortex. 
- Significantly higher % staining area of ChAT-positive neurites in the VDB/HDB. There was 
no change in % staining area of VAChT but the ratio of VAChT/ChAT neurite staining was 
significantly lower in D427V/WT than in WT/WT. Cell density and size were not different. 
- Significantly higher density of DCX-positive cells especially those with PCNA in 
D427V/WT mice than in WT/WT. No difference in HuB/D-positive cells between the 
groups.    
The main findings of this study were that D427V/WT GBA1 mice at 12 mo have significantly less 
VAChT % area but relatively higher % staining area of ChAT than the WT/WT mice in the DG. The 
reduction in VAChT staining was accompanied by a decrease in SPP immunoreactivity. The same 
patterns of alterations were observed in the motor cortex but were less pronounced. A separate 
analysis of the cholinergic hippocampal proteins by Western blotting showed similar trends of 
change but only VAChT/ChAT ratio between 12 mo D427V/WT and WT/WT was significantly 
reduced. In the VDB/HDB, the ratio of VAChT/ChAT staining intensity was also decreased but 
there was no change in VAChT % area of staining. The numbers of DCX-positive cells especially 
those with PCNA were significantly higher in the D427V/WT mice.      
The differential staining intensity of VAChT and ChAT contrasts with their coupled transcription 
by the same R promoter in the cholinergic locus. ChAT exclusive M promoter was hypothetically 
one of the possible differential cholinergic gene regulators (de Castro et al., 2009). For the WB 
results in the hippocampus of 12-mo D427V/WT compared with the WT/WT, we at least observe 
a decrease in the VAChT level of 66.6% that was not statistically significant because of high 
variability. The reduction in cortical VAChT level in the D427V/WT at 12 mo, however, was 
negligible at 10.4%. Nonspecific binding of this VAChT antibody to neuronal nuclei was higher in 
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the cortex (Figure 5.4A) than in the hippocampus (Figure 5.3A) and certainly more noticeable in 
D427V/WT GBA1 mice. This nonspecific binding might have confounded the difference in 
punctate VAChT level. On the other hand, we have not proved that this nonspecific binding in 
IHC also occurred in WB and that this supposedly nonspecific band had been included in the 69 
kDa band of VAChT protein.         
One of the first studies of a VAChT-globally-knockdown model showed intracellular 
accumulation of ACh without any alterations in activity and expression of ChAT and in the rate 
of choline uptake (Prado et al., 2006). A later study by the same group on VAChT knockout found 
that both homozygous and even hemizygous VAChT knockout mice have significantly higher ACh 
level and higher ChAT mRNA expression in the brain at E18.5 (de Castro et al., 2009). The authors 
speculated that this upregulation of ChAT expression was directly driven by shorter distance 
between R-promoter and M-promoter after the removal of VAChT gene segment, but enhanced 
ACh synthesis as a compensatory mechanism of cholinergic system was also possible considering 
that CHT1 expression was significantly increased in the VAChT knockout mice as well. 
Nonetheless, RT-PCR results in 12 mo mice by Dr Emily Clarke demonstrated a significant 
decrease in both ChAT and VAChT mRNA in the hippocampus hence confirming the transcription 
coregulation of the cholinergic locus (Dr Emily Clarke, personal communication; Appendix Figure 
A.2). 
Our study showed significant elevation in hippocampal ChAT axon density and also an increase, 
but not significant, in the cortical ChAT axon density in D427V/WT GBA1 mice compared with 
WT/WT. VAChT knockout only in cholinergic neurons of the Six3 forebrain lineage (VAChTSix3-Cre-
flox/flox) including mainly the BFCNs and striatal large cholinergic interneurons induced no change 
in the levels of cortical ChAT but slight decrease in the hippocampal ChAT levels by Western 
blotting (Martyn et al., 2012). While our concerning ChAT axon density in the cortex or 
hippocampus does not agree with the study on forebrain VAChT knockout, our ChAT Western 
blot results at 12 months showed similar patterns of negligible change in the cortex and slight 
decrease in the hippocampus in the D427V/WT compared with the WT/WT. Nonetheless, it 
should be noted that VAChT knockout hemizygous and homozygous mice were investigated at 
embryonic stage and forebrain VAChT knockout mice at young age of 21-40 days old.  
Another possible explanation to account for higher ChAT percentage area of staining but lower 
or same ChAT protein levels is enlargement or higher branching incidence of axons without 
changes in total protein level. This study found that ChAT-positive axons in the D427V/WT have 
less en passant punctate characteristics or varicosities (Figure 5.3A) and this was congruent with 
the lower density of VAChT-positive puncta.  Cholinergic axon swelling was also reported in AD 
patients and mouse models except that the swellings were less homogeneous and more 
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extreme in size as conspicuous beading/blebbing due to protein accumulation rather than loss 
of punctate characteristics (Stokin et al., 2005). AD-like swellings in cholinergic axons was also 
accompanied by loss of ChAT-positive fibre density in the basal forebrain specifically nbM, but 
our study instead found that D427V/WT GBA1 mice had higher density of ChAT-positive fibre 
especially with respect to VAChT in the VDB/HDB.  
There was no change in the density or number of BFCNs in the VDB/HDB. This result 
recapitulated the lack of cell loss in the MS/VDB in PDD patients (Hall et al., 2014). The authors 
did not report a result on cholinergic fibre density but the representative image of the MS/DB 
in PDD patients seems to have slightly denser cholinergic fibres than controls and to higher 
extent than idiopathic PD patients. This could be similar to our results on higher % area of ChAT-
positive neurites from the VDB/HDB BFCNs. 
Furthermore, we found lower immunoreactivity of SPP in both the DG and the motor cortex, 
statistically significant in the former but just below criterion in the latter. This raises the 
possibility that GBA mutation-induced synaptic degeneration, either by terminal loss or 
dysfunction of vesicular systems, may upregulate ChAT protein level especially in BFCNs of the 
MS/DB in compensation. Similar to VAChT, hippocampal SPP level by WB was lower in the 
D427V/WT mice but not statistically significant due to variability of data and cortical SPP level, 
in the same fashion as that of VAChT, was not changed at all between the two groups at 12 mo. 
Overall, these data suggest that replication of the study with a larger sample size is required to 
explore this further. 
BFCNs and dopaminergic neurons in non-human primates also have high expression of GCase 
(Dopeso-Reyes et al., 2018) and hence are likely sensitive to GBA1 mutations. One study showed 
that GlcSph decreased neurite outgrowth, lowered GCase activity, and importantly decreased 
ACh production in cholinergic neuron-like neuroblastoma LA-N-2 (Schueler et al., 2003). 
Homozygous D427V/D427V GBA1 mice at 6 mo have GlcSph accumulation (Sardi et al., 2011) 
and it is possible that D427V/WT mice at 12 mo may have developed this feature as well. 
Since VAChT was not significantly decreased in the VDB/HDB, loss of VAChT could result from 
defects in local production or degradation of VAChT protein in the axons, loss of presynaptic 
terminals, or abnormality in vesicular protein trafficking. Considering that hippocampus-
projecting BFCNs also corelease GABA from the same active zone (Takács et al., 2018), it would 
be interesting to check whether vesicular GABA transporter (VGAT)-positive GABA vesicles or 
terminals were affected as well. To check for the direct loss of presynaptic terminals, co-staining 
of CHT1 and VAChT would be helpful that predominant colocalisation and significant loss of both 
proteins in D427V/WT would serve as good preliminary evidence that synaptic terminals are 
degraded. Furthermore, VAChT-positive terminals are usually paired with postsynaptic cluster 
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of gephyrin (Takács et al., 2018), so staining for gephyrin would help identify any changes in 
synaptic structures. Mechanisms of VAChT axonal transport and production has not been fully 
elucidated but direct interaction with some proteins such as clathrin and synaptobrevin has 
been identified (reviewed in Prado et al., 2013). A recent article has shown that active zone and 
presynaptic vesicle proteins such as Bassoon and VGluT1 in mouse hippocampal neurons were 
anterogradely transported from the cell body along the axon via Arl8-dependent mechanisms 
to the presynaptic terminals via LAMP1-positive presynaptic lysosome-like vesicles (PLV) that 
did not have digestive cathepsin enzymes or acidic pH (Vukoja et al., 2018). Arl8 is a small GTPase 
lysosomal kinesin adaptor. Although loss of Arl8 function also result in accumulation of Bassoon- 
and VGluT1-positive PLVs in the soma of Drosophila neurons, this thesis did not show an increase 
in VAChT within the soma of BFCNs. The possibility of simultaneous defects in multiple pathways 
could not be ruled out. Nonetheless, since Dr Emily Clarke has shown that mRNAs of both VAChT 
and ChAT were decreased, there were likely specific post-transcriptional mechanisms that 
enhanced or at least preserved ChAT levels. For example, RNA splicing factor B52 was required 
for ChAT splicing specifically at intron 2 and intron 4-7 and therefore had no effect on VAChT 
splicing (Liu and Bossing, 2016). An endoplasmic reticulum-associated co-chaperone 
p97/valosin-containing protein was also found to play an important role in ubiquitin-dependent 
ChAT degradation (Morey et al., 2017). It was possible that upregulation of B52 mouse analogue 
and/or downregulation of p97 could have contributed to the ChAT upregulation/preservation 
observed in D427V/WT mice.    
An earlier recent study has reported that approximately 49% of LAMP1 in the cell body was 
colocalised with GCase but 79% of GCase was colocalised with LAMP1 (Cheng et al., 2018). While 
it has not been confirmed, PLV likely contain low GCase level or at least non-optimally active 
GCase because of its non-acidic pH (Lieberman et al., 2009). It is possible that D427V GCase 
could be mis localised to the LAMP1-positive PLVs and disrupted their role in transporting 
presynaptic proteins including VAChT and SPP.  
The higher number of DCX-positive cells in the DG of the D427V/WT compared with the WT/WT 
mice recapitulated the higher number of DCX-positive cells in DLB patients compared with 
controls (Johnson et al., 2011; Gatt et al., 2018). Although the same study (Johnson et al., 2011) 
found a significant increase and decrease in staining percentage area of PCNA and ChAT 
respectively, correlations between factors were not reported.  Direct cholinergic synapses on 
immature adult-born DGCs have been shown to regulate their survival into NeuN-positive 
postmitotic mature neurons through m1-AChR-related pathways (Zhu et al., 2017). ACh was 
shown to regulate maturation of adult-born DGCs through α7-nAChR-associated pathways, one 
of which was NKCC1 reduction as a late stage of functional maturation (Campbell et al., 2010). 
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Since cholinergic axons in the hippocampus corelease ACh and GABA in the same terminals 
(Takács et al., 2018), stimulation of BFCNs may dynamically monitor maturation of adult-born 
DGCs via both ACh and GABA signalling pathways. Reduction in ACh signalling from loss of VAChT 
may delay α7-nAChR-associated maturation and simultaneously reduce survival of late-term 
adult-born DGCs, leading to an accumulation of immature population. There is a possibility that 
general proliferation was also upregulated but slight increases in the number and ratio of PCNA-
positive HuB/D-positive cells were not significant in the present study. 
 
5.4.2 Limitations and Future directions 
This study so far had investigated only one 7-µm thick brain section for each set of staining or a 
combination of antibodies used on a single section. While lack of use of a gold standard 
stereological technique may not critically affect considerably significant and homogeneous 
feature such as VAChT deficits in the cholinergic axons in the DG, it possibly resulted in 
insufficient data sampling for cell counting in both the DG and the VDB/HDB and morphological 
changes of ChAT-positive neurites. Improved methods for future experiments should include 
stereology for at least the dorsal hippocampus and possibly duplicate set of staining in 
consecutive sections. Distribution of SPP-positive puncta in the Z-axis of thin paraffin-embedded 
section was more polarised toward the glass slide than that of cholinergic axons. In this 
experiment, we focused on a Z-slice that has maximum cholinergic axon density, but it may be 
better to choose the slice based on SPP staining or to code a macro that can process information 
from multiple slightly heterogeneous Z-slices together in a proper statistical procedure. A thicker 
section is also an alternative. 
We chose to investigate the motor cortex because despite its relatively high resistance to 
synuclein pathology as it is usually not affected until PD Braak stage 6 (Braak et al., 2003), its 
cholinergic activity-mediated short latency afferent inhibition (SAI) was significantly impaired 
(Di Lazzaro et al., 2007) and inversely correlated with hallucinations in DLB patients (Marra et 
al., 2012). SAI was also significantly decreased in PDD patients (Celebi et al., 2012) and 
potentially earlier in PD-MCI (Yarnall et al., 2013) compared with cognitively normal PD 
(reviewed in Cromarty et al., 2016). In the aspect of profiling, the motor cortex is more 
independent from the DG than the frontal cortex that has both input and output connections to 
the VDB/HDB (Do et al., 2016). In that regard, we had planned to investigate the nbM/SI as well 
but the variations across mouse brains from difference in levels of sagittal sections in terms of 
the BFCN and neurite density prevented this approach in the current group of animals. 
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In a single sagittal section, a single-field thin strip of the motor cortex is more heterogeneous in 
terms of cholinergic axon and synaptic punctate distribution than the ML. In the future, it is 
advisable to capture images of a wider strip of a specific cortex with a 20X objective lens that 
allows us to measure the cholinergic axon distribution in multiple separated bins of equal size. 
Each sub-sectors of the hippocampus such as ML and GCL of the DG, and CA1-3 can also be 
subdivided into bins for future study. 
The set of neurogenic markers in this study was selected to parallel my human study in the 
previous chapter. Likewise, with similar problems, while large HuB/D-positive cells could be 
easily excluded from the counting as large GABAergic interneurons, hilar mossy cells, or CA3 
pyramidal neurons, small- to medium-sized interneurons could have been incorrectly counted 
as DGCs. Another set of co-staining with the DGC lineage marker Prox1 could help identify 
HuB/D-positive immature DGCs in the future. Since Hu proteins were mainly expressed in early 
stage of DGC development up to DCX-positive phase (Liu et al., 2010), those HuB/D-positive cells 
that have not been fate-determined by Prox1 expression must still be pre-mitotic stage with 
PCNA expression. Hence, three groups of HuB/D-positive cells can be categorised: PCNA-
positive/Prox1-negative early neurogenic cells, Prox1-positive DGC-determined neuroblast or 
immature neurons, and lastly Prox1-negative non-DGC neurons. On that note, antibody 
stripping method optimised enough to completely remove nuclear marker staining would be 
tremendously helpful for the profiling study on adult hippocampal neurogenesis. 
The current WB data were also derived from a single set of samples. There was not enough 
homogenate from some brains to perform a duplicate or a triplicate set of experiments. Some 
hippocampal samples showed high level of proteins relative to the βIII-tubulin because their βIII-
tubulin bands were abnormally small. This might result from global protein degradation during 
loading dye incubation at 4°C as these samples also contained minimal levels of endogenous 
IgG-HC and LC  An exploratory analysis where  these cases were excluded modified the decreases 
in D427V/WT hippocampal VAChT and SPP at 12 mo to be statistically significant. However, 
there was not enough evidence to justify the case selection and a new experiment would need 
to be undertaken. 
Overall, these studies have demonstrated a novel and unexpected disruption of the cholinergic 
system in D427/WT GBA1 mice. From other work in the laboratory and other studies, these 
changes could be the basis of the cognitive changes seen in this model although this clearly 
needs further and more detailed confirmation. The heterozygous mice also had significantly 




6 Cholinergic system and adult hippocampal neurogenesis in a 
mouse model of Alzheimer’s disease, 5XFAD 
 
6.1 Introduction 
None of AD mouse models have faithfully replicated all major symptoms in human AD, but 
several models have been developed and demonstrated to share common features with human 
patients. 5XFAD is one of the well-investigated models with evidence of cholinergic 
degeneration Yan et al., 2018 and AHN deficits (Moon et al., 2014; Choi et al., 2018). In the 
5XFAD transgenic mice, human APP 695 with 3 FAD mutations (K670N/M671L, I716V, and V717I) 
and PSEN1 with 2 FAD mutations (M146L and L286V) co-overexpression are driven by neuron-
specific Thy1-promoter (Oakley et al., 2006). Intracellular Aβ42 accumulation and plaque 
deposition started very early at the ages of 1.5 and 2 months respectively. Furthermore, unlike 
other AD models such as Tg2576 but more similar to human, the Aβ42/Aβ40 elevated rapidly 
and early since 1-2 mo of age. There was no difference in AT8 phosphorylated-tau epitope 
staining between 5XFAD and WT. Therefore, most anomalies observed in the 5XFAD could be 
attributed to Aβ42-associated mechanisms and this could prove useful in distinguishing Aβ-
driven changes from those predominantly driven by phosphorylated tau toxicity.  
The number of BFCNs in the HDB was significantly decreased and the % staining area of the 
hippocampal cholinergic dystrophic axons hence was notably higher in the 5XFAD compared 
with those of WT (Yan et al., 2018). Regardless, the % area staining of non-dystrophic axons and 
% area of VAChT staining have not been investigated in the 5XFAD model. A recent study on 
5XFAD showed that reduction in survival of adult-born DGCs was directly related to partial loss 
of cholinergic terminals on dendrites of adult-born DGCs (Zhu et al., 2017). The above finding 
was supported by a significant decrease in the number of DCX-positive cells and calretinin-
positive immature neurons in 5XFAD (Moon et al., 2014).  
The main aim of this study was to examine the impact of Aβ and possible cholinergic changes in 
the 5XFAD mouse model and to qualitatively compare these with the observations from the 
D427V/WT GBA1 mouse model described in chapter 5. From these previous findings mentioned 
above, the hypothesis of this chapter is that 5XFAD at 11-mo would have loss of BFCNs in the 
VDB/HDB and also a reduction in both VAChT and ChAT % staining area in the DG and cortex. 
Although a previous study suggested that the proclivity of AHN deficits compared with the WT 
subsided after 7-mo, it should still be possible to detect reduction in DCX- and HuB/D-positive 
cells in 5XFAD compared with the WT. 
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6.2 Materials and Methods 
6.2.2 Immunohistochemistry 
For each mouse brain, two 7 µm-thick sagittal sections were stained for a set of cholinergic 
synaptic markers (SPP, VAChT, ChAT) and the other set of neurogenic markers (PCNA, HuB/D, 
DCX). See the details of standard IHC protocol (Section 2.1) and antibodies (Table 2.1) in Chapter 
2.  
6.2.2.1 Imaging methods  
For cholinergic staining, images of the entire dentate gyrus (about 3-4 fields), a strip of the 
somatosensory cortex (about 4-6 fields), and the VDB/HDB (about 3-4 fields) on a section were 
captured with Zeiss LSM 710 upright confocal microscope at 20x objective magnification using 
Zen software. Staining was visualised in 4 channels: 405 nm (DAPI), 488 nm (SPP), 568 nm 
(VAChT), and 647 nm (ChAT). For each field, a single slice from Z-stack with approximately 
highest density of ChAT-positive axons was selected for analysis. For adult hippocampal 
neurogenesis, images of the DG were captured with Zeiss Axiocam fluorescence microscope at 
20x objective magnification using Axiovision SE64 Rel 4.9.1 software.  
6.2.2.2 Quantification methods 




IHC in the DG of both WT (Figure 6.1A-E) and 5XFAD (Figure 6.1F-J) showed standard staining 
pattern as previously demonstrated in Chapter 5. ChAT-positive dystrophic neurites were also 
present in the DG of 5XFAD but mainly in the hilus (data not shown). There was no significant 
difference between WT and 5XFAD in the staining of SPP (Figure 6.2A), VAChT (Figure 6.2B), 
ChAT (Figure 6.2C), or VAChT/ChAT ratio (Figure 6.2D). There were trends of decrease in both 
VAChT and ChAT % area of staining. Representative images seemed to show more noticeable 
differences in cholinergic axons between WT and 5XFAD in the GCL than in the ML. However, 
the decreases in VAChT (27.5%, p = 0.244) and ChAT (19.8%, p = 0.676) in the GCL of 5XFAD 






Figure 6.1 – Representative images of SPP, VAChT, ChAT in the DG of WT and 5XFAD mice  
Representative images of DAPI (A, F), SPP (B, G), VAChT (C, H), ChAT (D, I), and VAChT-ChAT colocalisation 
(E, J) in the DG of WT (A-E) and 5XFAD (F-J) mice. The borders of the GCL were depicted by dotted blue 







Figure 6.2 – Cholinergic axons in the DG of 11-mo 5XFAD 
Mean grey value of SPP staining (A), VAChT % area of staining (B), CHAT % area of staining (C), and the 
ratio of VAChT to ChAT staining (D) were shown. Data are expressed as scattered dot plots and the 
horizontal line represents the mean and the error bars SEM (n=3).  There was no statistically significant 
change by Student’s t-test with Welch’s correction.       
 
IHC results in the somatosensory cortex also followed the standard staining patterns of the 
respective markers. Only the staining in 5XFAD (Figure 6.3B) but not WT (Figure 6.3A) showed 
abnormal features such as ChAT-positive dystrophic neurite particles, round patches of SPP 
staining, and clusters of cell nuclei. Changes in the staining of SPP (Figure 6.4A), VAChT (Figure 
6.4B), ChAT (Figure 6.4C), or VAChT/ChAT ratio (Figure 6.4D) were not statistically significant. 
Nonetheless, % staining areas of VAChT and ChAT were lower in 5XFAD compared with the WT 





Figure 6.3 – Representative images of SPP, VAChT, ChAT in the somatosensory cortex of WT 
and 5XFAD mice  
Representative images of DAPI (A, F), SPP (B, G), VAChT (C, H), ChAT (D, I), and VAChT-ChAT colocalisation 
(E, J) in the somatosensory cortex of WT (A-E) and 5XFAD (F-J) mice. Dystrophic cholinergic neurites 
(arrow), round agglomeration of SPP-positive particles (dotted open arrow), and large cluster of cell nuclei 






Figure 6.4 – Cholinergic axons in the somatosensory cortex of 11-mo 5XFAD 
Mean grey value of SPP staining (A), VAChT % area of staining (B), CHAT % area of staining (C), and the 
ratio of VAChT to ChAT staining (D) were shown here from n=3 of each group. Data are expressed as 
scattered dot plots and the horizontal line represents the mean and the error bars SEM (n=3). There was 
no statistically significant change by Student’s t-test with Welch’s correction.       
 
The VDB/HDB on sagittal sections can be located by its posterior proximity to the olfactory 
tubercle, which is located under the nucleus accumbens shell (Figure 6.5). The density of ChAT-
positive neurons was not significantly different between WT and 5XFAD (Figure 6.6A) with an 
averaged VDB/HDB area of 0.31 mm2. There was no statistically different change in VAChT 
(Figure 6.6B), ChAT (Figure 6.6C), or VAChT/ChAT ratio (Figure 6.6D) of staining intensity within 
ChAT-positive neurons. The % area of VAChT- (Figure 6.6E) or ChAT-positive axons (Figure 6.6F) 
and VAChT/ChAT ratio (Figure 6.6G) of % staining area were also not significantly different 






Figure 6.5 – Representative images of VAChT and ChAT in the VDB/HDB 
Montage images of the VDB/HDB from sagittal sections (dotted polygonal shape) did not show noticeable 











Figure 6.6 – Immunoreactivity of cholinergic markers and neurite density in the VDB/HDB  
The density of ChAT-positive cells (A) and the intensity of VAChT (B) and ChAT (C) staining and their 
staining ratio (D) within the ChAT-positive cells were quantified. Percentage staining areas of VAChT- (E) 
and ChAT-positive neurites (F) and their ratio (G) were measured separately. Data are expressed as 
scattered dot plots and the horizontal line represents the mean and the error bars SEM (n=3). There was 
no statistically significant change by Student’s t-test with Welch’s correction.    
 
Representative images of the DG from both WT (Figure 6.7A-C) and 5XFAD (Figure 6.7D-G) 
showed standard cytoplasmic immunoreactivity of DCX, in which some positive cells had 
immature neuron morphology but others still retain neuroblast characteristics. Mostly small and 
flat HuB/D-positive cells in the GCL and SGZ were included in the quantification since large 
HuB/D cells were probably hilar mossy cells, GABAergic interneurons, or CA3 pyramidal neurons. 
Nonetheless, few medium to large HuB/D cells in the GCL also express DCX and PCNA and hence 
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were included in the analyses. There was no significant difference in neurogenic cell density 
between the two groups (Figure 6.7H-I).    
 
 
Figure 6.7 – Adult hippocampal neurogenesis in 5XFAD mice 
Representative images of neurogenic subpopulations of WT (A-C) and 5XFAD (D-G) showed PCNA-
negative DCX-positive cells (right-downward arrow), PCNA-positive DCX cells (left-upward green arrow), 
PCNA-negative HuB/D-positive cells (dotted open arrow), PCNA-positive DCX cells (green dotted open 
arrow), and few triple-positive cells (blue dotted box). There was no significant change in DCX-positive (H) 
or HuB/D-positive cells (I) by Student’s t-test with Welch’s correction. Data are expressed as scattered dot 






The findings of this chapter were as follows; 
- No significant difference in % staining area of VAChT or ChAT in the DG. There were few 
dystrophic neurites in the hilus but not in the ML of 5XFAD. 
- No significant difference in % staining area of VAChT or ChAT in the somatosensory 
cortex. In 5XFAD, dystrophic neurites were more prevalent in the cortex compared with 
the DG by observation. 
- No significant change in cell number, size, or marker staining in the VDB/HDB.  
- No significant change in the number of DCX- or HuB/D-positive cells. 
The main findings of this study were that the cholinergic system was relatively well preserved as 
judged by staining of cholinergic nerve terminals and ChAT-positive nbM neurons. Furthermore, 
there were no obvious changes in neurogenic markers. Small number of animals likely 
contributed to the low observed statistical power. If the number of animals was increased some 
of the changes might reach statistical significance.  
Decrease in the density of DCX-positive cells in young adult 5XFAD mice has been reported 
(Moon et al., 2014). Interestingly, the difference in DCX-positive cells between WT and 5XFAD 
increased with age during 2-4 mo but suddenly dropped to the statistically non-significant level 
at 7 mo. Another study that found defects in survival of adult-born DGCs was also conducted on 
5-mo 5XFAD (Zhu et al., 2017). Mice used in this study were 11-mo and there was a possibility 
that the AD transgene-induced prohibitive effects on adult neurogenesis in 5XFAD were 
outweighed by age-induced reduction in neurogenesis. On the other hand, APP23 mice with the 
Swedish K670N/M671L mutation had lower number of DCX-positive cells at 5-mo but later had 
higher number of DCX-positive cells at 25-mo compared with the WT (Ermini et al., 2008). It can 
be speculated that the rate of AHN decrease in the WT was faster than that of 5XFAD at older 
ages. The Swedish mutation was also one of three APP mutations in 5XFAD mice. Therefore, the 
lack of difference in adult hippocampal neurogenesis at old ages in 5XFAD was possibly a 
transition where AD-associated mutations started to upregulate AHN and delay age-induced 
reduction.  
In summary, the present study did not demonstrate any changes in either the cholinergic system 
or neurogenesis in this mouse model, however because of the small numbers and limited time 




7 General Discussion 
 
7.1 Summary of findings 
The Chapter 3 pilot study on a cohort of 9 cases verified the potency of ChAT and VAChT as 
markers of cholinergic innervation and of DCX and HuB/D as markers of fate-determined 
neuroblasts or immature neurons in the AHN process. Estimated cm from the front of the 
section, sex, age, PMI, and pH were identified as potential covariates. Percentage area of 
staining was chosen as a method of quantification for cholinergic axon markers and this was 
modelled with a univariate GLM. Cell count per mm DG length was used to quantify AHN and 
this was modelled with a negative binomial regression. Antibody stripping was effective enough 
to reveal that DCX- or HuB/D-positive cells may also express post-mitotic marker calretinin, 
confirming their identities as AHN markers.  
The Chapter 4 study on a main cohort of 36 cases revealed no change in VAChT % area of staining 
or colocalisation between VAChT and ChAT across Braak stages. Interestingly, ChAT % area of 
staining was upregulated in Braak III and significantly decreased compared with that of Braak III 
in Braak IV-VI. This study also showed that among the 6 basis groups of DCX or HuB/D-
immunoreactive cells, the numbers of xH, xHD, and xPH per mm DG length were significantly 
different across Braak stages but significant pairwise differences were found only in xH between 
Braak V and Braak II-III, VI and between Braak III and Braak IV. A combined group of HnP from 
xH and xHD had significant pairwise differences between Braak III-IV and Braak 0, II-III, VI. 
Correlation analyses also confirmed that colocalisation was more correlated to ChAT than to 
VAChT staining. In terms of interaction between cholinergic and neurogenic markers, only ChAT 
% area of staining was positively correlated with xH and xHD and negatively correlated with xPH.            
The Chapter 5 study on 12 mo D427V/WT GBA1 mice found significant reduction in VAChT % 
area of staining in the DG and the motor cortex compared with that of controls. On the other 
hand, ChAT % area of staining was elevated in the DG but not in the motor cortex. These findings 
by IHC were not completely corroborated by Western blotting as VAChT and CHAT levels 
individually were not decreased in the hippocampus or cortex of 12 mo D427V/WT compared 
with the 12 mo control. VAChT/ChAT ratio, however, was significantly reduced in the 12 mo 
D427V/WT hippocampus but still to a smaller extent than the reduction found by IHC. The 
VDB/HDB of 12 mo D427V/WT mice had higher % area of ChAT-positive neurites than that of 
WT but there was no change in the number of BFCNs or their immunoreactivity of ChAT or 
VAChT. In terms of AHN, the numbers of total DCX-positive cells and especially those double-
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positive with both DCX and PCNA were significantly higher in 12 mo D427V/WT than in controls. 
There was no change in the number of HuB/D-positive cells. 
The Chapter 6 study on 11 mo 5XFAD mice with the same IHC protocols performed in the 
Chapter 5, however, did not reveal any significant difference in ChAT or VAChT in the DG, 
somatosensory cortex, or VDB/HDB. There was no significant change in the number of BFCNs in 
the VDB/HDB or the number of DCX- or HuB/D-positive cells in the DG.    
 
7.2 Abnormal cholinergic innervation in AD cases and mouse models 
Hippocampal ChAT activity was reported to be upregulated in MCI patients compared with 
control and AD dementia patients (DeKosky et al., 2002) and a later study further specified that 
this upregulation in hippocampal ChAT activity occurred mainly in MCI patients with Braak III-IV 
(Ikonomovic et al., 2003). This study found a significant increase in % staining area of ChAT-
positive axons in cases with Braak III than cases with Braak IV-VI. However, it was impossible to 
prove whether MCI had any effects on ChAT % area of staining because the record of cognitive 
scores either MMSE or CDR in this cohort was incomplete. Upregulation in ChAT 
immunoreactivity was also observed in the hippocampus of D427V/WT GBA1 mice. However, 
unlike human Braak III where % area ChAT-positive dystrophic in the ML was prevalent, there 
was no large ChAT-positive particle that resembled an AD-associated dystrophic neurite in the 
D427V/WT mice. On the other hand, 5XFAD mice showed ChAT-positive dystrophic neurites in 
the DG. With the notion that swollen dystrophic cholinergic axons have not been associated with 
DLB/PDD unlike dystrophic dopaminergic axons (Johnson et al., 2011; reviewed in Duda, 2004), 
D427/WT and 5XFAD/AD likely do not share common ChAT upregulation mechanisms. 
Nonetheless, ChAT staining was significantly decreased in the DG of DLB/PDD cases (Johnson et 
al., 2011) unlike those of D427V/WT mice. This moderate increase in ChAT % area of staining in 
D427V/WT GBA1 mice was associated with severe loss of VAChT % staining area or VAChT-
positive presynaptic terminals. ChAT upregulation could be D427V/WT GBA1 mutation-specific 
effect. On the other hand, D427V/WT mice older than 12 mo may later have lower ChAT 
expression similar to a significant decrease in ChAT staining in Braak IV-VI.   
VAChT staining in the main cohort study decreased in Braak I, reached its peak in Braak II and 
subsequently gradually decreased along Braak stage progression. Unlike in both D427V/WT 
GBA1 and 5XFAD mice of which VAChT staining was mostly colocalised with ChAT staining, a few 
human cases had conspicuous VAChT staining with relatively much lower ChAT staining. Despite 
non-significant difference in % staining area of VAChT-positive axons or VAChT-ChAT 
colocalisation across Braak stages or CERAD NP scores, % area of colocalisation between VAChT 
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and ChAT was significantly higher in cases with Braak III and CERAD 0 than those with Braak III 
and CERAD score of 2. This pattern of changes in Braak III cases with and without moderate 
CERAD NP score was also observed in the % staining area of ChAT-positive axons. This suggested 
that despite the highest density of ChAT accumulation in dystrophic neurites, preservation of 
cholinergic axons in Braak III was accompanied by a sparing of VAChT level and potentially 
contributed to cholinergic function compensation. VAChT was more negatively correlated, albeit 
not significant after multiple p-value adjustment, with CERAD NP score than NFT Braak stage. 
Aβ42 oligomer treatment has been demonstrated to dose-dependently decreased VAChT-
positive bouton density in primary rat basal forebrain neuron culture (Kasa et al., 2004). 
However, a slight reduction in the % staining area of VAChT-positive axons in the DG and the 
somatosensory cortex of 5XFAD compared with the WT was not statistically significant in this 
study. 
Changes in the human basal forebrain were not investigated in this study. Previous studies have 
shown severe reduction in the number of BFCNs in the nbM/SI but less pronounced change in 
the VDB of AD patients. In this study, however, changes in the number of BFCNs and in ChAT or 
VAChT % area of staining were not significant between 5XFAD and WT. While this might result 
from low sample size, injection of Aβ42 oligomers into the rat nbM/SI was reported to induce 
non-significant decrease in the size of BFCNs, ChAT-positive axon density in the PFC, and cortical 
VAChT levels by WB (Parikh et al., 2014). The above study also showed that aging significantly 
decreased ChAT-positive axon innervation and cortical VAChT level. However, this thesis found 
that both hippocampal and cortical VAChT levels in 12 mo WT/WT GBA1 mice were higher than 
those in 6 mo mice. This discrepancy was possibly caused by differences in cholinergic regulation 
by aging between mice and rats, which unfortunately have not been investigated (Van der Zee 
and Keijser, 2011).    
 
7.3 Comparisons of adult hippocampal neurogenesis between human and mouse 
models 
Investigation on colocalisation of DCX and HuB/D in this thesis revealed that human HuB/D was 
expressed in the late neuroblast/immature neuron phase while mouse HuB/D was preferentially 
expressed in the early neuroblast/immature neuron phase. Unlike human HuB/D which was 
expressed in DCX- or calretinin-positive cells with immature DGC-like morphology, mouse HuB/D 
was mostly expressed in cells with flat neuroblast-like morphology in the SGZ. Few cells in the 
mouse GCL with immature DGC-like morphology also expressed faint DCX and HuB/D. In human, 
the percentages of cells immunoreactive for both DCX and HuB/D within the population of DCX- 
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and HuB/D-positive cells were 51.7% and 31.4% respectively. In mouse, the percentages of DCX- 
and HuB/D-double positive cells within the DCX- and HuB/D-positive populations were only 
22.6% and 9.0% respectively. This study found that HuB/D and HuC/D were colocalised in the 
nuclei of DGCs and therefore confirmed the results of the article that first studied the 
colocalisation between HuC/D and PCNA (Ekonomou et al., 2015). On the other hand, the first 
study on AHN in AD patients (Jin et al., 2004a) demonstrated that Hu proteins were colocalised 
with TUC-4 in the cytoplasm. Similarly, studies on mice in this thesis demonstrated that mouse 
HuB/D was primarily in the cytoplasm of neuroblasts. This study and several previous articles 
(Knoth et al., 2010; Sorrells et al., 2018) reported moderate to intense DCX immunoreactivity in 
nuclei of some DGCs. On the contrary, the studies on both D427V/WT GBA1 and 5XFAD 
confirmed that mouse DCX was predominantly present in the cytoplasm. While this nuclear DCX 
immunoreactivity potentially resulted from human-specific subcellular compartmentalisation, it 
could also be an artefact considering that the major study on a larger cohort with thorough 
investigation along the entire hippocampus did not report such phenomenon (Boldrini et al., 
2018).     
 
7.4 Potential effects of tau on AHN 
Injection with soluble non-aggregate tau is capable of impairing dendritic spine, Mossy 
terminals, morphology, and associated behaviours (Bolos et al., 2017). Interestingly, soluble tau-
treated mouse DGCs have several primary apical dendrites similar to DGCs found in AD patients 
(Llorens-Martin et al., 2013). Similar to previous studies (Perry et al., 2012; Boldrini et al., 2018; 
Tartt et al., 2018), DCX staining in this study also could not effectively visualise dendrites of the 
immature neurons to confirm any pathological morphology. One study showed that most DGCs 
immunoreactive for pS396 or pT205 (also recognised by AT8) were immunoreactive for DCX and 
they also demonstrated that GSK3-induced tau hyperphosphorylation promoted proliferation 
and increased the number of NeuroD- and DCX-positive cells (Hong et al., 2010). Staining of both 
pS396 and AT8 were performed in the main human cohort study of this thesis and higher 
number of cells positive for these phospho-tau markers also approximately increased with Braak 
stages with slight variations in terms of cell number and intracellular immunoreactivity. Future 
studies are required to confirm their colocalisation with neurogenic markers in each Braak stage.  
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7.5 Possible contributions of cholinergic innervation to adult hippocampal 
neurogenesis 
A study demonstrated that 192 IgG-saporin-induced MS/DB lesions in 8-10 wk mice had no 
significant effect on AHN in the baseline condition but increased proliferation and impaired 
survival of new-born DGCs in the group with running exercise (Ho et al., 2009). Another study, 
however, showed that 192 IgG-saporin-induced BFCN lesion significantly decreased baseline 
survival of new-born DGCs (Cooper-Kuhn et al., 2004). The 192-IgG-saporin has been shown to 
significantly decrease hippocampal ChAT activity and specifically induce higher BFCN loss in the 
MS/DB than in the nbM/SI (Berger-Sweeney et al., 2001). These previous studies seemed to 
suggest that baseline mouse AHN is relatively resistant to loss of BFCNs in the MS/DB. 
Nonetheless, this study seemed to suggest that D427V/WT GBA1 mutation-induced 
hippocampal cholinergic signalling impairment from loss of VAChT was sufficient to significantly 
increase proliferation of DCX-positive cells. A significant increase in the total number of DCX-
positive cells indicated that there could be a relative defect in postmitotic maturation step. 
However, it is impossible to conclude any information regarding survival of these adult-born 
neurons without using BrDU to mark a population born within a limited time range. In addition, 
while loss of VAChT was prominent in the DG, this increase in the number of DCX-positive cells 
could be partially attributed to the endogenous effects of D427V/WT GBA1 mutation within the 
DGCs or the other local cell types. A recent study found that DLB/PDD patients even without 
antidepressant treatment had higher number of DCX-positive cells than age-matched controls, 
albeit not significantly (Gatt et al., 2018). The above previous study and this study on D427V/WT 
GBA1 mice together supported the notion of association between DLB/PDD phenotypes and 
trends of upregulated AHN.  
In comparison to the previous study that showed significant impairment in new-born DGC 
survival by 192-IgG saporin in a runner mice group (Ho et al., 2009), another recent study on 4-
mo 5XFAD also showed that reduction in cholinergic terminals on new-born DGCs was 
associated with survival impairment and that theta burst stimulation of BFCNs in the VDB/HDB 
successfully rescued the survival of new-born DGCs (Zhu et al., 2017). This thesis, however, did 
not find any significant difference between 11-mo 5XFAD and WT mice likely due to the minimal 
sample size of 3. Nevertheless, the previous study on 5XFAD suggested that amyloid pathology 
contributed to the reduction in cholinergic synapses in the DG and supported the finding in this 
thesis on the main human cohort that ChAT-positive axon density was significantly decreased 




7.6 Strengths and Weaknesses 
The major overall weakness of this thesis was lack of postmortem tissues from DLB/PDD subjects 
in a human cohort despite a chapter on a GBA1 heterozygous mouse model. While % staining 
areas of ChAT, DCX, and PCNA of DLB cases have been investigated in a previous study (Johnson 
et al., 2011), co-staining of ChAT and VAChT in cholinergic axons or immunohistochemical 
marker profiles of DCX-positive cells have not been studied before in DLB/PDD subjects. This 
valuable opportunity was missed as the project originally focused on an AD cohort and the study 
on GBA1 mouse model only started in the late half of the 3rd year of this thesis project. 
Therefore, since the relatively short remaining time was not deemed enough for tissue request 
and subsequent imaging and analyses, a study on DLB/PDD cohort was not pursued.             
Importantly, this thesis only investigated immunoreactive patterns of certain markers or 
association between pairs of markers of interests without any mechanistic approaches. 
Therefore, it was impossible to conclude that higher ChAT activity directly promoted maturation 
and survival of HuB/D-positive cells or that drastic decrease in hippocampal VAChT or potentially 
loss of ACh signals induced higher number of DCX-positive cells in D427V/WT GBA1 mice.  
One major weakness of this study on AHN was the lack of stereological technique, a gold 
standard for cell density quantification especially for cell types which may be sparsely present 
in a given region such as DCX-positive cells in the human DG (Boldrini et al., 2018). While the 
estimated distance of a coronal section from the front (cm_front) was included in the model to 
account for the potential difference in AHN of different part of the DG, investigation on 3 parts 
of the DG as anterior, intermediate, and posterior separately would have been better. 
Nevertheless, acquiring different specified parts of the hippocampus from each case could be 
difficult as sections from some cases could have been requested by other studies and it would 
be impossible to obtain approximate cm_front-matched sections of all cases.  
This study requested all human cases only from London Neurodegenerative Disease Brain Bank 
and all of them therefore have BDR number and BBN-ID to look up for further information from 
the database. However, not all cases have information on cognitive scores such as MMSE for 
further analyses. Fortunately, unlike the pilot cases, all of the main cohort cases had CERAD NP 
score which was also included in separate analysis models. However, the number of cases was 
not large enough to conclusively determine the effects of different NP score within each Braak 
stage. Acquisition of brain tissues from the same brain bank minimised the differences in tissue 
processing. Only 3 cases were originally from Kent, but there was no apparent anomaly in terms 
of staining in these cases. Despite the lack of complete cognitive score record, all Braak IV-VI 
cases had dementia diagnosis so it was not necessary to include dementia status as a covariate 
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in a similar way performed by a previous study (Ekonomou et al., 2015). The same previous study 
only included the cases without any vascular or synuclein pathology. Acquisition of cases from a 
single brain bank limited an option of choosing only cases that were devoid of non-AD pathology. 
Despite the lack of conspicuous discrepancy from cases with high white matter degeneration, 
Lewy Braak stages, amygdala Lewy body, Hachinski ischemia score, small vessel disease, or TDP-
43 pathology (data not shown) because of a small sample size in each category, it would be 
recommended for the future study to exclude them or use proper statistical analyses to account 
for these factors.         
This study was the first to investigate the colocalisation of VAChT and ChAT in the hippocampus 
of AD cases. While the staining pattern was generally homogeneous across the entire DG within 
each section, staining repeat on consecutive sections from different longitudinal parts of the 
hippocampus would be advisable. Regarding the quantification of VAChT and ChAT, it was 
probable that quantification methods of both human cohort study and D427V/WT GBA1 mice 
study could have underestimated the % area of VAChT staining. For human study, the threshold 
limit of particle size of at least 5px to avoid noises also exclude some portion of verified small 
cholinergic terminals as determined by colocalisation between ChAT and VAChT or their 
positions along the axon-like chains of staining particles. It would be advisable for the future 
study to apply a smaller size threshold with colocalisation verification. For the mice study that 
used automatic threshold setting based on average particle size, VAChT-positive puncta were 
generally smaller than ChAT staining such that the maximum particle size-yielding threshold of 
VAChT staining was frequently higher than that of ChAT staining.  
The lack of stereology was also the weakness of this study on the number of DG neurogenic 
populations and the BFCNs in mice. Especially for the quantification and characterisation of 
BFCNs, the use of a single section exposed the potential variability from the relatively small size 
of the BF sub regions. The boundary of the nbM/SI was more difficult to define than that of the 
VDB/HDB in sagittal sections and the resulting high variability in the number of BFCNs in the 
supposed region was the main incentive to exclude the investigation on the nbM/SI from this 
thesis.     
Strong PCNA nuclear staining was occasionally observed in DCX- or HuB/D-positive cells in mice. 
However, intense PCNA nuclear staining was mainly in radial glia-like cells and rare in DCX- or 
HuB/D-positive cells. Most PCNA staining in the cells considered as positive for PCNA was 
moderately bright relative to the background and interestingly associated with the intensity of 
DAPI staining in those respective cells. A previous study has shown that PCNA could be localised 
with caspase-3 in DCX-positive cells (Knoth et al., 2010). In this case, intense DAPI staining could 
indicate an abnormally high amount of DNA caused by ectopic cell cycle re-entry, which has 
197 
 
been implicated in AD-associated neuronal cell death (Counts and Mufson, 2017; Kodis et al., 
2018). Staining for apoptotic markers could help identify the nature of PCNA staining in each 
cell.  
D427V/WT GBA1 and 5XFAD mice used in the study were at different ages of 12-mo and 11-mo 
respectively. This was a missed opportunity considering that both mouse lines have C57BL6 
background. In addition, these 5XFAD paraffin-embedded brains were originally parts of a 
separate project managed by Dr David Whitfield at least a year before the start of the GBA1 
project. Hence, there could be significant variability from different experimental conditions 
between the two mouse lines. Had these two mouse lines used in this thesis were managed and 
maintained together and sacrificed at the same age, it would be possible and interesting to 
compare cholinergic deficits and changes in AHN of both mouse line and both of their WT 
littermate together in the same analyses.      
 
7.7 Future studies 
A future human cohort will also include DLB/PDD subjects and cognitively healthy PD subjects 
with different extents of Lewy body pathologies and/or potentially GBA1 mutation genotypes. 
Local Lewy body pathologies including pS129 will be investigated in relation to the cholinergic 
and neurogenic changes. Subjects with comparable NFT Braak stages or other non-Lewy body 
pathological features from this Lewy body disease cohort and those from the AD cohort may be 
analysed together to study an exclusive effect of Lewy body pathology in different groups of 
subjects or different stages of the diseases. A recent study on Lewy pathology in CA2 also found 
overwhelming direct overlap between ChAT and α-synuclein but almost between ChAT and 
pS396 tau (Liu et al., 2019). Local neuropathological profiles of ChAT, α-synuclein, and phospho-
tau in AD and DLB/PDD cohort together in the DG could provide an insight on the dynamic of 
cholinergic changes in different types of dementia and reveal a specific neuropathological 
pattern that is highly associated with AHN.       
For human cohort, a larger sample size with a minimal number of 3 for each combination of each 
Braak stage and CERAD NP score or Thal amyloid stage would reveal the interaction and 
individual effects of these major AD-associated pathological hallmarks. Investigation on local 
NFT and Aβ staining within the DG would help to verify the association between the DG local 
pathology severity and the mandatory classical pathology staging. Furthermore, certain aspects 
of the local pathology are potentially more reflective of alterations in cholinergic and neurogenic 
markers in the DG. For each case, staining on consecutive sections and stereology would also be 
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applied for each of the 3 sets of sections from the anterior, intermediate, and posterior part of 
the DG. 
IHC antibody stripping techniques would be optimised in order to allow probing of multiple sets 
of different antibodies on the same section. In the pilot study, only the period of incubation and 
frequency of shaking were adjusted. In future studies, multiple rounds of shorter incubation and 
higher concentration may prove more efficient since the previous studies that established this 
protocol mainly tested this technique on a 3±1 µm thick section (Bolognesi et al., 2017) while 
the standard thickness of sections from the BDR was 8 µm. If the optimisation is successful, 
caspase-3, Sox2, NeuroD, Prox1, calretinin, calbindin, and/or NeuN would be included in the set 
of antibodies of AHN for a more complete profiling of DGC developmental stages. For cholinergic 
markers, CHT1, m1-mAChR, and α7-nAChR antibodies would be included.  
Future studies on D427V/WT GBA1 mice would include the same antibodies listed above for 
further characterisation of AHN and cholinergic changes. Furthermore, the staining would be 
performed over multiple sections in order to cover the 3-dimensional shape of the VDB/HDB 
and the nbM/SI. While it is not possible to distinguish the D427V GCase from the WT GCase, 
profiles of subcellular localisation of GCase within different types of cells in the brain especially 
the BFCNs may provide an evidence of functional abnormality that contributes to the loss of 
VAChT. The current GCase antibody used in our research group was generated in mouse cells. 
The background staining from the anti-mouse secondary on endogenous IgG within blood 
vessels or cells proximal to an accidental tissue injury can be digitally eliminated by prestaining 
with anti-mouse secondary antibodies tagged with different fluorescence channel. The physical 
exclusion can be achieved by pre-treatment of sections with the stripping method which 
destabilises endogenous IgGs by reducing their disulphide bonds as demonstrated in the pilot 
study Chapter 3. Interestingly, preliminary staining (data not shown) has shown that CA2 
pyramidal neurons were highly immunoreactive for anti-mouse secondary antibodies. AMIGO2 
or Adhesion molecule with Ig-like domain 2 is an established marker of CA2 pyramidal neurons 
(Hitti and Siegelbaum, 2014) and its immunoglobulin-like domain is probably a target of an anti-
mouse secondary antibody. Optimisation of either digital or physical exclusion of anti-mouse 
secondary antibody background signal would improve the staining clarity in any mouse models 
including the D427V/WT or AD-associated models such as 5XFAD. Lastly, future studies on the 
D427V/WT mice and AD-associated mice models should include other age points as well in order 




Multiple experiments could be conducted to unravel the mechanisms behind the difference in 
VAChT and ChAT protein regulation. Since ChAT is a cytoplasmic protein but VAChT is an integral 
protein on vesicular membrane, defects in trafficking pathway could have caused the observed 
disparity in their levels. For example, loss of arl8 gene abolished anterograde transport of 
synaptic vesicular proteins VGluT1 and synaptotagmin (Vukoja et al., 2018). Considering that 
there was no significant change in VAChT immunoreactivity in the BFCNs, it would be of interest 
to screen for any changes in axonal transport-associated proteins or vesicular protein turnover 
regulator. If any of them turn up to be reduced in the mouse model, checking whether 
overexpression of that protein in the BFCNs (i.e. by injecting with AAV viral vector or generating 
bacterial artificial chromosome (BAC)  transgenic mice that overexpress the target gene under a 
specific promoter e.g. ChAT promoter) can rescue the phenotype would be a possible next step. 
On the other hand, VAChT can also be overexpressed in D427V/WT GBA1 mouse by crossing this 
heterozygous mouse with a ChAT-ChR2-EYFP transgenic line. Each cell of this mouse line has up 
to 50 copies of ChAT-containing BAC (Kolisnyk et al., 2013). A ChR2-EYFP insert is targeted to the 
ATG codon in the 4th exon of ChAT gene to drive channelrhodopsin-2 (ChR2) synthesis and 
simultaneously prevent translation of ChAT (Zhao et al., 2011). As a result, VAChT gene, which 
lies within an intron between exon I and exon II of ChAT, remains intact such that this mouse 
overexpresses functional VAChT together with ChR2. In a more general view, it would be 
important to check whether overexpression with WT GBA1 or ablation of SNCA gene can rescue 
the VAChT loss phenotype. Conversely, investigating AHN in a mouse model of specific VAChT 
loss in BFCNs of the MS/VDB by injecting AAV8-Cre into the MS/VDN of VAChTflox/flox mouse in a 
previous study (Kolisnyk et al., 2016) would help confirm whether loss of VAChT alone could 
increase DCX-positive cells in the same manner.  
AHN specifically the number of DCX-positive cells was found to be highly sensitive to 
neuropathology (Moreno-Jiménez et al., 2019). Subjects with Braak 0 and Braak I had similar 
degree of local NFT pathology in the DG, but Braak I cases had significantly less DCX-positive 
cells than Braak 0 cases. In this thesis, albeit not statistically significant, mean xHD and HnP cells, 
which were also significantly correlated with ChAT, also decreased sharply in Braak I (n=2) and 
Braak II (n=8) compared with Braak 0. Since AHN is a sensitive and dynamic system with close 
association to the cholinergic system, in vivo or CSF/blood based AHN markers may prove helpful 
for monitoring the changes in patients with preclinical or prodromal AD during clinical trials of 
therapeutic cholinergic interventions. Interestingly, a recent pre peer-reviewed published study 
demonstrated that suppression of AHN decreased hippocampal ACh release, induced 
septohippocampal projection rewiring, and eventually working memory deficits (Kirshenbaum 
et al., 2018). Potential mechanisms may include NGF/TrkA pathway, other retrograde signalling, 
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or possible interaction between MS-projecting hilar interneurons and adult-born DGC. Direct 
AHN-targeting approaches such as SSRI coupled with cardiovascular exercises may prove more 
beneficial to the whole septohippocampal circuitry than they had been expected.  
In conclusion, this thesis has demonstrated evidence to support a relationship between 
cholinergic innervation and neurogenesis in human hippocampus. The relationship is complex 
and is influenced by tau pathology. The examination of two animal models provided some 
potential mechanistic leads which could be followed up. The observed relationship between 
cholinergic innervation and neurogenesis may provide some explanations for symptomatic 
benefit of cholinomimetic therapy and it would be interesting to follow this in patients if and 
when suitable ligands for neurogenic markers become available to complement those for the 
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Table A.1 – Mean and SEM of each marker by Braak stage in the pilot study 
Data are represented as mean (red highlight) ± SEM. Note that an estimated marginal mean after uniGLM 
remains the same as a mean of the raw data (=) but SEM can be changed. ANOVA is a special case of a 
uniGLM without covariate. Therefore, in the above data of the pilot study, F and p-value calculated from 
a regular ANOVA were the same as F and p-value calculated from a uniGLM that computed η2 value for 













1  A053/11 BBN_18399 L-00289 1    3,3    0 0 
2  A473/15 BBN002.2835 L-SUH001 1 2,      4 0 0 
3  A127/11 BBN_16213 L-00338 1    3,3 0 0 
4  A250/14 BBN_24243 L-Kent027 1       3,4 0 0 
5  A367/12 BBN_10191 L-00396 0    3,3 0 0 
6  A319/11 BBN_13802 L-00391 0    3,3 0 0 
7  A404/12 BBN_11073 L-00268 1    3,3 0 1 
8  A130/12 BBN_4578 L-00161 1    3,3 0 0 
9  A242/15 BBN002.2615 L-00308 1       3,4 0 0 
10  A176/15 BBN_25987 L-00849 1       3,4 0 1 
11  A368/13 BBN_20012 L-00313 1    3,3 0 0 
12  A246/14 BBN_24246 L-01003 1    3,3 0 0 
13  A174/14 BBN_23398 L-00175 0    3,3 0 0 
14  A448/15 BBN002.2812 L-Kent013 1       3,4 0 0 
15  A085/11 BBN_9948 L-00392 1 2,3 0 0 
16  A282/14 BBN_24370 L-00293 1    3,3 0 0 
  17  A112/12 BBN_4582 L-00462 1    3,3 3 0 
18  A402/14 BBN_24578 L-00990 1       3,4 0 0 
19  A347/10 BBN_16217 L-00252 1       3,4 0 0 
-1  A132/13 BBN_16199 L-00411 0  0 0 
-2  A160/12 BBN_4247 L-00701 0    3,3 3 0 
20  A160/11 BBN_16210 L-00112 0    3,3 0 0 
21  A233/13 BBN_18795 L-00947 Do, Me    3,3 0 0 
22  A160/13 BBN_17592 L-00954 0    3,3 0 1 
23  A383/11 BBN_13796 L-00203 1       3,4 0 0 
24  A451/15 BBN002.2812 L-WL004 Ri 2,      4 5 0 
25  A216/09 BBN_9918 L-01014 1       3,4 Am 0 
26  A170/13 BBN_18813 L-00668 Ga       3,4 0 1 
-3  A221/13 BBN_18800 L-01015 0       3,4 0 0 
27  A026/14 BBN_20618 L-00128 1 2,3 0 0 
28  A267/09 BBN_9919 L-01011 1    3,3 0 1 
29  A193/12 BBN_9972 L-00028 Ga       3,4 0 0 
30  A292/10 BBN_9943 L-00394 0       3,4 0 0 
31  A277/12 BBN_9984 L-00133 Do       3,4 0 0 
32  A255/14 BBN_24235 L-Kent011 1         4,4 Am 0 
33  A111/12 BBN_4583 L-00140 0       3,4 0 0 
34  A356/12 BBN_10193 L-00957 0    3,3 6 0 
35  A162/15 BBN_25982 L-00154 Me       3,4 Am 1 
36  A121/14 BBN_22593 L-00290 Me       3,4 4 0 
Table A.2 – Brain bank ID and other information of the main cohort cases  
Brain Bank Network (BBN) ID and Brain for Dementia Research No (BDR) for 36 cases and 3 excluded cases 
(negative label numbers). Thick borders separate cases with different Braak stages. Medication records 
(Med-rec) with 1 as existing and 0 as not commented: Ga – Galantamine; Do – Donepezil; Ri – 

















1  A053/11 .591 .324 .078 1.827 .007 .041 
2  A473/15 .042 .720 .017 .058 .040 .055 
3  A127/11 .491 .052 .004 9.415 .000 .039 
4  A250/14 .030 .306 .007 .098 .017 .038 
5  A367/12 .051 .090 .006 .566 .010 .009 
6  A319/11 .022 .047 .001 .465 .000 .021 
7  A404/12 .255 1.067 .134 .239 .012 .014 
8  A130/12 1.153 .045 .005 25.565 .004 .010 
9  A242/15 .193 .283 .034 .680 .067 .027 
10  A176/15 .205 .796 .083 .258 .000 .030 
11  A368/13 .249 .632 .103 .393 .009 .027 
12  A246/14 .090 .025 .001 3.669 .007 .005 
13  A174/14 .091 .532 .025 .171 .010 .023 
14  A448/15 .356 .025 .002 14.467 .003 .016 
15  A085/11 .337 1.695 .162 .199 .069 .033 
16  A282/14 .323 1.104 .158 .293 .047 .022 
  17  A112/12 .065 .439 .021 .147 .057 .023 
18  A402/14 .105 .337 .028 .311 .056 .027 
19  A347/10 .096 .634 .042 .151 .091 .045 
-1  A132/13 .005 .057 .001 .088 .005 .013 
-2  A160/12 .048 .068 .006 .699 .000 .019 
20  A160/11 .087 .951 .038 .091 .033 .039 
21  A233/13 .282 .037 .004 7.563 .000 .009 
22  A160/13 .130 .018 .000 7.417 .000 .000 
23  A383/11 .070 .035 .005 1.972 .010 .011 
24  A451/15 .116 .702 .064 .164 .018 .023 
25  A216/09 .079 .026 .006 3.031 .000 .007 
26  A170/13 .030 .069 .004 .435 .000 .000 
-3  A221/13 .167 2.396 .094 .070 .046 .077 
27  A026/14 .102 .062 .007 1.639 .024 .015 
28  A267/09 .021 .030 .004 .699 .019 .012 
29  A193/12 .497 .581 .182 .855 .036 .024 
30  A292/10 .064 .119 .008 .539 .025 .016 
31  A277/12 .091 .015 .002 6.121 .004 .005 
32  A255/14 .009 .027 .001 .317 .000 .002 
33  A111/12 .209 .095 .010 2.202 .016 .013 
34  A356/12 .091 .545 .052 .167 .009 .010 
35  A162/15 .202 .181 .026 1.117 .012 .031 
36  A121/14 .033 .053 .004 .618 .007 .034 
Table A.3 – Data on cholinergic markers of the main cohort cases  









Autopsy no. xD xH xPH xHD xPD xPHD DG (mm) 
1  A053/11 7 33 3 27 5 2 10.65 
2  A473/15 1 49 7 57 0 1 16.02 
3  A127/11 1 23 17 0 0 0 9.07 
4  A250/14 2 22 2 11 6 4 7.09 
5  A367/12 8 25 12 18 9 2 10.25 
6  A319/11 0 21 10 0 0 1 9.19 
7  A404/12 7 16 1 3 10 3 10.47 
8  A130/12 4 2 0 0 0 1 8.02 
9  A242/15 1 19 1 5 1 0 10.78 
10  A176/15 7 20 1 38 0 0 9.80 
11  A368/13 5 28 2 6 0 0 9.57 
12  A246/14 1 20 6 0 0 0 9.14 
13  A174/14 7 43 2 9 0 1 9.32 
14  A448/15 9 7 5 1 5 0 9.14 
15  A085/11 0 43 1 2 0 0 12.81 
16  A282/14 37 12 1 20 6 1 9.24 
  17  A112/12 1 6 0 2 4 3 8.97 
18  A402/14 2 21 5 2 0 5 8.16 
19  A347/10 4 32 1 8 1 2 9.46 
-1  A132/13 2 24 0 12 2 2 10.82 
-2  A160/12 4 29 20 1 1 0 15.03 
20  A160/11 1 23 0 8 0 0 8.92 
21  A233/13 21 5 3 3 0 5 9.59 
22  A160/13 7 1 5 0 5 0 8.65 
23  A383/11 18 9 3 0 3 2 8.86 
24  A451/15 3 18 4 13 3 2 10.31 
25  A216/09 3 4 23 3 3 6 10.45 
26  A170/13 1 7 4 0 0 0 5.20 
-3  A221/13 1 31 1 13 1 10 7.71 
27  A026/14 1 26 3 2 1 4 22.34 
28  A267/09 10 6 8 1 5 1 15.30 
29  A193/12 1 4 0 8 1 0 11.98 
30  A292/10 2 49 0 44 0 0 14.60 
31  A277/12 1 21 4 9 3 4 12.51 
32  A255/14 49 15 4 7 11 9 15.21 
33  A111/12 9 0 1 6 4 2 5.90 
34  A356/12 18 25 1 24 1 2 11.69 
35  A162/15 6 19 0 8 15 12 9.11 
36  A121/14 8 21 1 11 3 8 8.39 
Table A.4 – Data on neurogenic markers of the main cohort cases  
Quantification of 6 basis cell groups as raw cell counts. DG length was measured in mm. Note that the 
offset variable is natural logarithm of the DG length. The more inclusive groups can be calculated as 








NP VAChT ChAT Colocalised HnP HP DnP DP 
0 .374 ± .079 3.735 ± .106 .079 ± .016 2,33.25 ± .56 2.28 ± .08 2.21 ± .62 .19 ± .06 
1 .037 ± .111 .404 ± .149 .034 ± .022 2.54 ± .67 .55 ± .17 .74 ± .30 .69 ± .24 
2 .096 ± .106 .280 ± .142 .023 ± .021 01.31 ± .34 01.18 ± .29 .88 ± .34 1.26 ± .43 
3 .143 ± .082 0.152 ± .110 .027 ± .016 01.70 ± .33 .42 ± .10 1.12 ± .32 .22 ± .07 
Table A.5 – Adjusted means of markers across CERAD NP scores  
Markers of interest were modelled with an interaction term between Braak01 (where Braak 0 and I were 
grouped together) and CERAD NP score. Data are expressed as EMM ± SEM. Superscripted numbers in 
red indicate significant difference to the group of that CERAD NP score after BKY-FDR adjustment of 6 p-
values per marker.  
 
Pearson  xD xH xPH xHD xPD xPHD HnP HP DnP DP 
 VAChT  
(4th root) 
r .001 -.147 -.144 -.042 -.056 -.206 -.115 -.233 -.029 -.136 
p .994 .393 .402 .810 .746 .228 .503 .172 .866 .430 
ChAT  
(4th root) 
r -.059 .466 -.445 .427 -.070 -.185 .532 -.484 .271 -.135 
p .733 .004 .006 .009 .683 .279 .001 .003 .110 .433 
Colocalised 
(4th root) 
r .023 .284 -.420 .347 -.026 -.139 .373 -.438 .264 -.084 
p .893 .094 .011 .038 .879 .419 .025 .008 .120 .624 
Dys-ChAT 
ML (sqrt) 
r -.164 .279 -.475 .114 -.059 -.080 .238 -.455 -.020 -.076 
p .339 .100 .003 .508 .732 .643 .162 .005 .908 .659 
Dys-ChAT 
DG (sqrt) 
r -.254 .575 -.205 .409 -.074 .077 .589 -.138 .136 -.009 
p .135 .000 .230 .013 .667 .656 .000 .422 .428 .959 
Spearman  xD xH xPH xHD xPD xPHD HnP HP DnP DP 
 VAChT  
(4th root) 
rs .085 -.149 -.283 -.031 -.061 -.231 -.130 -.365 -.050 -.137 
p .620 .386 .094 .859 .723 .176 .451 .029 .773 .425 
ChAT  
(4th root) 
rs -.126 .467 -.527 .538 -.122 -.151 .589 -.560 .269 -.200 
p .464 .004 .001 .001 .479 .378 .000 .000 .112 .241 
Colocalised 
(4th root) 
rs -.069 .309 -.582 .511 -.042 -.105 .447 -.612 .252 -.138 
p .690 .067 .000 .001 .809 .544 .006 .000 .138 .421 
Dys-ChAT 
ML (sqrt) 
rs -.319 .288 -.495 .280 .052 -.001 .270 -.477 .008 -.026 
p .058 .088 .002 .099 .762 .996 .111 .003 .963 .880 
Dys-ChAT 
DG (sqrt) 
rs -.293 .644 -.315 .421 -.145 -.067 .616 -.244 .113 -.147 
p .082 .000 .061 .011 .399 .699 .000 .151 .510 .392 
Table A.6 – Correlation between cholinergic and AHN markers   
Pearson and Spearman correlation coefficient with corresponding p-value between each cholinergic 
marker and each AHN cell group. All p-values listed are raw unadjusted. A pair of coefficient and p-value 
are shaded green if its coefficient is negative and p-value is less than 0.05. On the other hand, a pair of 
coefficient and p-value are shaded red if its coefficient is negative and p-value is less than 0.05. Darker 










Figure A.1 – Morris Water Maze and Y-maze in D427V/WT GBA1 mice.  
(Modified from Clarke, 2018; permission from personal communication) Learning curves showing 
duration in seconds to submerged platform over 5 consecutive days in 6 mo (A) and 12 mo (B) D427V/WT 
and age matched WT/WT mice. Data represented as mean trial duration ± SEM, repeated measures Two-
way ANOVA, Sidak post hoc test. Probe trial at 12 months old (C). Data represented as mean duration ± 
SEM, Student’s t-test; *p<0.05; **p<0.01; n= 8-9 mice per group. Y-maze of D427V/WT and WT/WT mice 
(D). Data represented as mean spontaneous alternation performance ± SEM, repeated measures Two-




Figure A.2 – Altered hippocampal gene expression in D427V/WT mice 
(Personal communication) Expression of vAChT, CHAT and SYP1 mRNA (VAChT, ChAT, and SPP as proteins) 
relative to ActB as calculated using ΔΔct. Two-way ANOVA with Bonferroni correction, F(1,18)=24.77; 






Table A.7 – ImageJ macro used for cholinergic quantification in GBA1 mice (i) 
This macro was coded with an ImageJ-specific language IJ1 Macro (.ijm) with the following colour codes: 
conditional (blue), Boolean (brown), variable (black), gold (built-in function), number (purple), pink 








Table A.7 – ImageJ macro used for cholinergic quantification in GBA1 mice (ii)  








Table A.7 – ImageJ macro used for cholinergic quantification in GBA1 mice (iii)  















Table A.8 – ImageJ macro for division of a polygonal selection into bins of equal thickness (i)  
This macro was also coded with an ImageJ-specific language IJ1 Macro (.ijm). This macro was not used for 
the analyses in this thesis but would be beneficial for future studies on distribution of cholinergic 







Table A.8 – ImageJ macro for division of a polygonal selection into bins of equal thicness (ii)  









































Table A.14 – Approval letter for the main cohort tissue request (TRID 213) 
